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It is quite obvious from the available wide range of literature reports that the 
progress of diversity oriented fluorescent library approach along with the high 
throughput screening lead to novel bio-imaging probes/sensors discovery in a 
relatively faster manner. However, for the case presented here, efficient solid 
phase chemistry needs to be devised to provide a robust synthetic route for 
generating a large number of fluorescent libraries in a short span of time. In 
this view, I developed an elegant solid phase route to systemically apply in the 
synthesis of fluorescent libraries that cover wide emission color spectra from 
VIS to NIR. We designed the novel diversity oriented fluorescent libraries 
where each library contains single emission wavelength to develop both cell 
imaging and in vivo imaging probe. Single wavelength with different 
structural diversity provided a useful toolbox as it allowed easier structural 
activity relationships studies (B cell probe development). 
In the chapter 2, based on the previous work by our group, I have 
synthesized ultra-photostable , NIR cyanine dye libraries (CyR and its CA, AC 
and lipoic acid  derivatives)  utilizing CyNA-414 , the most  photostable dye 
from CyNA library. In Chapter 3, from macrophage screening of CyR 
derivatives, we developed a novel in vivo imaging macrophage probe 
(CyRCA-341).  From the SERS screening of the CyRLA compounds (Chapter 
4), we discovered the highly SERS-active compound CyRLA-572 which has 
been utilized as the multiplexing partner with the Cy7LA and Cy7.5LA 
compounds to detect  three germ layers of mESc in vitro. 
XIII 
 
Modifying the stable tetramethyl BODIPY scaffold, in the chapter 5, I 
have synthesized BDR library and its CA and AC derivatives to generate 
green emission compounds. From the cell based screening, we discovered a B-
cell selective probe CDg6 (BDRCA-656). For the SARs study, I synthesized 
BODIPY derivatives containing long alkyl chains (upto 24 carbons). 
In the chapter 6, Rhodol scaffold, a mixed hybrid from rhodamine and 
fluorescein was employed to produce longer wavelength, dye library (RDR 
and its CA, AC derivatives) in the range of orange emission color. Rhodol 
library inherited excellent photophysical properties such as good quantum 
yield, high extinction coefficient. Using cell based screening, we obtained 
primary results for discovering mitotic phase specific probe, RDR-567 which 
specifically stains to the mitosis compared to the inter phase cells. 
I synthesized COR library (chapter 7) and its respective chloroacetyl 
(CA) and acetyl derivatives (AC) to cover the large stokes shift (150 nm), 
green emission dyes. Here, based on the previous work and the studies,  I 
opted a coumarin scaffold which contains dimethyl amino group at 7- position 
for better photophysical property and acid group at 4-position for 
diversification. Over all, I constructed a coumarin library (COR, CORCA and 
CORAC) with diversity at the 4-position using our efficient solid phase 
synthesis to explore these compounds in the evaluation of biological function 
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Of late, the use of fluorescent molecules in biological research is the 
benchmark in many applications, and their utilization is constantly mounting 
owing to their adaptability, sensitivity and quantitative potentiality.  Moreover, 
the use of fluorescence small molecules remarkably diminishes the most 
challenging task in the process of the identification of small molecule probes 
with a high selectivity towards the specific targets. In this case, the ligands of 
specific targets from the organelles in complex biological systems are usually 
labeled with fluorescent molecules and subsequently visualized by taking 
images using fluorescence microscopy. As a result, in recent times, the 
fluorescent probes or sensors are widely being utilized to detect protein 
location, to recognize protein complex formation as well as activation, to 
detect conformational changes and to examine biological processes both in 
vitro and in vivo. 
The conventional strategy for the design of ﬂuorescent probes or sensors is 
based on the target oriented synthesis (TOS) where the combination of 
ﬂuorescent dye molecules and designed receptors for speciﬁc analytes is used 
for the recognition of the receptor-analyte complex which in turn can induce 
the photophysical property changes of the dye moiety. Though, this approach 
has played a critical role throughout the decades, it has its own limitation in 
the process of novel sensor discovery. Recently, the application of 
combinatorial chemistry techniques along with the diversity-oriented strategy 
has impelled the emergence of diversity-oriented ﬂuorescence library 
approach (DOFLA) to the discovery of novel ﬂuorescence sensors. By 
2 
 
applying this approach, the ﬂuorescent dye libraries are generated to avoid the 
concept of recognition of speciﬁc analytes. Here, during the process of 
synthesis, the ﬂuorophore scaffolds are typically designed with certain 
functionality to introduce the diversity and the efficient synthetic routes are 
customized to produce a diverse set of dyes. So far several DOFLA scaffolds 






hemicyanine, rosamine, and BODIPY and their applications have been 
demonstrated. 
The following sections of this thesis will review the research of the expansion 
of combinatorial approach on fluorescent small molecules in sensor or probes 
development using different fluorescent scaffolds and their recent 
applications. 
1.1 Overview of Small Molecule Fluorophores 
 Fluorescence is a form of optical spectroscopy where a molecule 
usually absorbs ultraviolet, visible, or near infrared radiation to be promoted to 
an electronically excited state. The excited molecule then discharges the 
energy in the form of light emission to return to the ground state, or to a 
lower-lying excited electronic state. The emitted light can be detected either 
visually or through the detectors. Due to its high flexibility, sensitivity and 
quantitative capabilities, fluorescence technique
1
 has been applied in 
biological research for over 100 years. The developments in fluorescence 
chemistry along with technical discoveries have stimulated the advancement 
of many different kinds of fluorophores. Three general groups of fluorophores 
are developed due to enormous research. These are biological fluorophores, 
quantum dots and organic dyes. Bioluminescence, generated from biological 
3 
 
fluorophore is quite well known for a long time as the first use of a biological 
fluorophore for research applications took place in the 1990s, when green 
fluorescent protein (GFP)
2 
was utilized as a gene expression reporter. Since 
then, derivatives of the original GFP and many other proteins have been 
designed for application in biological expression systems. However, the 
biological fluorophores or fluorescent proteins are quite bulky in size. Hence 
in the biological research, the fluorescent proteins become slow labeling, and 
difficult handling agents
3
.Quantum dots also used as fluorophores, were 
developed in the 1980s by Alexei Ekimov and since the 1990s have gradually 
been used more in fluorescence applications in biological research. While the 
use of quantum dots in biological applications is increasing, there are reports 
of cell toxicity
4
 in response to the breakdown of the particles and their use can 
be cost-prohibitive. Additionally, in case of QDs, the fact that these behave 
not as molecules but as nanocolloids complicates their application in 
biological environments
5
. In biological research, organic synthetic dyes are the 
most useful dyes. However, there are a very limited number of scaffolds found 
to be fluorophores. Interestingly, these few fluorescent scaffolds cover almost 
all colors in the spectra, from UV-visible to near–infrared (NIR). 
  
Figure 1.1 Spectral range of different well known fluorophores   
 
 Well known fluorophores
6
 with different wavelengths used as DOFLA 
scaffolds are: DAPI, FITC, TRITC, Texas Red , BODIPY, Rhodol, rosamine, 
styryl, xanthone, oxazine and cyanine. These DOFLA scaffolds have been 
utilized for a range of applications in the bioorganic field.  Among the 
different fluorophores, NIR dyes (i.e., molecules absorbing light in the range 
4 
 
of 700 to 1000 nm) are more suitable for the optical imaging in vivo
7
, while 
the shorter wavelength dyes ranging from blue to red are mainly used for in 
vitro
8
 cell imaging studies. Therefore, NIR light absorbing dyes have attracted 




Figure 1.2 Representative fluorophores with emission ranging from blue to 
NIR. 
1.2 Synthetic strategies for novel fluorescent probes 
1.2.1 Target oriented approach 
There are two commonly used synthetic strategies for probes 




and diversity oriented approach
11
. In the target oriented approach, the 
target recognition moiety of the molecule is designed on the basis of empirical 
knowledge, and the fluorophore is simply used as a signal amplifier. However, 
in this approach, the complex designed receptor structures usually need bulky 
5 
 
synthetic work for each individual sensor. Also, the sensor‟s scope of 
application is intrinsically limited to the preselected analytes that the sensor 
was designed for. 
 
Figure 1.3 Schematic diagram for Target-oriented fluorescent sensor design 
 
1.2.2 Diversity oriented approach  
In the diversity oriented approach, the library of diversified 
synthesized fluorescent compounds is screened against a broad range of 
analytes without a limitation
12
. The application of combinatorial chemistry 
techniques and the diversity-oriented strategy have spurred the appearance of 
diversity-oriented ﬂuorescence library approach (DOFLA)13 to the discovery 
of novel ﬂuorescence sensors. Here, the design and preparation of the dye 
library is unbiased to any speciﬁc target analyte so the library can be evaluated 
with quite distinct analytes to maximize the chance of applications in different 
ﬁelds. The effectiveness of this approach has been demonstrated with the 
impressive discoveries of novel sensors for organelle
14
, polymers such as 
DNA and heparin
15








Figure 1.4 Schematic diagram for diversity-oriented fluorescent sensor design 
 
1.3 Solid Phase Synthesis 
This DOFL approach needs quite efficient synthetic work with 
relatively easier chemistry to acquire a diverse set of dyes. A number of 
parallel synthesis methods for the synthesis of dye molecules in solution phase 
have already been reported
18
 in literatures. However, the methods comprise 
tedious purification steps along with typical low recovery yields. Although the 
synthesis of individual compounds could overcome this limitation, it would 
critically trouble the combinatorial derivatization of the fluorescent scaffold 
because of its labour intensive purification processes.  The challenges have 
been overcome by incorporating the solid phase methodologies in the 
synthesis process pioneered by Bruce Merrifield who first introduced this 
method for synthesizing peptide molecules
19
. In the process of solid phase 
synthesis, one of the reactant molecules is attached to an insoluble material i.e 
the solid support which can be easily modified in to the products by means of 
appropriate chemical reactions. Although this technique initially was used for 
peptide synthesis, later it was adopted for oligonucleotide
20
 synthesis.  
Recently, solid phase synthesis is broadly employed in combinatorial 
7 
 
chemistry for the development of the huge number of molecules in a very 
short time. One of the major advantages of the solid phase synthesis is that it 
can help to circumvent the technical difficulties related with the solubility and 
purification. In this method, purification is basically carried out by washing 
the resin with a variety of solvents. The use of suitable washing solvents or 
solvent mixtures can remove all the unbound impurities, by-products and the 
excess solution phase reagents entirely. An additional advantage of this solid 
phase synthesis is that the use of excess reagent can lead to the completion of 
the reaction with relatively higher yields. So far, a number of solid-phase 
methodologies have been successfully applied for diversifying the various 
ﬂuorescent scaﬀolds encompassing challenging puriﬁcation steps. Syntheses 
of libraries of cyanine 
21,22











) have been carried out on solid 
supports and hence demonstrated the effectiveness of this technique. One of 
the general Schemes for the solid phase synthesis is given in the Figure 1.5. 
 





Optical bio-imaging research labs mainly focus on the development of 




















 in living cells by means of ﬂuorescence microscopy. At 
present, ﬂuorescent probes based on small organic molecules have turn out to 
be crucial tools in modern biology as they offer dynamic information 
regarding the localization and quantification of the molecules of interest, 
exclusive of the requirement for genetic engineering of the sample. Practically, 
it is also quite desirable in the field of life science research that the techniques 
used should not comprise any invasive method, in other way it should not 
involve any experiment related with cutting into the body or isolating cellular 
components. Therefore, methods to visualize physiological or 
pathophysiological changes in the body or in other word in vivo imaging have 
become gradually more crucial in biomedical sciences. The bio-imaging probe 
consists of two apparent classes of probes. One is cell-based imaging probe to 
study the cellular events thoroughly and another is in vivo imaging probe for 
non-invasive detection and monitoring the different events. 
1.4.1 Cell imaging Probes or sensor: target oriented design 
Application of modern synthetic organic chemistry allows proficient 
modification on the chemical structure to obtain probes for particular 
biological experiments inside the cell. Here, often, the chemistry are used to 
activate fluorogenic compounds (fluorophores) by means of substrate specific 
enzymes and photoactivatable compounds that can facilitate the improvement 
of imaging experiments with low background ﬂuorescence. Many cases, 
rationally designed ligands attached in the fluorescent molecules which are 
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essentially cell permeable are used to discover the probes or sensors to 
understand the cell biology.  There are many reports on the development of 
cell imaging probes using the targeted design strategies with the various 
fluorescent scaffolds in the literatures. For instance, Jung et. al. in 2009 
developed a fluorescence quenching based copper sensor
34 
(Figure 1.6) where 
coumarin scaffold was intentionally attached with 2-picolyl group to obtain 
the  selective coordination with the Cu
2+ 
over other heavy metal ions. They 
also demonstrated the utility of this sensor in the cell imaging study.  
 
Figure 1.6 Confocal ﬂuorescence images of Cu2+ in LLC-MK2 cells. (a) 
Represents the brightﬁeld transmission image of LLC-MK2 cells. (b) 
Represents the fluorescence image of LLC-MK2 cells after incubation with 
Cu
2+
 sensor.  (c) to (e) stands for the fluorescence image of further incubation 
with addition of various concentrations of CuCl2 [(c) 5, (d) 10, and (e) 20 
equiv, respectively] and finally (f) fluorescence image corresponds to return of 
intracellular Cu
2+
 to the resting level was achieved by addition of EDTA (500 
µM). This picture has been copied from reference 34 under copyright 
permission.  
 
1.4.2 Cell imaging Probes or sensor: diversity oriented design 
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In connection to the development of imaging sensors or probes, the 
deficit of enough information at a molecular level for many biological events 
(e.g. protein–protein interactions, cellular differentiation stages35) and major 
dissimilarities between in vitro and living cell situations have barred the 
design of imaging probes by rational-based methodologies
36
. A useful 
substitute would be the diversity-oriented strategies, which methodically 
diversify the chemical structure and consequently facilitate the research in the 
development of imaging probes or sensors. Combinatorial approach for 
fluorescent libraries syntheses and their extensive cell based screening (Figure 
1.7) enable us to develop multiple probes or sensors efficiently and that would 
partially overcome our restricted capability of envisaging particular interaction 
between the biological actions and the designed fluorescent molecules. 
 
Figure 1.7 Schematic diagram for a development method of cell imaging 




Recently our group (Chang and co-workers) reported  a neural stem 
cell specific boron-dipyrromethane (BODIPY) derivative, compound of 
designation red 3 (CDr3)
37
 which has been developed through a high 
throughput/content screening of in-house generated diversity oriented 
fluorescence library in stem cells at different developmental stages. This novel 
compound specifically detects living neural stem cells of both human and 
mouse origin.  
 
Figure 1.8 Development of neural stem cell specific probe; Figure 1.8B 
image represent the selective Staining of NS5 by CDr3 where nuclei of E14, 
NS5, D-NS5, and MEF were visualized by Hoechst 33342; but only NS5 was 
selectively stained by CDr3. Figure 1.8C is the flow cytometry dot plot 
images of E14, NS5, D-NS5, and MEF incubated with CDr3. In this case, they 
12 
 
have added DMSO for unstained control cells. This picture has been copied 
from reference 37 under copyright permission.  
 
Chang et al. have also synthesized several diversity oriented libraries 
including rosamine, cyanine, chalcone, dapoxyl, bemzimidazol, libraries and 
evaluated their photophysical properties and successfully applied them in live 
cell imaging study that includes β-amyloid38, human serum albumin39, 
embyronic stem cell probe
40
, etc. 
1.5 In vivo imaging 
In vivo imaging is an approach where biology is studied at an 
organismal instead of the cellular, level. During the in vivo imaging, light is 
shone on animal subjects which are commonly mice or rats and then an 
answer in the form of a map of emitted light intensity as a function of 
anatomic position is derived (Figure 1.9) 
 





Among the different techniques of in vivo imaging, in vivo 
ﬂuorescence imaging using NIR light has a great potential for molecular 
diagnostics and therapeutic studies. In addition, there is another practical 
benefit too. As the in vivo imaging is non-invasive, animals may be tracked 
over time, for example to investigate as a tumor grows. 
1.6 NIR fluorophores 
As it is well known that the shorter wavelength dyes in the range of 
UV-Vis emissions are mainly used for  in vitro or cell imaging studies, 
therefore, NIR light absorbing dyes have attracted much interest for the 
development of the in vivo optical imaging probes. NIR light has been used 
enormously in biomedical applications due to its deep tissue penetration. UV-
visible light often has high autofluorescence and background limitations. In 
contrast, NIR light reduces the background problems and therefore paves the 
way for the NIR light absorbing dyes in the bio-imaging research. The benefits 
of imaging in NIR region are numerous: (a) the low absorbance from tissue 
allows a deeper tissue penetration; (b) low auto-fluorescence decreases the 
fluorescence background and (c) low Raman scattering makes very high signal 
to noise ratio. In recent time, the research spotlights on tissue imaging or in 
vivo imaging lead to the development of different NIR fluorophores. Till now, 









). Recently few limited 
structures from the BODIPY and rhodamine scaffolds have been reported as 








1.6.1 Tricarbocyanine dyes: in vivo imaging 
Among the available fluorophores, cyanine structures
44
 have been 
accepted as one of the best scaffolds compared to the other NIR dye scaffolds, 
especially for the development of imaging probes due to their synthetic 
accessibility, large molar extinction coefficient and broad wavelength 
tunability. Moreover, photo-switchable cyanine dyes are useful for high 
resolution microscopy (e.g. STORM and PALM
46
). However, major limitation 
15 
 
of cyanine dyes is the photobleaching or photodestruction characteristics. 
Cyanine dyes upon irradiation of light in presence of aqueous media 
undergoes the chemical reactions with the various reactive oxygen species 




, peroxide, superoxide and redox active 
metabolites and that leads to their degradation. Particularly, tricarbocyanine 
dyes are identified to be comparatively low photostable owing to their long 
conjugation. Very few reports about the photostability of cyanine dyes are 
available in the literature. To take up this challenge, our group developed a 
combinatorial approach to develop photostable tricarbocyanine library and 
screened them to identify best stable candidate, CyNA-414
48
 which has the 
stronger emission intensity and higher photostability than the NIR standard 
IndoCyanine Green (ICG). The possible reason hypothesized by our group 
that the modiﬁcation of the bridgehead nitrogen atom by removing lone pair 
electron would restrict the likelihood of forming iminium intermediate which 
is the presumed culprit for facilitating the incorporation of the reactive oxygen 
species in to the dye scaffolds. Therefore, various structurally diverse amine 
tricarbocyanine (CyN) compounds were modiﬁed with an electron-
withdrawing acetyl group to afford the corresponding acetylated compounds 
(CyNA) which showed remarkably improved photostability over the CyN 
(Figure 1.11). Later, Chang and co-worker modified the CyNA-414 
derivatives with the succcinimidyl ester (CyNE790)
49
 for the bioconjugation. 
The CyN790 dye was labled with the EGFR monocholnal antibody preserving 
the excellent photostability and NIR fluorescence intensity of the amine 
acetylated tricarbocyanine scaffold and applied this dye for in vivo NIR 
imaging. Theses superior property attracts me to opt out the CyNE-790 
16 
 
derivative to generate another set of NIR compounds which may have wide 
possibility to develop in vivo imaging probe (Figure 1.12). 
 
Figure 1.11 Design and synthesis for the photostbale cyanine compounds. 
This picture has been copied from reference 48 under copyright permission.  
 
Figure 1.12 Application of photostbale cyanine compounds in in vivo 
imaging. This picture has been copied from reference 49 under copyright 
permission.  
1.6.2 Tricarbocyanine dyes: SERS imaging 
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In recent times, the application of SERS in the sensitive detection of 






 or the 
investigation of sensitive biological samples are continuously increasing
53
. In 
this view, reporter molecules (i.e. Raman-active dyes) having thiol 
functionality are used to attach with the surface of silver or gold NPs with 
variable sizes (10–80 nm) to acquire SERS nanotags. The reproducibility and 
spectral intensity of these nanotags can be monitored by encapsulation and 
shielding from the environment. Now-a-days, the stable and biocompatible 
nanoparticles (NPs) have widely been used for SERS cellular imaging.  
 
Figure 1.13 Schematic diagram for high-throughput SERS screening strategy 
 
Antibody-conjugated gold nanoparticles (AuNPs) and nanorods have 
also been utilized to detect cancer using the target specific imaging technique 
where the cell surface of the cancer cell is highly expressed by the cancer 
markers. Therefore, the antibody-conjugated AuNPs which are attached with 
Raman reporter can selectively target the cancers cells and thereby provide the 
higher intensity SERS signal from the targeted cancer cells and allow their 
imaging and detection capability. For instance, epidermal growth factor 
receptor (EGFR)
54
 recognizing anitbodies have been conjugated to SERS 
nanotags and applied them to detect in vivo where the EGFR are over-
expressed in the human tumors
54
. NIR dyes (e.g.diethylthiatricarbocyanine 
18 
 
(DTTC)) have also been in used as the specific Raman reporters for in vivo 
surface-enhanced resonance Raman scattering (SERRS).
55
 Recently, Samanta 
et.al. synthesized lipoic acid-containing NIR-active tricarbocyanine library 
(CyNAMLA), and screened their SERS properties after chemisorption in 
AuNPs. Among them, they identified CyNAMLA-381 NIR SERS reporter
56
 
molecule which has a 12-fold higher sensitivity than the current standard 
DTTC. Next, they applied CyNAMLA-381 as the SERS probe for in vivo 
cancer imaging by conjugating CyNAMLA-381–AuNPs to scFv anti-HER2 
antibodies and that exhibits a very good SERS intensity and selectivity 
towards HER2-positive cancer cells under both Raman and dark-field 
microscopes. Later, Maiti et. al. developed  a novel multiplex SERS partners 
using the combination of  triphenylmethine and cyanine Raman reporters 
(B2LA and Cy3LA)
57
. Then, they derivatized nanotags (B2LA and Cy3LA) 
with anti- EGFR and anti-HER2 antibodies and demonstrated the speciﬁc 
recognition of their nanotags towards the respective cancer cells (e.g. OSCC 
and SKBR-3) with non-overlapping SERS peaks. Maiti et al. also developed 
another multiplexing partner (Cy7LA, Cy7.5LA and CyNAMLA-381)
58 
and 





Figure 1.14 In vivo multiplex detection in xenograft tumor:  SERS spectra 
from tumor site from EGFR positive nanotags. This picture has been taken 
from reference 58 under copyright permission.  
 
1.7 Scope and Outline 
It is quite  obvious  from the wide  literature reports discussed in the 
earlier section that  the progress of diversity oriented fluorescent library 
approach  along with the high throughput screening lead to the  novel bio-
imaging probes/sensors  discovery  in a  relatively faster manner. However, 
the case presented here, efficient solid phase chemistry needs to be devised to 
provide a robust synthetic route for generating a large number of fluorescent 
libraries in a short span of time. In this view, I aim to develop an elegant solid 
phase route to systemically apply in the synthesis of fluorescent libraries that 
cover wide emission color spectra from Vis to NIR. We aim to design the 
novel diversity oriented fluorescent libraries where each library contains 
single emission wavelength to develop both cell imaging and in vivo imaging 
probe. Single wavelength with different structural diversity may be useful as it 
allows easier structural activity relationships studies.  
The aims of this thesis are: 
1) Photostability is one of the key issues in NIR dyes and we previously 
reported a photostable CyNA library. To develop an ultra-photostable 
cyanine-based NIR fluorescence library, I designed and synthesized 
CyR library, utilizing the stability component of CyNA. Efficient solid 
phase chemistry was also devised to provide a robust synthetic route to 
the new NIR dye library. 
20 
 
2) To develop in vivo bioimaging probes, first, I derivatized CyR library 
with acetyl and chloroacetyl moiety to make CyRAC and CyRAC 
compounds respectively. Then, we screened these compounds against 
macrophage cells and found out an in vivo macrophage probe CyRCA-
341 in mouse inflammation model. 
3) To design multiplex partners using three different surface-enhanced 
Raman scattering (SERS) cyanine dyes (CyRLA-572, Cy7LA, and 
Cy7.5LA) for the multiplex detection of 3 different germ layers of 
differentiated mouse embryonic stem cells in vitro.  To find out 
CyRLA as the novel cyanine based Raman active dye, I incorporated a 
thiol linker motif (lipoic acid) to chemisorb an 55-member CyRLA 
library on gold nanoparticles (AuNPs) and then screened the full 
library and selected the most responsive compounds. 
4) To develop novel fluorescent small molecule probe for B-lymphocytes 
cell, cell-based screening was performed with the BDR library and its 
chlororacetyl (BDRAC) and actyl derivatives (BDRAC). Then, we 
found that the BDRCA-656 (CDg6) showed excellent B-cell staining 
selectivity over T-cell. Here, I synthesized BDR and its derivatives 
(BDRCA and BDRAC) using BODIPY as the core fluorescent scaffold 
and solid phase route as the synthetic technique.   
5) To develop M phase probe, Rhodol scaffold based library, RDR and its 
chloroacetyl (RDRCA) and acetyl derivatives (RDRAC) were screened 
and found a mitotic phase staining compound RDR-567, as the primary 
hit. The solid phase synthetic methodology was adopted to diversify 
the Rhodol scaffold to generate RDR and its derivatives. 
21 
 
6) To develop a coumarin based library and to apply in bio-imaging, I 
synthesized COR library, using diversity oriented solid phase synthetic 
methodology. Then, I derivatized COR library with chloroacetyl and 
acetyl moiety to generate CORCA and CORAC library. In order to 
explore the photo physical properties of COR, CORCA and CORAC 
compounds, full spectral characterisation was also carried out. 
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Solid Phase Synthesis of Ultra-Photostable Cyanine 




Near-infrared (NIR) ﬂuorescence (λmax: 700-1000 nm) has recently 
received substantial attention in various chemical and biological studies
1,2
. The 
advantages of NIR fluorescence are the deep penetrating ability through tissue 
and the significant reduction of auto ﬂuorescence which often come across in 
visible light emission. Therefore, NIR probes are extensively used in a broad 
range of biological research as in vivo imaging probe
3
, proteins labelling 
agent
4
 and fluorescence tag in DNA sequencing
5
. To date, a very limited 









been employed for organic NIR fluorophores. Among them, cyanine dyes
10
 
have attracted the most attention, due to their synthetic accessibility, broad 
wavelength tunability, and large molar extinction coefficient with moderate 
ﬂuorescence quantum yields. However, the photostabilty of the dyes 
diminishes significantly along with the increase of the -conjugation system. 
Especially, the photodegradation is a serious problem for the NIR cyanine 
dyes having absorbance λmax longer than 700 nm
11
. To overcome this 
limitation, our group has recently developed a photostable NIR cyanine dye 
library CyNA in which amine group of CyN was acetylated and thus the 
photoactivating lone pair electron was removed
12
. As a result, CyNA was 
much more stable than CyN in general, and CyNA-414 was selected as the 
most photostable dye among CyNA library (discussed in previous chapter).  
2.2 Objectives 
While a derivative of CyNA-414 was proved to be superior to 
currently available commercial NIR dye in in vivo mouse imaging
13
, to further 
improve the photostability, I aimed to design a new library utilizing CyNA-
28 
 
414 structure as the key component. Here, I aimed to synthesize the ultra-
photostable cyanine library using highly efficient and clean solid phase 
chemistry. The previous CyNA library was synthesized by solution phase 
chemistry and the laborious purification step was unavoidable.  Inspired by an 
efficient solid phase chemistry reported for cyanine dyes
14
, I designed a new 
solid phase route to secure pure NIR cyanine dyes library (CyR) in high speed 
manners by minimizing crucial purification step. 
2.3 Results and discussion 
2.3.1 Library design, characterization and photostability studies 
In order to synthesize CyR library (Scheme 2.1), firstly, 3-
bromopropylamine was loaded to the 2-chlorotrityl resin quite efficiently, and 
then, a broad range of structural diversity was introduced by a series of 
primary amines (Chart 2.1). Here, the nucleophilic displacement of bromide 
occurred in N-methyl-2-pyrrolidone (NMP) solvent under moderate heating 
condition, was carried out with primary amines to lead structurally diversified 
solid supported secondary amines.  The key intermediate 1 (CyNA-414 
derivative)
13
 was coupled to this solid phase amine building blocks (scheme 
2.1) by using standard acid-amine coupling protocol
15
. The final step of acidic 
cleavage from the solid supported compounds 2 yielded highly pure 80-
members of CyR library (average purity is 94% without further purification at 
365 nm, Table 2.2). It is noteworthy that the current synthetic protocol 
provides a linker motif with amino group incorporated in cyanine scaffold in 
addition to the structural diversity. The amino linker will be useful for further 
derivatization of the library compounds with various reporter or affinity tags 







Scheme 2.1 Synthesis of CyR library 
 
Reagents and conditions: (a) DIEA, THF, 3-bromopropylamine, r.t., 12 h.; (b) 
DIEA, RNH2, NMP, 70 
o
C, 12 h.; (c) HATU, DIEA, r.t. 24 h.; (d) 2% TFA in 




















Table 2.1 Characterization and purity determination by HPLC-MS, 
photophysical properties and preliminary photostability assessment of CyR 
library compounds and CyNA-414 by using the SpectraMax M2 












CyR 28 1025.8 1025.9 807 824 0.12 93 98 
CyR 32 947.6 947.6 806 822 0.11 92 89 
CyR 49 963.6 963.6 807 823 0.13 93 91 
CyR 77 947.6 947.7 806 824 0.10 96 90 
CyR 92 913.7 913.6 807 823 0.08 93 86 
CyR 100 1023.7 1023.6 807 823 0.12 92 92 
CyR 101 933.6 933.7 807 825 0.10 97 90 
CyR 103 963.6 963.7 807 822 0.10 95 93 
CyR 105 926.7 926.6 807 822 0.12 95 94 
CyR 111 934.6 935.6 807 823 0.10 92 92 
CyR 131 961.7 961.8 807 822 0.16 95 91 
CyR 135 987.5 987.5 806 822 0.08 91 89 
CyR 164 911.6 911.8 806 824 0.10 91 92 
CyR 165 901.6 901.6 807 822 0.10 93 94 
CyR 167 915.6 915.6 807 824 0.11 92 100 
CyR 177 887.6 887.6 806 823 0.10 92 93 
CyR 180 897.6 897.6 807 822 0.12 92 98 
CyR 185 899.6 899.6 807 824 0.10 91 96 

















CyR 218 937.6 937.6 807 822 0.13 92 82 
CyR 220 937.6 937.7 806 823 0.09 92 97 
CyR 221 953.6 953.6 807 822 0.12 93 91 
CyR 222 871.6 871.7 807 824 0.10 95 97 
CyR 230 941.7 941.7 807 823 0.10 91 96 
CyR 240 995.5 995.6 806 822 0.11 88 93 
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CyR 262 979.6 979.6 806 823 0.10 91 93 
CyR 272 940.7 940.6 806 822 0.11 91 95 
CyR 274 929.7 929.6 806 821 0.10 96 91 
CyR 275 961.7 961.6 807 822 0.08 91 88 
CyR 277 927.7 927.7 806 823 0.10 92 95 
CyR 282 942.7 942.7 807 822 0.10 90 91 
CyR 319 979.6 979.7 806 822 0.08 91 95 
CyR 323 915.6 915.6 806 821 0.14 90 94 
CyR 329 997.57 997.6 806 822 0.11 91 100 
CyR 330 988.3 988.6 806 823 0.10 96 91 
CyR 335 947.6 947.7 806 821 0.08 94 92 
CyR 341 997.5 997.7 806 821 0.11 94 100 
CyR 358 979.6 979.7 806 822 0.10 94 95 
CyR 359 978.6 978.5 807 823 0.10 94 94 
CyR 360 941.7 941.7 806 822 0.11 94 94 
CyR 361 964.6 964.5 807 822 0.13 95 90 
CyR 364 953.6 953.5 807 822 0.11 93 93 
CyR 368 998.7 998.7 807 822 0.13 95 91 
CyR 374 919.6 919.6 807 822 0.11 96 97 
CyR 375 937.6 937.6 807 823 0.09 94 94 
CyR 381 949.6 949.7 807 825 0.10 89 95 
CyR 384 941.7 941.7 807 822 0.13 96 100 
CyR 387 949.6 949.7 807 823 0.10 91 98 
CyR 388 949.6 949.7 806 823 0.12 92 89 
CyR 395 963.6 963.7 806 823 0.10 90 100 
CyR 396 933.6 997.8 807 822 0.10 98 100 
CyR 399 955.6 955.7 806 822 0.11 91 80 
CyR 403 953.6 953.6 807 823 0.11 93 100 
CyR 405 951.6 951.6 807 822 0.12 91 100 
CyR 407 969.7 969.7 806 821 0.10 92 100 
CyR 412 955.6 955.6 806 824 0.11 96 86 
CyR 414 968.7 968.6 807 823 0.12 94 94 
CyR 419 899.6 899.6 807 823 0.10 93 100 






 Quantum yields were measured in DMSO, using Cardiogreen as a standard 
(:0.13, in DMSO).16 *3 Quotients of fluorescent intensities after 8 h vs. 
fluorescent intensities (after 0 h), in a time-course fluorescence measurement 
using 10 M (1% DMSO) solutions in HEPES buffer (10 mM, pH 7.4). *2 
Purities were determined according to UV absorption at 365 nm. *
4 
CyNA-414 
was used as the standard for the photostability evaluation. 
2.3.2 Spectral properties of CyR library 
These compounds show the maximum absorption wavelengths around 800 nm 
and emission around 820 nm with an average quantum yield 0.1 (Table 2.1).   
CyR 425 899.6 899.7 806 824 0.09 94 94 
CyR 429 925.7 925.6 807 824 0.10 93 96 
CyR 439 913.7 913.6 807 823 0.12 94 94 
CyR 442 899.6 899.6 806 823 0.11 94 91 
CyR 446 909.6 909.7 806 821 0.12 93 92 
CyR 447 987.6 987.6 806 822 0.10 93 100 
CyR 477 951.6 951.5 806 823 0.10 91 91 
CyR 479 951.6 951.7 807 820 0.10 93 95 
CyR 526 969.7 969.7 807 824 0.12 92 100 
CyR 548 1009.7 1009.8 807 823 0.12 91 100 
CyR 554 955.7 955.6 807 822 0.12 92 92 
CyR 565 989.2 989.6 807 823 0.12 92 93 
CyR 572 933.6 1013.5 807 822 0.11 96 100 
CyR 574 899.6 899.7 806 822 0.10 92 100 
CyR 577 997.8 933.7 807 822 0.13 93 92 
CyR 599 1009.7 1009.7 807 823 0.12 89 90 
CyR 602 913.7 913.6 806 822 0.11 93 93 
CyR 677 967.6 967.6 806 824 0.10 91 100 
CyR 686 1001.6 1001.6 807 822 0.11 92 94 




Figure 2.1 Absorption and Emission spectra of a representative CyR library 
compounds 
 
2.3.3 Photostability evaluation  
To evaluate the photostability of CyR in comparison with CyNA and 
CyN, I examined the decrease of fluorescence intensity of the compounds 
under xenon lamp (6W/cm
2
) for 8 h. The average fluorescence intensity 
decreases of  CyNA and CyN compounds
12
 were around 17% and 70% 
respectively, whereas newly synthesized CyR library shows only 5% decrease 
by average (Table 2.1) reflecting the superior photostability in general. To 
differentiate the relative photostability among CyR compounds, we introduced 
a stronger light condition (UV Blak-Ray® B-100AP high intensity mercury 
lamp, 100W, 365 nm) to the whole CyR compounds and monitored the 
relative fluorescence intensity (F/F0) at 1 h and 2 h respectively (Table 2.2). 
Three most stable CyR compounds (CyR 167, CyR 387, CyR 526) were 
selected and further compared with representative CyN and CyNA compounds 
including CyNA-414 (structures available in Table 2.3, 2.4, 2.5) and the 
results are summarized in figure 2.1 It clearly shows that the three selected 
CyR compounds exhibit much better photostability compared to CyN and 
CyNA, even the previous best compound CyNA-414. 
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Table 2.2 Photostability evaluation of CyR library compounds and CyNA-





CyR 28 44 34 
CyR 32 55 43 
CyR 49 48 37 
CyR 77 44 39 
CyR 92 50 40 
CyR 100 56 48 
CyR 101 46 44 
CyR 103 52 39 
CyR 105 62 53 
CyR 111 51 41 
CyR 131 43 36 
CyR 135 54 42 
CyR 164 58 45 
CyR 165 60 47 
CyR 167 67 63($) 
CyR 177 59 50 
CyR 180 48 40 
CyR 185 55 43 
CyR 193 43 36 
CyR 201 57 48 
CyR 211 62 55 
CyR 218 51 39 
CyR 220 49 46 
CyR 221 41 37 
CyR 222 43 34 
CyR 230 63 52 
CyR 240 48 33 
CyR 262 43 32 
CyR 272 47 37 
CyR 274 48 42 
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CyR 275 43 35 







CyR 323 61 58 
CyR 329 51 40 
CyR 330 44 39 
CyR 335 51 37 
CyR 341 59 50 
CyR 358 45 40 
CyR 359 45 38 
CyR 360 57 39 
CyR 361 45 37 
CyR 364 56 47 
CyR 368 51 40 
CyR 374 62 57 
CyR 375 58 49 
CyR 381 45 39 
CyR 384 52 46 
CyR 387 70 68($) 
CyR 388 43 39 
CyR 395 62 50 
CyR 396 37 35 
CyR 399 49 41 
CyR 403 48 39 
CyR 405 45 36 
CyR 407 47 37 
CyR 412 47 36 
CyR 414 49 39 
CyR 419 42 36 
CyR 420 48 34 
CyR 425 61 57 
CyR 429 47 38 
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CyR 439 48 39 
CyR 442 45 38 







CyR 479 49 41 
CyR 526 69 60 ($) 
CyR 548 62 60 
CyR 554 48 38 
CyR 565 57 44 
CyR 572 61 54 
CyR 574 48 46 
CyR 577 44 35 
CyR 599 49 38 
CyR 602 53 40 
CyR 677 48 43 
CyR 686 51 36 
CyNA-414 51 47 
 
($) Best selected three compounds 
*
5
 Quotients of fluorescent intensities after 1 h vs. fluorescent intensities (after 
0 h), in a time-course fluorescence measurement under the strong Hg-lamp 
(high intensity UV radiation) using 10 M (1% DMSO) solutions in HEPES 
buffer (10 mM, pH 7.4). *
6
 Quotients of fluorescent intensities after 2 h vs. 
fluorescent intensities (after 0 h), in a time-course fluorescence measurement 
under the strong Hg-lamp ( high intensity UV radiation) using 10 M (1% 




2.3.4 Photostability comparison of best selected compounds 
 
Figure 2.2 Photostability assessments under strong UV irradiation in each 10 
min interval for 2 h of CyN, CyNA (including CyNA-414) and 3 selected CyR 
compounds. 1% DMSO in 10 mM HEPES buffer (pH 7.4) was used to 
dissolve the compounds at final concentration 10 M. The bar graphs exhibit 
mean fluorescence intensity after 1 h and 2 h. Values are means ± s.d acquired 
from three experiments. 
 
Table 2.3 Structures of best selected photostable CyR compounds compared 




Table 2.4 structures of the CyNA compounds used in high intensity UV 
condition 
 
 Table 2.5 Structure of CyN used in high intensity UV condition 
 
2.3.5 Kinetic analysis 
A further detailed kinetic analysis was performed for the three CyR 
dyes in comparison with CyNA-414 and the kinetic constant was measured 
(Table 2.6, Figure 2.3) showing the superior photostability of new CyR 
compounds to CyNA-414.  
 
Table 2.6 Decomposition rate constants of three selected compounds 













2.3.6 Detailed photodecomposition Study 
 Here for the photodecomposition study, 10 M CyR 526, CyR 387, 
CyR 167 and CyNA-414 solutions in 10 mM HEPES buffer (pH 7.4) 
containing 1% DMSO were placed in a 96-well black plate under the strong 
UV light, and fluorescence intensity measurements were performed every 10 
min for a total period of 2 h (excitation-emission: 790-820 nm).Values are 
fitted to a non-linear regression one-phase exponential decay (Figure 2.3). 
Rate constants of dye photodecomposition were acquired from the plots of -





Figure 2.3 Photodecomposition of CyR 167, CyR 387, CyR 526 and CyNA-
414  
 
2.4 Conclusions  
Photostability is one of the key issues in NIR dyes and we have 
previously reported photostable CyNA library. Here, we successfully designed 
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and developed an ultra-photostable cyanine-based NIR fluorescence library, 
CyR, utilizing the stability component of CyNA. Photostability evaluation 
reveals that the CyR library, in general, consists of the better photostable 
compounds compared to previous reported CyNA compounds. Moreover, 
three selected CyR compounds exhibit much better photostability compared to 
the previous best compound CyNA-414. The reported synthetic procedure is 
quite straightforward and practical to be applied to much bigger library 
construction with almost no purification step required. Therefore, the CyR 
library and derivatives might be an extremely useful tool box to develop novel 
in vivo bioimaging probes.  
2.5 Experimental methods 
Materials and Methods 
Amine building block and all other chemicals and solvents for the synthesis 
were purchased from the Alfa Aesar, Fluka, Acros, MERCK, and Sigma 
Aldrich and were used without any purification. Merck Silica Gel 60 (particle 
size: 0.04-0.063 mm, 230-400 mesh) was used for the normal phase column 
chromatographic purification. From BeadTech Inc., Korea, 2-chlorotrityl 
alcohol resin (1.37 mmol/g) was purchased. All the, CyN, CyNA derivatives 
which were previously synthesized by our group were used for the 
comparative photostability study with CyR derivatives. For analytical 
characterization of CyR compounds HPLC-MS (Agilent-1200 series) with a 
DAD detector and a single quadrupole mass spectrometer (6130 series) with 
an ESI probe was routinely used. Analytical process, except specified: eluents: 
A: H2O (0.1% HCOOH), B: ACN (0.1% HCOOH), gradient from 0 to 100% 
B in 4 min; C18 (2) Luna column (4.6 x 50mm
2






C-NMR spectra were recorded on both Bruker Avance 300 
MHz and 500 MHz NMR spectrometer, and chemical shifts are expressed in 
parts per million (ppm) and approximate coupling constants were calculated in 
Hz. Quantum yields and all other photophysical properties, photostability 
evaluation study of CyN, CyR and CyNA derivatives were performed in 
SpectraMax M2 spectrophotometer (Molecular Devices) instrument and the 
obtained data were analyzed using the Microsoft Office Excel 2007. In order 
to employ the strong UV irradiation to the compounds of interest, UVP Blak-
Ray® B-100AP high intensity mercury lamp (100W, 365 nm) at 2 cm distance 
was used. 
2.5.1 Synthesis and characeterization of cyanine derivatives 





Synthesis of CyN-414 
 
IR-780 iodide (600 mg, 0.9 mmol, 1 eq.) and 1-(3-aminopropyl)-2-
pipecoline (340 mg, 1.8 mmol, 2 eq.) were dissolved in ACN (2 mL), and 
N,N-diisopropylethylamine (DIEA) (174 L, 1.34 mmol, 1.5 eq.) was added. 
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The  reaction mixture was heated to  80 
o 
C for 40 min, and  the resulting blue 
color crude CyN-414 was neutralized with  0.1 N HCl  (aq.)  and  concentrated 
under vacuum. The crude product obtained was directly used for the next step 
synthesis of 1. 
Synthesis of 1 
 
The  crude compound CyN-414 was  dissolved  in DCM under N2 
atmosphere, and treated with excess DIEA (1.4 mL, 10.8 mmol, 12 eq.) and 
methyl 4-(chloroformyl)butyrate  (220 L, 1.34 mmol, 1.5 eq.) at 0 o C for 15 
min. The resulting green product (ester) was washed with 0.1 (N) HCl and 
brine, concentrated under vacuum. The obtained crude product (ester) was 
directly employed for next step synthesis. 
The crude product (ester) was dissolved in solvent mixture of 
CHCl3:THF:H2O:HCl(conc) (6:3:2:1)(v/v/v/v) (90  mL). The resulting mixture 
was stirred at 0
o
 C. After 5 min., the reaction mixture was refluxed at 80 
o
C  
for  12 h,  and monitored  by  LC-MS. After complete hydrolysis of the methyl 
ester, CHCl3 was added to the reaction mixture, and the organic layer was 
collected (3 x 40 mL), washed with water and purified by a normal-phase 
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silica column using DCM-MeOH (ranging from 100:0 to 88:12) as the eluting 
solvent. 
Characterization data for 1 (140 mg, 20% from IR-780 iodide) 
Characterization of Compound 1 
1
H-NMR (300  MHz,  CDCl3): δ 1.06  (t,  6H, J=7.5Hz),  1.24 (d, 3H, J=6.6 
Hz), 1.39 (m, 2H), 1.61 (s, 6H), 1.62 (s, 6H), 1.79-1.95 (m, 6H), 2.22 (t, 2H, 
J=7.8 Hz), 2.33  (t, 2H, J=6.6 Hz), 2.52-2.56  (m, 4H), 2.82  (t, 2H, J=5.4 Hz), 
2.87  (t, 2H, J=5.4 Hz), 2.96-2.98 (m, 2H), 3.09-3.12 (m, 1H), 3.36 (t, 4H), 
3.53 (t, 2H, J=6.6 Hz), 3.67 (t, 2H, J=6.6 Hz), 4.06 (t, 2H, J=4.2 Hz), 4.15 (t, 
2H, J=4.8 Hz), 6.15 (d, 1H, J=14.1Hz), 6.20 (d, 1H, J=14.1Hz), 7.07-7.38 
(m,8H), 7.51 (d, 1H, J=14.1Hz),  7.60 (d, 1H,  J=14.1Hz). 
13
C-NMR  (75 
MHz, CDCl3): δ 106.2,  110.6,  110.8,  114.9,  118.8,  122.3,  125.5,  125.6,  
127.7, 128.1, 128.6, 140.6, 140.9, 141.4, 142.1, 142.2, 144.6, 153.9, 160.9, 
161.4, 171.7, 172.5, 173.6, 174.3, 101.5,  101.9,  102.4, 11.6, 12.2, 19.5, 20.4, 
20.6, 20.7, 22.2, 22.9, 24.8, 28.1, 28.2, 28.3, 31.3, 32.3, 41.9, 43.9, 48.3, 49.1, 
49.3, 50.2, 51.8,  53.7,  60.4,   
ESI (HRMS) m/z (C50H69N4O3
+
), calc: 773.5364; found: 773.5351. 
Synthesis of CyNA-414 
The CyNA-414 was synthesized according to the reported procedure.
12
 
Preparation of 2-chlorotrityl chloride from 2-chlorotrityl alcohol resin  
Thionyl chloride (1.2 mL, 16.48 mmol, 3 eq) was added to 2-
Chlorotrityl alcohol resin (4g, 1.37mmol/g, 5.48 mmol, 1 eq) suspended in 40 
mL of anhydrous DCM. Then the solution mixture was shaken for overnight at 
room temperature. Then the resin was filtered and washed thoroughly with 
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DMF (3X 40 mL) followed by DCM (3X40 mL) and then the resin was dried 
in vacuum. 
General procedure for loading of solid supported 3-bromopropylamine  
(3.5 g, 15.75 mmol, 5 eq) 3-bromopropylamine was dissolved in THF 
(5 mL/g) and then (6 mL, 32.5 mmol, 10 eq ) DIEA was added to the solution. 
The resulting solution was then added to 2-chlorotrityl chloride resin (2.5 g, 
3.25 mmol, 1 eq, 1.3 mmol/g) suspended in dichloromethane (10 mL/g). After 
stirring for 12 h, the resin was filtered through 10 mL cartridge and washed 
with DMF (5X 40 mL), methanol (5X 40 mL), and dichloromethane (10X 40 
mL). The resin was then shaken with 20% MeOH in DMF for 2 h for the 
capping of excess 2-chlorotrityl chloride resin. The resin obtained was again 
washed with DMF (5X 40 mL), methanol (5X 40 mL), and dichloromethane 
(5X 40 mL) and then was dried using high vacuum. 
General procedure for synthesis of solid supported secondary amines 
For each reaction, resin (solid supported 3-bromopropylamine) (100 
mg, 0.1 mmol, 1 eq, 1 mmol/g) was suspended in 2 mL of N-
Methylpyrrolidone (NMP) in a 20 mL of glass vial. 7 eq of each amine (0.7 
mmol) and 14 eq of DIEA (1.4 mmol) were then added in 2 ml of the same 
solvent The reaction mixture was shaken for overnight at 70 
o
C temperature in 
the heat block and the resin was filtered through 10 mL cartridge and washed 
with DMF (5X 5 mL), methanol (5X 5mL), and dichloromethane (5X 5mL). 
The solid supported secondary amine resins obtained, were dried and used for 
next step reactions. 
General procedure for synthesis of CyR library 
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  To synthesize CyR library, each of (solid supported secondary amine) 
resin  (50 mg, 0.035 mmol, 1eq, 0.7 mmol/g ) was suspended in 3 mL of DMF 
in a 10 mL syringe then (28 mg, 0.07 mmol, 1 eq) 1 (30 mg, 0.77 mmol, 2.2 
eq),2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HATU) and (30 L, 0.168 mmol, 4.8 eq) DIEA were 
added. At a time 40 individual reaction mixtures were placed on orbital shaker 
for 24 h at room temperature and after complete the reaction the resin was 
filtered through 10 mL cartridge washed with DMF (5X 5mL), methanol (5X 
5mL), and dichloromethane (5X 5mL). The resin was dried under high 
vacuum to afford solid supported compounds resin 2 and then the 
subsequently the dried resin of 50 mg was treated with 2% TFA in 
dichloromethane (5 mL) for 10 min. The solution was drained to the 20 mL 
vial and then organic layer was washed with the saturated NaHCO3 solution, 
and then the organic layer was separated and dried using Speed Vacuum to 
afford the CyR library products. Each of CyR compound was solid and 
primarily characterized by LC-MS. The representative products are 





Representative CyR compounds characterization 





H-NMR (500 MHz, CDCl3): δ 1.03-1.64 (m, 18H), 1.61 (s, 6H), 1.64 (s, 6H), 
1.70-1.89 (m, 6H), 2.05 (m, 2H), 2.19-2.34 (m, 5H), 2.62-2.87 (m, 11H),  
3.38-3.60 (m, 4H), 3.67 (m, 2H), 3.69 (s, 3H), 3.8 (s, 2H), 3.99-4.06 (m, 6H), 
6.15 (d, 1H, J=13.85 Hz), 6.17 (d, 1H, J=13.85 Hz), 6.6-6.89 (m, 4H), 7.07-
7.37 (m, 8H), 7.54 (d, 1H, J=13.85 Hz), 7.57 (d, 1H, J=13.85). 
13
C-NMR  (75 
MHz, CDCl3): δ 11.60, 14.09, 15.02, 15.11, 20.41, 20.76, 22.66, 23.53, 24.74, 
25.08, 27.70, 27.75, 27.77, 28.02, 28.70, 29.67, 31.93, 32.21, 36.87, 41.34, 
44.80, 45.93, 48.61, 49.22, 49.26, 49.30, 66.11, 66.14, 66.84, 67.87, 101.76, 
101.96, 110.48, 110.54, 115.64, 117.97, 122.67, 125.49, 125.58, 127.89, 
128.52, 128.59, 140.87, 141.11, 141.23, 141.31, 141.94, 142.05, 142.09, 
153.36, 153.39, 161.76, 162.03, 172.38, 172.63, 173.90, 175.16 
ESI (HRMS) m/z (C58H87N6O3
+
) calc: 915.6834; found: 915.6864. 
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CyR 387 (12 mg, 52%) 
 
1
H-NMR (500 MHz, CDCl3):  1.04-1.59 (m, 12H), 1.65 (s, 6H), 1.66 (s, 6H), 
1.71-2.06 (m, 20H), 2.25-2.39 (m, 6H), 2.57-2.77 (m, 6H), 2.90-3.0 (m, 2H), 
3.30-3.46 (m, 11H), 3.67 (m, 2H), 4.01 (m, 4H), 6.14 (d, 1H, J=13.9 Hz), 6.13 
(d, 1H, J=13.85 Hz), 7.07-7.44 (m, 8H), 7.52 (d, 1H, J=13.85 Hz), 7.54 (d, 
1H, J=13.25 Hz). 
13
C-NMR  (75 MHz, CDCl3):  11.51, 11.56, 20.58, 20.78, 
21.02, 24.76, 28.03, 28.11, 28.13, 32.32, 32.64, 37.57, 42.33, 44.63, 44.98, 
45.93, 47.97, 49.09, 49.13, 49.20, 49.26, 50.44, 50.77, 51.46, 55.09, 55.17, 
56.59, 59.79, 101.66, 101.91, 110.64, 110.74, 110.82, 11.94, 112.60, 112.79, 
113.39, 114.47. 118.08, 118.26, 120.07, 121.38, 122.26, 122.45, 125.27, 
125.36, 125.42, 125.51, 128.31, 128.66, 129.89, 138.07, 141.00, 141.25, 
141.53, 142.22, 142.25, 150.30, 160.04, 161.69, 171.96, 172.16, 173.21, 
174.38 
ESI (HRMS) m/z (C61H85N6O3
+
) calc: 949.6678; found: 915.6671. 
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CyR 526 (17 mg, 55%) 
 
1
H-NMR (500 MHz, CDCl3): 0.88-1.77 (m, 16H), 1.24 (s, 6H), 1.20 (s, 6H), 
2.2 (m, 7H), 2.61 (s, 3H), 2.98 (m, 10H), 3.17 (m, 5H), 3.32 (m, 8H), 3.45-
3.65 (m, 11H), 3.98 (m, 2H), 4.21 (m, 1H), 5.35 (m, 2H), 6.42-7.13 (m, 12H). 
13
C-NMR  (125 MHz, CDCl3):  14.17, 14.23, 22.58, 22.60, 22.68, 26.40, 
29.15, 29.20, 29.38, 29.41, 29.62, 29.69, 30.68, 31.73, 31.75, 31.92, 39.50, 
39.68, 39.84, 40.01, 40.17, 40.34, 40.5, 59.00, 59.05, 59.13, 63.78, 64.06, 
67.80, 67.93, 114.62, 114.83, 115.15, 123.61, 124.28, 126.35, 131.80, 132.21, 
132.35, 133.68, 140.30, 140.46,  141.74, 141.83, 154.80, 155.01, 161.43, 
161.72, 162.22, 162.35, 162.70, 168.13, 168.59 
ESI (HRMS) m/z (C61H93N8O2
+
) calc: 969.7416; found: 969.7410. 





H-NMR (500 MHz, CDCl3):  1.10 (t, 6H, J=4Hz), 1.18 (d, 3H, J=5Hz), 
1.2(d, 3H, J=8.5Hz), 1.33(m, 2H), 1.43-1.45(m, 2H), 1.66(s, 12H), 1.88-
1.92(m, 6H), 2.02-2.04(m, 1H), 2.22(t, 2H, J=8Hz), 2.33 (t, 2H, J=5Hz), 2.51-
2.55(m, 4H), 2.75 (t, 4H, J=5Hz), 3.12 (m, 2H), 3.22-3.24 (m, 1H), 3.29 (t, 
4H, J=5Hz), 3.68 (t, 2H, J=5Hz), 4.03 (t, 2H, J=4.7Hz), 4.33 (t, 2H, J=5Hz), 
6.15 (d, 1H, J=14.5Hz), 6.34 (d, 1H, J=15Hz), 7.08-7.13 (m, 5H), 7.21-7.28 
(m, 5H), 7.49 (d, 1H, J=14Hz). 7.55 (d, 1H, J=15 Hz). 
ESI (HRMS) m/z (C63H89N6O2
+
), calc: 961.7042; found 961.7057 
CyR 477 (13 mg, 56%) 
 
1
H-NMR (500 MHz, CDCl3):  0.89 (t, 6H, J=7Hz), 1.10 (d, 3H, J=5Hz), 
1.28-1.34 (m, 2H), 1.64 (s, 12H), 1.828 (m, 2H), 1.91-1.94 (m, 2H), 2.04 (t, 
2H, J= 6Hz), 2.22 (t, 2H, J=8Hz), 2.228 (t, 2H, J=7Hz), 2.33 (t, 2H, J=5), 2.37 
(t, 2H), 2.49-2.58 (m, 4H), 2.77 (t, 2H, J=6Hz), 2.86 (t, 2H, J=7Hz), 2.89 (t, 
2H, J=7.5Hz), 2.94-2.96 (m, 2H), 3.03-3.05 (m, 1H), 3.45 (t, 4H), 3.58 (t, 2H, 
J=7Hz), 3.64 (t, 2H, J=8Hz), 4.01 (t, 2H, J=8Hz), 4.13 (t, 2H, J=6.5Hz), 6.07 
(d, 1H. J=14 Hz), 6.11 (d, 1H, J=14Hz), 6.97-7.05 (m, 4H), 7.07-7.2 (m, 8H), 
7.48 (d, 1H, J=14Hz), 7.54 (d, 1H, J=14Hz) 
ESI (HRMS) m/z (C61H84FN6O2
+




CyR 164 (15 mg, 52%) 
 
1
H-NMR (300  MHz,CDCl3):  0.825 (t, 6H, J=7.2Hz), 1.03 (d, 3H, J=7.2Hz), 
1.25-1.4 (m, 12 H), 1.61 (s, 12H), 1.79-1.91 (m, 6H), 1.84-1.89 (m, 2H), 2.0 
(t, 2H), 2.12 (t, 2H, J=3.3 Hz), 2.21 (t, 2H, J=7.8Hz), 2.31 (t, 2H, J=2.1Hz), 
2.41-2.52 (m, 4H), 2.71-2.76 (m, 4H), 2.95-3.0 (m, 4H), 3.25-3.26 (m, 1H), 
3.34 (t, 4H), 3.5-3.62 (m, 4H), 3.93 (t, 4H, J=3.9Hz), 6.0 (d, 1H. J=14.1 Hz), 
6.17 (d, 1H, J=14.1Hz), 7.0-7.39 (m, 8H), 7.54 (d, 1H, J=14.1 Hz), 7.47 (d, 
1H, J=14.1 Hz)  
ESI (HRMS) m/z (C61H84FN6O2
+
), calc: 911.6885; found 911.6882 
2.5.2 Photostability experiment  
Procedure: 1% DMSO in10 mM HEPES buffer (pH 7.4) was used for 
dissolving all the CyR derivatives and CyNA-414 compound. The final 
concentrations of all the compounds were 10 M. The compound solution 
were taken in 96-well black plate and then fluorescence intensity 
measurements were carried out in each 10 min interval for a total period of 8 h 
(excitation-emission 790-820 nm for CyR and CyNA compounds). For the 
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Monocyte/Macrophage Specific Fluorescent Probe 





3.1 Introduction  
The advances in molecular imaging enable development of tools to 
display and quantify molecular and cellular targets
1
 for in vivo disease 
imaging. This is especially due to the richness of new fluorescent/nuclear 
medicinal reporter technologies for tagging of many cellular and subcellular 
processes in vivo. Non-invasive molecular imaging methods allow detection of 
early pathophysiological changes before conventional radiological imaging 
techniques including ultrasound, MRI (Magnetic Resonance Imaging) and CT 
(Computed tomography) detect anatomical changes
2
.  Furthermore, this 
targeted imaging may detect molecular and cellular changes associated with 
inflammation prior to the onset of diseases. Therefore the application of 
molecular imaging to target inflammation has significant importance in 
clinical diagnosis of several major diseases. This is because chronic 
inflammation
3
 is related to the onset of many diseases that do not have 
permanent cure. Alzheimer disease (AD) is a neurodegenerative disease 
characterized by progressive memory loss and dementia
4
. The effective 
treatment to AD is defied unless the important factors leading to the cause of 
the disease is known. The initial stages of the disease involve oxidative 
induced inflammatory damaged to blood vessels and dysregulated amyloid 
metabolism and this has implications for early detection and therapy
5
.  





pylenamine oxime (HMPAO) are still considered as „gold standard‟9 nuclear 





methylpro-pylenamine oxime (HMPAO) are lipophilic
6
 compounds that can 







methylpro-pylenamine oxime (HMPAO) in imaging lies in its specificity as 










methylpro-pylenamine oxime (HMPAO) requires the ex-vivo labeling of the 
leucocytes and re-injecting the leucocytes back into the patient. This can lead 





 has emerged as inflammation targeting 
agent for PET imaging since immune cells including monocyte/macrophage 
show relatively high metabolic ability. 
18
F-FDG is a well-established 
diagnostic tool in oncology and suitable for clinical PET imaging due to 
relatively long physical half-life of 
18
F (110 min). However, 
18
F-FDG is a very 
non-specific tracer because it shows uptake in any type of cell with high 
glycolytic activity and may therefore provide a false-positive result.  
The characteristics of an ideal probe includes efficient accumulation and good 
retention in inflammatory foci, rapid clearance from background, no 
accumulation in non-target organs, no toxicity, early diagnostic imaging, ready 
availability and low cost, easy low-hazard preparation, differentiation between 
infection and low radiation burden
9







F-FDG meet all the criteria for an ideal probe, 
this project aims to develop a specific fluorescence probe that can bind to 
monocytes/macrophage cell lineage specifically offering accurate assessment 
ability of inflammation in vivo.  
 NIR region is highly suitable for in vivo imaging (e.g., deep tissue 
penetration, low auto-fluorescence background) and the utility of the NIR dyes 
extensively described
11-13
. Diversity oriented solid phase synthesis enables us 
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to provide a number of NIR compounds and subsequently apply them in live 
cell based high-throughput image screening technology, intending to find 
novel chemical probes to stain monocyte/macrophage specifically which have 
the potential for clinical application to assess inflammation in vivo.   
 
3.2 Objectives 
I synthesized CyRCA and CyRAC compounds by modifying the CyR 
library. By using cell based high throughput screening with these compounds, 
we found a macrophage probe, CyRCA-341 which specifically stained to the 
monocyte/macrophage cells. Then, the compound was utilized to detect 
inflammation in vivo of mouse to demonstrate the applicability of this NIR 
fluorescent. 
3.3 Results and discussion  
3.3.1 Design and synthesis 
In the Chapter 2, I have mentioned that the availability of reactive 
primary amine group in the CyR library allows us to modify the structure in 
further. Utilizing that possibility, I synthesized CyRCA and CyRAC 
compounds by applying the solid phase activated ester chemistry. To do that, 
firstly, active ester resins were prepared by treating the nitrophenol resin with 
chloroacetyl chloride (for CA) and acetyl chloride (for AC). The reaction 
between the resulting resin with the highly reactive primary amine of CyR 
library in the presence of catalytic amount of mild base NaHCO3 aﬀorded the 
corresponding CyRCA and CyRAC compounds (Scheme 3.1, Chart 3.1). The 
reaction was completed within 2 hours and the products were obtained after a 
simple ﬁltration with an average purity of above 90% without further 
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puriﬁcation (at 365 nm, Table 3.2 & 3.3). These compounds show 
fluorescence in the NIR range (average absorption 805 nm and emission at 
820 nm). The quantum yield of each molecule varied from 0.01 to 0.08 (Table 
3.1 & 3.2, Figure 3.1). 
Scheme 3.1: Synthesis of CyRCA and CyRAC compounds 
 
Reagents and conditions: (a) DCM/ACN (7:1), NaHCO3, r.t., 2 h. 
 
Figure 3.1 Absorption and Emission spectra of representative CyRCA and 
CyRAC compound 
 
Table 3.1 Characterization by HPLC-MS and photophysical property of 





















CyRCA 28 1101.8 1101.4 806 825 0.05 91 
CyRCA 32 1023.6 1024.3 806 825 0.05 90 
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CyRCA 49 1039.6 1039.2 806 825 0.02 89 
CyRCA 77 1023.6 1023.3 806 825 0.06 92 
CyRCA 92 989.7 989.3 806 825 0.05 92 
CyRCA 100 1099.7 1100.8 806 825 0.04 91 















CyRCA 111 1010.6 1010.3 806 825 0.04 91 
CyRCA 131 1037.7 1038.3 806 825 0.03 91 
CyRCA 135 1063.5 1064.2 806 825 0.02 90 
CyRCA 164 987.6 987.3 806 825 0.05 89 
CyRCA 165 977.6 978.3 806 825 0.04 92 
CyRCA 167 991.6 992.3 806 825 0.05 92 
CyRCA 177 963.6 963.6 806 825 0.04 91 
CyRCA 180 973.6 973.3 806 825 0.04 90 
CyRCA 185 975.6 976.3 806 825 0.02 88 
CyRCA 193 1075.7 1076.3 806 825 0.01 92 
CyRCA 201 1037.6 1037.3 806 825 0.01 91 
CyRCA 211 1009.6 1009.3 806 825 0.05 92 
CyRCA 218 1013.6 1013.3 806 825 0.03 93 
CyRCA 220 1013.6 1013.2 806 825 0.05 94 
CyRCA 221 1029.6 1030.2 806 825 0.05 94 
CyRCA 222 947.6 948.3 806 825 0.03 92 
CyRCA 230 1017.7 1018.3 806 825 0.02 95 
CyRCA 240 1071.6 1071.2 806 825 0.01 89 
CyRCA 262 1055.6 1055.2 806 825 0.05 91 
CyRCA 272 1016.6 1017.3 806 825 0.02 91 
CyRCA 274 1005.6 1005.3 806 825 0.05 90 
CyRCA 275 1037.6 1037.3 806 825 0.02 89 
CyRCA 277 1003.7 1003.3 806 825 0.04 92 
CyRCA 282 1018.6 1018.3 806 825 0.04 92 
CyRCA 319 1055.6 1055.3 806 825 0.04 91 
CyRCA 323 991.6 991.3 806 825 0.04 90 
CyRCA 329 1073.5 1074.6 806 825 0.04 88 
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CyRCA 330 1063.6 1063.3 806 825 0.05 92 
CyRCA 335 1023.6 1024.8 806 825 0.05 91 
CyRCA 341 1073.5 1075.1 806 825 0.05 91 
CyRCA 358 1055.6 1055.3 806 825 0.05 90 















CyRCA 364 1029.6 1030.2 806 825 0.04 91 
CyRCA 368 1074.7 1074.4 806 825 0.05 90 
CyRCA 374 995.6 996.2 806 825 0.02 88 
CyRCA 375 1013.6 1013.2 806 825 0.05 92 
CyRCA 381 1025.6 1025.3 806 825 0.01 91 
CyRCA 384 1017.7 1017.3 806 825 0.03 90 
CyRCA 387 1025.6 1025.2 806 825 0.05 89 
CyRCA 388 1025.6 1026.2 806 825 0.05 92 
CyRCA 395 1039.6 1040.3 806 825 0.03 92 
CyRCA 396 1009.6 1009.3 806 825 0.05 91 
CyRCA 399 1031.6 1031.2 806 825 0.05 90 
CyRCA 403 1029.6 1030.2 806 825 0.05 88 
CyRCA 405 1027.6 1029.3 806 825 0.03 92 
CyRCA 407 1045.7 1046.7 806 825 0.01 91 
CyRCA 412 1031.6 1031.2 806 825 0.04 92 
CyRCA 414 1044.7 1045.3 806 825 0.03 93 
CyRCA 419 975.6 975.3 806 825 0.06 94 
CyRCA 420 1004.6 1005.3 806 825 0.02 94 
CyRCA 425 975.6 975.3 806 825 0.05 92 
CyRCA 429 1001.6 1002.3 806 825 0.03 95 
CyRCA 439 989.6 990.3 806 825 0.05 89 
CyRCA 442 975.6 976.3 806 825 0.04 91 
CyRCA 446 985.6 985.2 806 825 0.05 91 
CyRCA 447 1063.6 1063.2 806 825 0.05 90 
CyRCA 477 1027.6 1029.2 806 825 0.05 89 
CyRCA 479 1027.6 1027.2 806 825 0.05 93 
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CyRCA 526 1045.7 1045.2 806 825 0.02 95 
CyRCA 548 1085.6 1086.3 806 825 0.05 94 
CyRCA 554 1031.7 1031.3 806 825 0.04 93 
CyRCA 565 1063.5 1063.2 806 825 0.05 94 
CyRCA 572 1087.5 1087.3 806 825 0.04 94 















CyRCA 602 989.6 989.3 806 825 0.03 92 
CyRCA 677 1043.6 1044.2 806 825 0.05 92 
CyRCA 686 1077.5 1078.2 806 825 0.03 91 
 
Table 3.2 Characterization by HPLC-MS and photophysical property of 





















CyRAC 28 1067.8 1067.7 805 825 0.06 90 
CyRAC 32 989.7 989.6 805 825 0.05 90 
CyRAC 49 1005.6 1005.6 805 825 0.03 95 
CyRAC 77 989.7 989.6 805 825 0.02 94 
CyRAC 92 955.7 955.6 805 825 0.04 91 
CyRAC 100 1065.7 1065.6 805 825 0.05 90 
CyRAC 101 975.7 976.6 805 825 0.05 95 
CyRAC 103 1005.7 1006.6 805 825 0.05 93 
CyRAC 105 968.7 968.6 805 825 0.05 93 
CyRAC 111 976.6 976.6 805 825 0.05 90 
CyRAC 131 1003.7 1004.6 805 825 0.04 93 
CyRAC 135 1029.6 1029.5 805 825 0.05 93 
CyRAC 164 953.7 953.6 805 825 0.02 94 
CyRAC 165 943.6 943.6 805 825 0.05 91 
CyRAC 167 957.7 957.6 805 825 0.05 90 
CyRAC 177 929.6 929.6 805 825 0.05 90 
CyRAC 180 939.6 939.6 805 825 0.02 90 
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CyRAC 185 941.7 941.6 805 825 0.04 89 
CyRAC 193 1041.7 1041.7 805 825 0.02 91 
CyRAC 201 1003.7 1041.6 805 825 0.05 92 
CyRAC 211 975.6 975.6 805 825 0.03 93 
CyRAC 218 979.6 980.6 805 825 0.05 94 
CyRAC 220 979.6 980.6 805 825 0.04 94 















CyRAC 240 1037.7 1037.6 805 825 0.04 90 
CyRAC 262 1021.6 1022.6 805 825 0.05 93 
CyRAC 272 982.7 982.6 805 825 0.02 93 
CyRAC 274 971.7 971.6 805 825 0.03 94 
CyRAC 275 1003.7 1004.6 805 825 0.05 91 
CyRAC 277 969.7 970.7 805 825 0.05 92 
CyRAC 282 984.7 984.6 805 825 0.03 92 
CyRAC 319 1021.6 1021.6 805 825 0.02 90 
CyRAC 323 957.7 957.6 805 825 0.01 90 
CyRAC 329 1025.6 1025.6 805 825 0.01 93 
CyRAC 330 1029.6 1030.6 805 825 0.03 91 
CyRAC 335 989.7 990.6 805 825 0.05 91 
CyRAC 341 1025.6 1025.6 805 825 0.03 91 
CyRAC 358 1021.7 1021.6 805 825 0.05 93 
CyRAC 359 1020.7 1021.6 805 825 0.05 94 
CyRAC 360 983.7 983.6 805 825 0.03 95 
CyRAC 361 1006.7 1006.7 805 825 0.04 94 
CyRAC 364 995.6 995.5 805 825 0.04 92 
CyRAC 368 1040.8 1041.7 805 825 0.02 93 
CyRAC 374 961.7 961.6 805 825 0.04 93 
CyRAC 375 979.7 979.5 805 825 0.05 96 
CyRAC 381 991.7 992.6 805 825 0.02 90 
CyRAC 384 983.7 983.6 805 825 0.02 91 
CyRAC 387 991.6 992.6 805 825 0.05 88 
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CyRAC 388 991.6 992.6 805 825 0.05 90 
CyRAC 395 1005.7 1006.6 805 825 0.05 91 
CyRAC 396 975.6 976.6 805 825 0.05 91 
CyRAC 399 997.6 997.6 805 825 0.05 90 
CyRAC 403 995.6 995.5 805 825 0.04 92 
CyRAC 405 993.6 993.6 805 825 0.02 91 
CyRAC 407 1011.7 1011.7 805 825 0.02 91 















CyRAC 420 970.7 970.6 805 825 0.04 93 
CyRAC 425 941.7 942.6 805 825 0.05 93 
CyRAC 429 967.7 968.6 805 825 0.05 90 
CyRAC 439 955.7 956.6 805 825 0.02 90 
CyRAC 442 941.6 941.6 805 825 0.04 91 
CyRAC 446 951.6 952.6 805 825 0.05 92 
CyRAC 447 1029.6 1029.6 805 825 0.04 93 
CyRAC 477 993.6 993.5 805 825 0.01 93 
CyRAC 479 993.6 994.6 805 825 0.03 91 
CyRAC 526 1011.7 1011.6 805 825 0.02 90 
CyRAC 548 1051.7 1051.6 805 825 0.02 90 
CyRAC 554 997.7 997.7 805 825 0.02 91 
CyRAC 565 1029.6 1030.5 805 825 0.03 93 
CyRAC 572 1054.0 1055.5 805 825 0.01 92 
CyRAC 574 941.7 942.6 805 825 0.02 90 
CyRAC 577 1039.8 1040.7 805 825 0.01 91 
CyRAC 599 1051.7 1052.6 805 825 0.05 90 
CyRAC 602 955.7 955.6 805 825 0.03 91 
CyRAC 677 1009.6 1009.6 805 825 0.02 92 
CyRAC 686 1043.6 1043.5 805 825 0.02 92 
 
3.3.2 Human Blood Cell Line Screening 
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In order to discover macrophage probe, CyRCA and CyRAC 
compounds were screened against a set of human macrophage/ macrophage 
related cells (cancer cells: HL60, U937, M) in presence of negative control 
Molt4 cell (T cells). After the fluorescence image intensity based analysis as 
well as visual confirmation, we found that one CyRCA compound (CyRCA-
341/CyRCA-E4) stained macrophage/ macrophage related cells more brightly 
than the negative control Molt4 cell (Figure 3.2). It is noted that the 
compound name CyRCA-341 and CyRCA-E4 are same where 341 represents 
the amine building block number according to our chemical inventory and E4 
represents the plate position of the compounds we screened. For the screening, 
dye has been used in 1 M concentration with 1 h incubation at 37 oC.  
 
 
Figure 3.2 Discovery of  Macrophage probe a) Chemical structure of 
macrophage probe, CyRCA-341 b)  Nuclei of  Molt4 (negative control cells) 
and HL-60, U937, M (macrophage related cells) were visualized by Hoechst 
33342 (middle panel); macrophage related cells were selectively stained by 
CyRCA-341(lower  panel). (Upper panel represents phase contrast bright-field 
(BF) images; fluorescent (FL) images obtained with DAPI and Cy7 filter set. 
Scale bar, 50 µm.  
3.3.3 Human Peripheral Blood Leucocytes Screening 
Molt 4, HL60 and U937 (T cell, myeloid cell and monocytes 
respectively) are all cancer cell lines which are derived from patients 
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diagnosed with leukemia. The difference in genetic expressions between 
cancer cell and normal cell can result in different phenotypic expressions. As 
such, compound staining specificity in cancer cell lines (Molt 4, HL60, and 
U937) might differ from normal cells (T cell, myeloid cell and monocytes). 
Therefore, the compounds were further tested on peripheral human blood and 
the result demonstrates that the compound shows specificity towards 
monocytes/macrophage (Figure 3.3). CyRCA-E4/341 was incubated at 5 M 
concentration at 37 
o
C for 1 h. 
 
Figure 3.3 Discovery of  Monocyte/macrophage probe a) Chemical structure 
of macrophage probe, CyRCA-341 b)  Nuclei of  T Lymphocytes , 
Granulocytes , Monocytes and M were visualized by Hoechst 33342 (middle 
panel); monocytes and macrophage cells were selectively stained by CyRCA-
341(lower  panel). (Upper panel represents phase contrast bright-field (BF) 
images; fluorescent (FL) images obtained with DAPI and Cy7 filter set. Scale 
bar, 200 µm.  
3.3.4 Mouse macrophage probe 
After discovering the human monocytes/macrophage probes, it is time 
to check quickly whether the same compound can be applied in mouse 
macrophage case or not, as our eventual goal is to apply our probe into the 
mouse inflammation model. To quickly verify this, RAW (mouse macrophage 
cell line) cells were treated with CyRCA-E4/341 and the staining was 
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investigated. Our probe nicely stained to the mouse macrophage too (Figure 
3.4). 
 
Figure 3.4 Mouse macrophage staining; nuclei of RAW cells were visualized 
by Hoechst 33342 (left); RAW cells were stained by CyRCA-341(right) 
fluorescent (FL) images obtained with DAPI and Cy7 filter set. Scale bar, 50 
µm. Total x100 magnification. 
3.3.5 In Vivo imaging with LPS Induce inflammation Model 
To check the applicability of our probe, first, inflammation was 
generated to the right paw of a   mouse by using LPS injection (3 days, 
1mg/kg LPS). Then, the NIR fluorescence image (IVIS: Perkin Elmer) was 
taken after intravenous (tail vein injection) treatment of CyRCA-E4/341 
compound. The imaging result indicates that our probe can comparatively 
enter more into the inflammation area over the healthy regions (Figure 3.5). 
CyRCA-341 was treated with 100 M concentration and the image was taken 




Figure 3.5 Inflammation detection in vivo a) LPS induced inflammation (three 
day after injection of 1 mg/Kg LPS)  into the right paw of the mouse b)  NIR 
fluorescence image (excitation 745 nm and emission 820 nm); Image was 
taken using IVIS (Perkin Elmer ) machine, 1 h after the tail vein injection of   
200 L (100 M)  probe c) (CyRCA-341).  
 
3.3.6 In Vivo Imaging with Hind Limb Ischemia Model
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Applicability of this probe was further tested by comparing our probe 
with ICG which is known to be regularly used in macrophage detection. To do 
that Hind limb Ischemia model was utilized to produce inflammation 
(Ischemia) in the hind limb area of a mouse using artery ligation method. 5 
days after artery ligation, 100 M of ICG and CyRCA-E4/341 were treated 
separately through the tail vein injection of two individual mice and then 2 h 
after fluorescence images were taken with IVIS machine. Imaging results 
show that our probe can more specifically enter to the inflammation area 




Figure 3.6 Inflammation detection in vivo ; (Right panel) NIR fluorescence 
image was taken using IVIS (Perkin Elmer ) machine, 1 h after the tail vein 
injection of   200 L of 100 M ICG. (Left) NIR fluorescence image 
(excitation 745 nm and emission 820 nm) was taken using IVIS (Perkin Elmer 
) machine, 1 h after the tail vein injection of   200 L (100 M)  CyRCA-341.  
 
To have a better view of the image from Ischemia model, fluorescence 
combined with X-ray image was taken using In Vivo MS FX PRO 
(Carestream) machine. The inflammation area in the hind limb area can now 




Figure 3.7 Inflammation detection in vivo using Hind Limb Ischemia Model; 
inflammation was induced 5 day after femoral artery ligation of mouse. 
Fluorescence plus X-ray image was taken using MS FX PRO (Carestream) 
machine, 2 h after tail vein injection of CyRCA-341. Scale bar 1.58 inch. Cy7 
filter set. 
 
3.3.7 Histological Identification of macrophage staining area 
To confirm the specificity of macrophage probe and also to validate 
that the inflammation causes due to macrophage, the macrophage staining area 
from the hind limb inflammation region was identified. Figure 3.8 
demonstrates the histological identification experiment where macrophage 
specific antibody (CD11b+) was employed to identify the existence of 
macrophage in the inflammation area. „Hot spot‟ area identified by in vivo 
animal imaging (orange frame in a)) is characterized by CD11b+ 
monocyte/macrophageinflux. Immunohistochemistry for CD11b was 
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performed on 10-mm cryosection corresponding to the area that revealed 
enhanced CyRCA-341 signal by in vivo fluorescence imaging. The CD11b 
expression in the entire region of interest, indicated by the frame in a), is 
shown in b), where both the „hot spot‟ area (orange frame) and the „cold spot‟ 
area (blue frame) were identified. 
 
Figure 3.8 Histological Identification of macrophage staining area; The „hot 
spot‟ area was characterized by massive macrophage infiltration (upper panel) 
compared with the „cold spot‟ area (lower panel). (Upper panel)  (left) bright 
field phase contrast image, (middle) Hoechst staining image, (right)  
fluorescence image of Cy7 conjugated CD11b+ antibody ; (lower panel) 
Images for non inflammation area; (left) bright field phase contrast image, 
(middle) Hoechst staining image, (right)  fluorescence image of Cy7 




In summary, I have synthesized the acetyl and chloroacetyl version of NIR-
cyanine dye library. Then, we have developed a novel in vivo imaging probe, 
CyRCA-341 for inflammation detection which exhibits comparable staining 
selectivity as well as monocyte/macrophage specificity.  
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3.5 Experiment and Methodology 
3.5.1 Characterization data of representative CyRCA and 
CyRACcompounds 
CyRCA-341(10 mg, 30%) 
 
1
H-NMR (500 MHz, CDCl3); δ 1.05-1.58(m, 12H), 1.63 (s, 6H), 1.64 (s, 6H), 
1.67-2.0 (m, 9H), 2.19-2.23 (m, 6H), 2.45-2.72(m, 6H), 2.91 (m, 2H), 3.16-
3.36 (m, 11H), 3.68 (m, 2H), 3.98 (m, 4H), 4.14 (s, 2H), 6.10 (d, 1H, J=14 
Hz), 6.11 (d, 1H, J=14 Hz), 7.06-7.39 (m, 11H), 7.53 (d, 1H, J=11.5 Hz), 7.54 
(d, 1H, J= 14 Hz), 7.71 (m, 1H). ESI-MS m/z (M 
+
), calc‟d: 1073.5, found 
1075.1 (due to bromine isotope) 
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LC-MS spectra of CyRCA-341 
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CyRCA-477 (12 mg, 32%) 
 
1
H-NMR (500 MHz, CDCl3): δ 1.19-1.52(m, 12H), 1.57 (s, 6H), 1.58 (s, 6H), 
1.72-1.90 (m, 9H), 2.14-2.20 (m, 6H), 2.66-2.83(m, 6H), 2.92 -3.11 (m, 15H), 
3.27-3.30 (m, 2H), 3.94 (s, 2H), 3.95 (m, 4H), 6.04 (d, 1H, J=13.5 Hz), 6.07 
(d, 1H, J=13 Hz), 6.95-7.20 (m, 12H), 7.43 (d, 1H, J=13 Hz), 7.49 (d, 1H, 
J=13 Hz). ESI-MS m/z (M 
+
), calc‟d: 1027.6, found 1027.4 
CyRCA-167 (9 mg, 27%) 
 
1
H-NMR (500 MHz, CDCl3): δ 1.05-1.64 (m, 20H), 1.63 (s, 6H), 1.65 (s, 6H), 
1.69-1.97 (m, 8H), 2.01-2.37 (m, 5H), 2.51 -3.12 (m, 11H), 3.21-3.36 (m, 
11H), 3.68 (m, 2H), 3.97-399  (m, 6H), 6.10  (d, 1H, J=14 Hz), 6.12 (d, 1H, 
J=14 Hz), 7.05-7.37 (m, 8H), 7.52 (d, 1H, J=14 Hz), 7.53 (d, 1H, J=14.5 Hz). 
ESI-MS m/z (M 
+
), calc‟d: 991.7, found 991.6 
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CyRCA-358 (12 mg, 35%) 
 
1
H-NMR (500 MHz, CDCl3 ): δ 1.06-1.59 (m, 12H), 1.66 (s, 6H), 1.67 (s, 6H), 
1.70-2.0 (m, 14H), 2.21-2.77 (m, 12H), 3.29 (m, 2H), 3.64-3.86 (m, 13H), 
3.99-4.03 (m, 4H), 6.10 (d, 1H, J=13 Hz), 6.13 (d, 1H, J=13 Hz), 7.06-7.36 
(m, 12H), 7.53 (d, 1H, J=13.5 Hz), 7.54 (d, 1H, J=13.5 Hz). ESI-MS m/z (M 
+
), calc‟d: 1025.6, found 1025.1 
CyRAC-341 (8 mg, 28%) 
 
1
H-NMR (500 MHz, CDCl3): δ 1.05-1.58(m, 12H), 1.63 (s, 6H), 1.64 (s, 6H), 
1.67-2.0 (m, 9H), 2.19-2.23 (m, 6H), 2.45-2.72(m, 6H), 2.91 (m, 2H), 3.16-
3.36 (m, 11H), 3.68 (m, 2H), 3.98 (m, 4H), 4.14 (s, 2H), 6.14 (d, 1H, J=14 
Hz), 6.17 (d, 1H, J=14 Hz), 7.04-7.39 (m, 11H), 7.53 (d, 1H, J= 4 Hz), 7.56 
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(d, 1H, J=15 Hz), 7.70 (m, 1H). ESI-MS m/z (M 
+
), calc‟d: 1039.6, found 
1041.1(due to bromine isotope). 
Materials and Methods 
Amine and few bromide building block and all other chemicals and 
solvents for the synthesis were purchased from the Alfa Aesar, Fluka, Acros, 
MERCK, and Sigma Aldrich and were used without any purification. Merck 
Silica Gel 60 (particle size: 0.04-0.063 mm, 230-400 mesh) was used for the 
normal phase column chromatographic purification. From BeadTech Inc., 
Korea, 2-chlorotrityl alcohol resin (1.37 mmol/g) was purchased. For 
analytical characterization of CyRCA and CyRAC compounds HPLC-MS 
(Agilent-1200 series) with a DAD detector and a single quadrupole mass 
spectrometer (6130 series) with an ESI probe were used. Analytical process, 
except specified: eluents: A: H2O (0.1% HCOOH), B: ACN (0.1% HCOOH), 
C18 (2) Luna column (4.6 x 50mm
2
, 5m particle size) was used. 1H-NMR  
spectra were recorded on 500 MHz NMR spectrometer, and chemical shifts 
are expressed in parts per million (ppm) and approximate coupling constants 
were calculated in Hz. Quantum yields and all other photophysical properties 
of CyRCA and CyRAC derivatives were performed in Spectramax M2 
instrument and the obtained data were analyzed using the Microsoft Office 
Excel 2007.  
3.5.2 Cell preparation and screening  
Preparation of U937 Medium: U937 medium was prepared by adding 
500mL of RPMI medium, 5% (vol/vol) FBS (Fetal Bovine Serum), 
1%(vol/vol) Glutamax, 1% (vol/vol) Pen Strep (Penicillin Streptomycin) and 
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1%(vol/vol) NEM NEA (NEM non-essential amino acids). The medium was 
mixed and filtered using 0.22um filter system and stored at 4 ⁰C. 
Preparation of Freezing Medium: Freezing medium was prepared by adding 
50mL of FBS (Fetal Bovine Serum) and 5% (vol/vol) DMSO (Dimethyl 
Sulfoxide). DMSO was filtered using 0.20um filter before it was added into 
FBS. The medium was stored at -20 ⁰C. 
 Cell Growth and Cell Storage 
The cell lines (Molt 4, HL60 and U937) were purchased and grown in 
200 mL, growth area 75cm
2
 cell flask, containing 10 mL of U937 medium at 
37 ⁰C. Cells growth was maintained by replacement of fresh U937 medium 
every 1 to 2 days. To change cell medium, the cell solution contained in the 
cell flask was transferred to a 50mL tube and was centrifuged at 1500 rpm, 10 
minutes and 21 ⁰C.  After centrifugation, the supernatant was aspirated and 20 
mL of U937 medium was added to the cell pellet and re-suspended. Next, 10 
mL of cell solution was transferred to a new cell flask and the remaining 10 
mL of cell solution was transferred to a 15 mL tube, centrifuged using the 
same setting and the supernatant was aspirated and cell pellet was re-
suspended in freezing medium. The cells suspended in freezing medium were 
counted using manual cell counting (appendix) and was stored at -80 ⁰C. 
Macrophages were derived from U937 cell line by adding 15L of 
100 M of PMA (Phorbol 12-myristate 13-acetate dissolved in DMSO)8 in a 
10 cm cell dish containing 2x10
6
 U937 cells in 10 mL medium.  The cells 
were incubated for 1 day at 37 ⁰C. The attached macrophages were removed 
from cell dish by firstly aspirating the cell medium. Next, the cells were 







 at pH 7.3) and DPBS was aspirated. 1 mL of 0.25% Trypsin-
EDTA 1x was added to cell dish and incubated for 4 minutes at 37 ⁰C. After 4 
minutes, macrophages were detached as (observed from microscope) from cell 
dish and 10mL of U937 medium was added. The cell solution was transferred 
into a 15mL tube and centrifuged at 1500 rpm, 10 minutes and 21 ⁰C. The 
supernatant was removed and the cell pellet was re-suspended in U937 
medium and the number of macrophages was counted.  
Human Blood Screening Experiment  
40 mL of human blood was extracted by Pilip William Kuchel, M.D 
from a volunteer (Ethnic group: Indian, Age: 30+, Sex: Male). Mononuclear 
cells and granulocytes were isolated from human blood using Ficoll- Paque 
separation media (GE Healthcare, Isolation of mononuclear cells, 
methodology and applications). Monocytes and T cells were further separated 
from mononuclear cells by negative magnetic separation. Monocytes were 
obtained by using BD IMag Streptavidin particles and BD IMag human 
monocyte Enrichment set (BD IMag, Human Monocyte Enrichment Set DM) 
while T cells were obtained by using BD IMag Streptavidin particles and BD 
IMag Human T lymphocyte Enrichment Set(BD IMag, Human T Lymphocyte 
Enrichment Set). Macrophages were differentiated from monocytes by 
incubation of 1×10
7
 monocytes with 10 mL of RPMI medium containing 40 
L of 50 L/mL M-CSF (Macrophage Colony-stimulating factor).  After the 
cells were separated, (T cell, granulocytes, Monocytes and Macrophages), the 
cells were screened with Nikon Ti microscope.  
3.5.3 General synthesis procedure  
General procedure for the synthesis of p-nitrophenol resin  
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In a 50 mL polystyrene cartridge, to an amino polystyrene resin (1 g, 
1.2 mmol) in DMF (15 mL) were added 4-hydroxy-3-nitrobenzoic acid (1 g, 
5.5 mmol), HOBt (1 g, 7.4 mmol), and DIC (1 mL, 6.4 mmol). After overnight 
shaking, the reaction mixture was washed with DMF (20 mL, 5 times), DCM, 
and methanol (20 mL, 5 times alternatively). To remove any undesirable side 
product, DMF (5 mL) and piperidine (0.5 mL) were added to the cartridge and 
allowed to shake for 1.5 h. The resin was filtered and washed with DMF (20 
mL, 5 times). The resulting piperidine salt was removed via the addition of a 
10% HCl solution (in DMF, 20 mL) and was allowed to shake for 1.5 h. The 
resin (1 g) was then filtered; washed with DMF, methanol, and DCM (20 mL, 
5 times each); and dried by nitrogen gas flow. This nitrophenol resin (1 g, 1 
mmol, 1eq.) was then suspended in DCM and then 7 eq. of DIEA (7 mmol, 
1.22 mL) followed by 5eq of chloroacetyl chloride at 0 
o
C was added under 
nitrogen and then the stirred slowly at room temperature for 4 hours. Resin 
was filtered through the syringe fitted with cartridge and then washed with 
DMF (5X 10 mL) , DCM (5X 10mL) and then dried over vacuum to get active 
ester resin. 
General procedure for synthesis of CyRCA and CyRAC library 
To synthesized CyRCA library, each of 1 mol CyR library compound 
(80 compounds) was taken according to their plate code in the 2 mL of 96-
deep well plate. About 30 mg (~ 20 mol, 20 eq.) of active-ester resin was 
added to the each well of the CyR library containing plate. Then, DCM:ACN 
(7:1) solvent mixture of around 500 L and catalytic amount of saturated 
solution of NaHCO3 were poured in to each well. The plate was kept in the 
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shaker with moderate shaking for 2 hours. Then, the solution was filtered from 
the resin and dried to obtain pure products.  
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Multiplexing SERS nanotags for in vitro Detection of 
Differentiated Mouse Embryonic stem cells (mESc)  
 




























High spectral sensitivity of SERS nanotags is extensively useful in 
multiplexing detection in the bio-analytical applications. The multiplexing 
capability derives because of its narrow bandwidths of the Raman spectra of 
the associated reporter molecules. Therefore, it offers a precious chance for 
the simultaneous identification of closely connected targets.
1-3 
Maiti et al 
recently accomplished the multiplex detection of cancer cells using cyanine 
and triphenylmethine based SERS nanotags.
4
 Here, they used the different 
antibody-conjugated SERS nanotags simultaneously (e.g. anti-EGFR and anti-
HER2) to recognize different types of cancer cells (i.e. OSCC and SKBR-3 
respectively) utilizing a single excitation wavelength.  In vitro multiplexing of 
cell lines detection using SERS nanotags of commercial RMs has also been 
recently studied.
5
 Additionally, Maiti et al demonstrated the applicability of 
polymethine cyanine dyes as multiplex partners that can clearly identify the 
various tumors in vivo
6
. Recently, the application of pluripotent stem cell 
therapies in clinical study faces a major threat due to the potential teratoma
7
 
formation. A teratoma is a monstrous mass/tumor
7 
that consists of tissue from 
all three germ layer (ectoderm, mesoderm, and endoderm) formation. Hentze 
et al. demonstrates the semiquantitative histopathological analysis of the 
teratomas
8 
that includes several cell lines, injection sites and cell numbers.  
Motivated by all these researches, we aimed to simultaneously detect different 
germ layer of a mESc in vitro as it exists in teratoma. As a tool, SERS 





Here, SERS nanotags were prepared to obtain the simultaneous 
detection of three different germ layer of teratoma. To do that, we first 
synthesized the lipoic acid-containing cyanine derivatives, CyRLA a 55 
memberd library and screened them to identify CyRLA-572 as an NIR SERS 
reporter with excellent sensitivity. Later, we evaluated the multiplexing 
capacity of this CyRLA-572 with our previously reported highly sensitive 
SERS active cyanine dyes, Cy7LA and Cy7.5LA under a single excitation 
wavelength (e.g. 785 nm laser). These cyanine based SERS nanotags have 
been then applied for the detection of different layers of mESc in in vitro using 
different antibodies. Specifically, multiplex antibody-conjugated SERS 
nanotags (anti-CD34, anti-CD184, anti-Notch1) that recognize different types 
of germ layer of teratoma (mesoderm, endoderm and ectoderm respectively) 
were applied to detect different layer of differentiated mESc using a single 
excitation wavelength. Multiplex peaks were also identified from three 
different nanotags. 
4.3 Results and discussion  
4.3.1 Design and synthesis  
Chang et al. recently, developed the combinatorial approach to identify 
cyanine based Raman reporter. Encouraged by this strategy, I have 
synthesized the lipoid acid containing 55 memeber, cyanine dye library, 







Scheme 4.1: Synthesis of CyRLA library 
 
Reagents and conditions: (a) DCM/ACN (7:1), NaHCO3, r.t., 6 h. 
 










 abs/nm em/nm 
CyRLA-677 1155.7 1155.6 90 803 820 
CyRLA-599 1197.7 1197.6 94 803 820 
CyRLA-396 1121.7 1121.6 82 803 821 
CyRLA-221 1141.7 1141.6 84 805 820 
CyRLA-358 1137.7 1137.6 93 804 822 
CyRLA-574 1087.7 1087.6 90 802 820 
CyRLA-262 1167.7 1167.6 86 803 820 
CyRLA-565 1175.6 1175.5 93 801 819 
CyRLA-330 1175.7 1175.5 92 804 820 
CyRLA-329 1185.6 1185.7 89 802 823 
CyRLA-335 1135.7 1135.6 93 801 820 
CyRLA-388 1137.7 1137.6 92 802 819 
CyRLA-399 1143.7 1143.6 92 803 820 
CyRLA-479 1139.7 1139.6 93 804 823 
CyRLA-548 1197.7 1197.6 82 803 820 
CyRLA-222 1059.7 1059.6 90 802 821 
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CyRLA-447 1175.7 1175.6 81 803 822 
CyRLA-360 1129.7 1129.6 91 804 823 
CyRLA-319 1167.7 1167.6 89 801 820 
CyRLA-240 1183.7 1183.6 92 802 820 
CyRLA-193 1187.8 1187.7 93 803 819 
CyRLA-384 1129.8 1129.7 83 802 820 
CyRLA-275 1149.7 1149.6 84 804 820 
CyRLA-92 1101.7 1101.7 89 801 820 
CyRLA-111 1122.7 1122.6 72 803 821 
CyRLA-165 1089.7 1089.6 89 802 820 
CyRLA-167 1103.7 1103.6 92 803 822 
CyRLA-405 1139.7 1139.6 93 801 820 
CyRLA-341 1185.6 1185.5 92 803 820 
CyRLA-414 1156.8 1156.7 93 801 819 
CyRLA-477 1139.7 1139.6 92 803 820 
CyRLA-554 1143.8 1143.7 93 802 823 
CyRLA-572 1199.6 1199.5 92 805 820 
CyRLA-100 1211.8 1211.7 91 803 819 
CyRLA-180 1085.7 1085.6 92 804 820 
CyRLA-211 1121.7 1121.6 93 803 823 
CyRLA-274 1117.7 1117.6 92 802 820 
CyRLA-359 1166.7 1166.6 90 803 821 
CyRLA-403 1141.7 1041.6 91 802 822 
CyRLA-442 1087.7 11087.7 92 803 823 
CyRLA-602 1101.7 1101. 6 85 804 820 
CyRLA-32 1121.7 1121.6 89 802 820 
CyRLA-177 1075.7 1075.6 81 803 821 
CyRLA-361 1152.7 1152.6 82 802 820 
CyRLA-375 1125.7 1125.6 75 804 822 
CyRLA-412 1143.7 1143.6 85 803 820 
CyRLA-429 1113.7 1113.6 90 803 820 
CyRLA-135 1175.6 1175.5 92 801 819 
CyRLA-201 1149.7 1149.6 92 804 820 
CyRLA-374 1107.7 1107.6 91 805 823 
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CyRLA-364 1141.7 1141.6 92 802 820 
CyRLA-185 1087.7 1087.6 92 801 819 
CyRLA-164 1099.7 1099.6 89 802 820 
CyRLA-395 1151.7 1151.6 85 803 823 
 
(a) ESI-MS m/z corresponding to [M+] values.  
*(b) Purities were determined by integration of the UV absorbance signal at 
780 nm.  
55-member CyRLA compounds were characterized by HPLC-MS analysis. 
The purities of the whole library were determined by integration of the UV 
absorbance signal at 780 nm. The spectra of 10 M in DMSO solution was 
recorded in SpectraMax M2 plate reader.  
 
4.3.2 SERS Measurement 
For CyRLA library, 60 nm diameter AuNPs were employed for the 
SERS measurement.  CyRLA are NIR compounds having absorbance 

























Figure 4.1 Absorbance spectra of the 6 selected CyRLA compounds (10 M 
concentration, pH=7.4, 20 mM PBS). 
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As, 800 nm is the excitation maxima for the CyRLA compounds, 785 
nm laser sources were used for the excitation of Au-nanotags. In practice, 
there are two available laser sources for SERS microscopes; these are 633 nm 
and 785 nm. Among them, 785 nm sources produce a higher SERS signal 
intensity because of its resonance between the excitation frequency and 
electronic transition of NIR reporter molecules. The SERS property of every 
CyRLA compound was evaluated under a compact Raman scanner after 
incubating them with citrate-stabilized gold nanoparticles. It is noted from the 
primary screening that the SERS intensities of CyRLA compounds varied 
significantly throughout the library (Figure 4.2) indicating that the SERS 
properties depend on the amine structures.   
  
Figure 4.2. Comparative SERS intensities of the whole CyRLA library. SERS 
spectra were measured in a compact Raman scanner with excitation at 785 nm 
and 60 mW laser power.  
 
Notably, six derivatives (CyRLA-335, 329, 240, 364, 572 and 442, 
represented in figure 4.2 as C5, C4, D5, H5, E10 and F9 respectively) 
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exhibited very high SERS intensities. The selected SERS active reporter 
molecules were further carried out in a Renishaw InVia Raman microscope 
(Renishaw, UK, model: HPNIR785) using an excitation wavelength of 785 
nm.  
 
Figure 4.3 SERS spectra of BSA-encapsulated nanotags; that were derivatized 
with CyRLA-329, CyRLA-335, CyRLA-240, CyRLA-572; Raman spectral 
range: 400 to 2000 cm
−1
, resolution: 1 cm
−1
, acquisition time: 10s.   
 
4.3.3 Design and synthesis of Cy7 and Cy7.5 based NIR Raman reporters   
Here, I applied the same (like CyRLA synthesis) lipoic acid (LA) 
linker strategy to NIR dyes Cy7 and Cy7.5 to form two new RMs (Cy7LA and 
Cy7.5LA) that could be chemisorbed on the  Au-NPs for SERS studies.31-32  
First, I prepared the Cy7 and Cy7.5 with an aminopropyl linker according to 
the previously synthesized protocol.
6
 The amine intermediates then reacted 
with activated ester resin of lipoic acid (Scheme 4.2) to obtain the target 
compounds Cy7LA and Cy7.5LA with an average purity of 90%. 




Reagents and conditions: (a) DCM/ACN (7:1), NaHCO3, r.t., 6 h 
 
4.3.4 Encapsulation of AuNPs and TEM characterization  
Encapsulation strategy for SERS-active nanoparticles is very important 
due to its aggregation prevention characteristics.
9-12
 Moreover, encapsulated 
nanoparticles can be used for bioconjugation by introducing the functional 
groups on their surface. Long-term stability of the six selected CyRLA-NPs 
was evaluated after bovine serum albumin (BSA) and glutaraldehyde 
modification. Here, coated cross-linked organic layer of BSA contains 
carboxylic acid group on the surface that can be modified further with amine-
containing molecules (i.e. antibodies, proteins or other macromolecules) 
(Scheme 5.2).
13
 Previously Qian et al. reported that, under harsh conditions 
the gold nanoparticles rapidly undergo precipitation or aggregation .
14
 
Samanta et al. adopted BSA encapsulation strategy  to increase the stability of 
SERS signal intensity and minimize the aggregation among the nanoparticles.
6 
The same strategy has been adopted for the coating of the CyRLA compounds. 
The increased size (65-70 nm) of the BSA-encapsulated CyRLA-AuNPs was 
confirmed by transmission electron microscopy (TEM). Additionally, a minor 
band around 600 nm of the plasmon spectra in Figure 4.4 indicates that there 











































 Figure 4.4 Surface plasmon absorption spectra of Au-colloids containing 
CyRLA , Cy7LA and Cy7.5LA reporters.  
 
Three encapsulated dyes Cy7LA, Cy7.5LA and CyRLA-572 showed 
strong atleast one unique SERS signal when excited at NIR laser (785 nm) and 
therefore could provide high sensitive multiplex detection capability (Figure 
4.5) 
 
Figure 4.5 SERS spectra of BSA-encapsulated nanotags of Cy7.5LA, Cy7LA, 
CyRLA-572. Raman spectral range:  400 to 2000 cm.
−1
, resolution: 1 cm
−1
, 





4.3.5 SERS with multiplex peaks 
Previously Maiti et al synthesized a highly Raman active NIR Raman 
reporter-set (Cy7LA, Cy7.5LA and CyNAMLA-381) as a Raman multiplex 
partner.
15
 Similarly, in this chapter, SERS spectra of chemisorbed CyRLA, 
Cy7LA and Cy7.5LA on AuNPs were analyzed under the 785 nm laser and 
consequently  their multiplexing capability was evaluated. Notably, a number 
of peaks are useful for uniquely identifying the three different nanotags: 503, 
523, 586 cm
-1 
for Cy7.5LA, CyRLA and Cy7LA respectively (Figure 4.6). 
The combination of these cyanine Raman reporters can be useful for the 
construction of multiplex SERS nanotags, and we aimed to explore their 
application for the detection of germ layers in differentiated mESc. 
 









Figure 4.6  Normalized  SERS  spectra  of  Cy7.5LA,  CyRLA-572  and  
Cy7LA after chemisorption  on  AuNPs.  Spectra were measured using a 
Raman microscope (785 nm laser excitation, 30 mW laser power, acquisition 
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time: 10s) and plotted as average intensities (n=3). The most distinctive peaks 
from each reporter are highlighted in three different colours.   
 
4.3.6 Signal stability 
After encapsulating NPs-RM complexes using bovine serum albumin 
(BSA) and glutaraldehyde as a cross-linking agent, the excess glutaraldehyde 
was removed by treatment with  glycine treatment and then the long-term 
stability of SERS-signals of CyRLA-E10-AuNPs was studied for 20 days 





Figure 4.7 Time course SERS measurement of CyRLA-E10 nanotag. SERS 
intensities of the highest Raman peaks (i.e. 523 cm
-1 
for CyRLA-572) are 
plotted as means ± standard deviation of 5 independent measurements taken 
from the same sample at different time points. 
 
Notably, there is no significant aggregation among all these nanotags 
and they exhibited stable SERS intensities over time, shown in figure 4.7. 
Figure 4.8, transmission electron microscopy (TEM) image indicates that the 
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size of these nanotags was around 65 nm.  Here, 5 nm increments in size 
featured to the encapsulation BSA layer. 
 
Figure 4.8 Transmission electron microscopy (TEM) images of: a) BSA-
encapsulated  Cy7.5LA  b)  Cy7LA c) CyRLA-572 nanotag;   Scale bar: 50 
nm for Cy7 and Cy7.5 . 100 nm for CyRLA-572 
4.3.7 SERS study in differentiated mouse Embryonic stem Cells (mESc) 
In order to examine the multiplex differential recognition of CyRLA-
572 anti-CD34, Cy7LA anti-CD184 and  Cy7.5LA anti-Notch1 nanotags  in 
three different germ layers of differentiated mESC, an  equal  amount of  all 
these three  nanotags were incubated  with teratoma (consisted of Endoderm, 
mesoderm, ectoderm). After washings with PBS buffer, the SERS 
measurement in differentiated mouse embryonic  was carried out (Figure 4.9). 
SERS spectra for anti-CD34 (mesoderm) treated teratoma resembled to the 
spectra of CyRLA-572, SERS signal of anti-CD184 (endoderm) treated 
teratoma resembled to the spectra of Cy7LA and SERS spectra from anti-
Notch1 (ectoderm) treated teratoma resembled to Cy7.5LA spectra.  No 
significant SERS signal was recorded where nanotogs without antibody was 





Figure 4.9 Obtained SERS signal from the differentiated mESc; (1) signal 
from mesoderm; CyRLA-572-anti-CD34 (2) signal from endoderm; Cy7LA-
anti-CD184 (3) signal from ectoderm; Cy7-5LA-anti-Notch1(4) signal from 
all the three differentiated layers; CyRLA-572-anti-CD34, Cy7LA-anti-
CD184 and Cy7-5LA-anti-Notch1 
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4.4 Conclusions  
In summary, we report three lipoic acid-containing NIR active 
tricarbocyanine Raman reporters (CyRLA-572, Cy7LA and Cy7.5LA) as 
multiplex partner where Cy7LA and Cy7.5LA were previously reported as 
well as used for in vivo multiplex targeted imaging. Here, I have synthesized 
CyRLA library and screened them to identify Raman reporter having high 
Raman intensity and high signal stability and consequently used it for 
multiplex Raman partner with Cy7LA and Cy7.5LA to detect the three 
different germ layers of differentiated mESc in vitro.  
4.5 Experimental Method 
Material and method 
Surface plasmon absorption spectra were measured on a SpectraMax M2 
spectrophotometer  (Molecular  Devices),  and  the  data  analysis  was 
performed using Microsoft excel 2007. SERS measurements were carried out 
in a Renishaw InVia Raman (UK) microscope with a laser beam directed to 
the sample  through  50×  and  20×  objective  lens  and  a  Peltier  cooled  
CCD  detector  in Singapore  Bioimaging  Consortium,  Agency  for  Science,  
Technology  and  Research (A*STAR),  Singapore.  Samples were excited 
with a 785 nm excitation wavelength laser and Stokes shifted Raman spectra 
were collected in the range of 400 to 2000 cm
−1
 with 1 cm
−1
 resolution. Prior 
to every measurement, a calibration with a silicon standard (Raman peak 
centered at 523 cm
−1
) was performed.  WiRE 3.0 software package was used 









4.5.1 Characterization data of representative CyRLA compounds 
CyRLA-442 (7 mg, 20%) 
 
1
H-NMR (500 MHz, CDCl3): δ 0.87-1.60 (m, 18 H), 1.65 (s, 6H), 1.66 (s, 6H), 
1.7-1.92 (m, 14H), 2.14-2.72 (m, 12H), 3.03-3.28 (m, 11H), 3.48-3.72 (m, 
13H), 4.0-4.1 (m, 6H), 6.12 (d, 1H, J=13.5 Hz), 6.24 (d, 1H, J=13.5 Hz), 7.04-
7.44 (m, 8H), 7.52 (d, 1H, J=13 Hz), 7.55 (d, 1H, J=13Hz). 
ESI-MS m/z (M 
+
), calc‟d: 1087.7, found 1087.4 





H-NMR (500 MHz, CDCl3): δ 1.06-1.62 (m, 18 H), 1.66 (s, 6H), 1.68 (s, 6H), 
1.69-2.06 (m, 9H), 2.18-2.78 (m, 10H), 3.04 -3.31 (m, 11H), 3.44-3.73 (m, 
13H), 3.93-4.06 (m, 6H), 6.14 (d, 1H, J=14.5 Hz), 6.17 (d, 1H, J=14.5 Hz), 
6.99-7.43 (m, 12H), 7.53 (d, 1H, J=14.5 Hz), 7.56 (d, 1H, J=14.5Hz). ESI-MS 
m/z (M 
+
), calc‟d: 1199.6, found 1201.1(due to bromine isotope). 
CyRLA-364 (7.5 mg, 15%) 
 
1
H-NMR (500 MHz, CDCl3): δ 1.06-1.62(m, 18H), 1.67 (s, 6H), 1.68 (s, 6H), 
1.70-1.92 (m, 9H), 1.99-2.46 (m, 10H), 2.52-2.62 (m, 6H), 2.72 (m, 2H), 3.0-
3.72 (m, 15H), 4.0-4.12 (m, 6H), 4.53(s, 2H), 6.10 (d, 1H, J=14.5 Hz), 6.16 (d, 
1H, J=14.5 Hz), 7.07-7.49 (m, 12H), 7.52 (d, 1H, J=15 Hz), 7.55 (d, 1H, J=15 
Hz). ESI-MS m/z (M 
+
), calc‟d: 1141.7, found 1141.4 





H-NMR (500 MHz, CDCl3): δ 1.09-1.57 (m, 18 H), 1.61 (s, 6H), 1.63 (s, 6H), 
1.71-2.03 (m, 11H), 2.16-2.80 (m, 10H), 3.05 -3.33 (m, 11H), 3.54-3.76 (m, 
13H), 3.96-4.17 (m, 6H), 6.14 (d, 1H, J=13.5 Hz), 6.17 (d, 1H, J=13.5 Hz), 
7.09-7.45 (m, 13H), 7.56 (d, 1H, J=13.5 Hz), 7.59 (d, 1H, J=13.5Hz). ESI-MS 
m/z (M 
+
), calc‟d: 1135.7, found 1135.6 
CyRLA-240 (6 mg, 12%) 
 
1H-NMR (500 MHz, CDCl3): δ 1.04-1.51 (m, 16H), 1.62 (s, 6H), 1.64 (s, 6H), 
1.69-1.90 (m, 8H), 1.99-2.43 (m, 10H), 2.50-2.61 (m, 6H), 2.76 (m, 2H), 3.05-
3.74 (m, 15H), 3.97-4.13 (m, 6H), 4.64 (s, 2H), 6.10 (d, 1H, J=14 Hz), 6.16 (d, 
1H, J=14 Hz), 7.05-7.53 (m, 17H), 7.54 (d, 1H, J=13.5 Hz), 7.57 (d, 1H, 
J=13.5 Hz). ESI-MS m/z (M 
+
), calc‟d: 1183.7, found 1183.6 
4.5.2 Synthesis CyRLA library  
Synthesis of lipoic acid nitrophenol resin:  
Aminomethyl nitrophenol polystyrene resin was prepared according to 
reported procedures. The nitrophenol resin (2 g, 2.9 mmol, 1 eq.) was swollen 
in 10 mL of DMF, and lipoic acid (2 g, 10 mmol, 3.3 eq.), N,N'-
diisopropylcarbodiimide (1.2 mL, 12 mmol, 4 eq.) and a catalytic amount of 
DMAP (20 mg) were added to the  resin,  which  was  continuously  shaken  
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for  24  h  at  r.t.  Subsequently, the resin was washed with DCM (10 × 25 mL) 
and dried under vacuum until use.  
General procedure for the synthesis of the CyRLA library   
To synthesized CyRLA library, each of 1 mol CyR library compound 
(80 compounds) was taken according to their plate code in the 2 mL of 96-
deep well plate. About 30 mg (~ 20 mol, 20 eq.) of active-ester resin was 
added to the each well of the CyR library containing plate. Then, DCM: ACN 
(7:1) solvent mixture of around 500 L and catalytic amount of saturated 
solution of NaHCO3 were poured in to each well. The plate was kept in the 
shaker with moderate shaking for 6 hours. Then, the solution was filtered from 
the resin and dried to obtain pure products.  
4.5.3 Cell preparation and SERS screening 
mESC was maintained on gelatinized tissue culture dishes in high-
glucose DMEM supplemented with 20% ES FBS, 1% Pen Strep Glutamine, 
1% Non Essential Amino acid, 0.1% β-mercaptoethanol and 100 U/ml 
leukemia inhibitory factor (LIF, Chemicon). For trypsinization, after removing 
the old media and washing by PBS (pH 7.3) the cells were incubated in their 
culture plates using 0.25% trypsin with 1 mM EDTA solution (Invitrogen) for 
3 min at 37 °C to obtain a single cell suspension. After neutralizing the trypsin 
by media spin down (1500 rpm for 3min) in a falcon tube to collect the pellet 
which is subcultured in non gelatineted cell culture dishes in the mESC media 
without leukemia inhibitory factor (LIF) and incubate for a 4-6 days to make 
an embryonic body. After neutralizing the trypsin by media spin down (1500 
rpm for 3min) in a falcon tube to collect the pellet of embryonic body which is 
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subcultured in gelatin coated chamber slide with mESC culture media without 
LIF.  
4.5.4 SERS signal from mESc 
When the three germ layers has formed on the slide chamber, 50 L of 
each antibody conjugated three nanotags nanotags (Cy7LA-CD184, CyRLA-
10-CD-34 and Cy7.5LA-Notch1 anti) were applied in three individual slide 
chambers of glass slide. Furthermore, one of chamber was treated with the 
mixture of three nanotags having three different antibodies (intensity of three 
nanotags were equalized at their multiplexing peaks, 503 cm
-1
 for Cy7LA, 523 
cm
-1
 for CyRLA and 584 cm
-1
 for Cy7.5LA). The nanotags treated slide 
chamber was incubate for 2 h and washed carefully by media. Briefly, the 
washing steps were performed by applying 500 L of media and removed it 
after 5 min incubation. This process was repeated for three times to complete 
removal of excess non interacting nanotags. This glass slide chamber was 
covered with glass slide and SERS spectra were measured. Raman 
experiments were performed in a Renishaw InVia Raman microscope with a 
laser beam directed to the sample through 50X objective lens and a Peltier 
cooled CCD detector. Samples were excited with a 785 nm excitation 
wavelength laser, and Raman spectra were collected in the range of 400 to 
2000 cm
−1
 with 1 cm
−1
 resolution. Acquisition time for all spectra was 10 s. 
4.5.5 Antibody conjugation of SERS nanotags 
The carboxylic acids groups of BSA were activated with N-(3-
(dimethylamino)-propyl)-N‟-ethylcarbodiimide (EDC) (125 nmol) and N-
hydroxysuccinimide (NHS) (125 nmol. The activated particles were then 





°C for 2 h and then overnight incubation at 4 °C. Non-specific binding 
chemicals and antibodies were removed by centrifugation (10000 rpm, 10 
min) and the final nanotags were re-suspended in PBS and stored at 4 °C.  
4.6 References  
1) S. Keren, C. Zavaleta, Z. Cheng, A. de la Zerda, O. Gheysens and S. S. 
Gambhir, P. Natl. Acad. Sci. U.S.A., 2008, 105, 5844. 
2)  M. Gellner, K. Kompe and S. Schlucker, Anal. Bioanal. Chem., 2009, 
394, 1839. 
3)  K. C. Bantz, A. F. Meyer, N. J. Wittenberg, H. Im, O. Kurtulus, S. H. 
Lee, N. C. Lindquist, S. H. Oh and C. L. Haynes, Phys. Chem. Chem. 
Phys., 2011, 13, 11551. 
4)  K. K. Maiti, A. Samanta, M. Vendrell, K. S. Soh, M. Olivo and Y. T. 
Chang, Chem.Commun , 2011, 47, 3514. 
5)  A. Matschulat, D. Drescher, J. Kneipp, ACS Nano 2010, 4, 3259. 
6)  K. K. Maiti, U. S. Dinish, A. Samanta, M. Vendrell, K. S. Soh, S. J. 
Park, M. Olivo and Y. T. Chang, Nano Today, 2012, 7, 85. 
7)   J. J. Cunningham, T. M. Ulbright, M. F. Pera and L. H. J. Looijenga, 
Nat Biotechnol, 2012, 30, 849. 
8)  H. Hentze, P. L. Soong, S. T. Wang, B. W. Phillips, T. C. Putti and N. 
R. Dunn, Stem Cell Res, 2009, 2, 198. 
9)  H. Jang, Y. K. Kim, S. R. Ryoo, M. H. Kim and D. H. Min, Chem. 
Commun., 2010, 46, 583. 
10)   C. C. Lin, Y. M. Yang, Y. F. Chen, T. S. Yang and H. C. Chang, 
Biosens. Bioelectron., 2008, 24, 178. 
102 
 
11)   S. Lee, H. Chon, M. Lee, J. Choo, S. Y. Shin, Y. H. Lee, I. J. Rhyu, 
S. W. Son and C. H. Oh, Biosens. Bioelectron., 2009, 24, 2260. 
12)   D. Graham, D. G. Thompson, W. E. Smith and K. Faulds, Nat. 
Nanotechnol., 2008, 3, 548. 
13)   L. Sun, K. B. Sung, C. Dentinger, B. Lutz, L. Nguyen, J. W. Zhang, 
H. Y. Qin, M. Yamakawa, M. Q. Cao, Y. Lu, A. J. Chmura, J. Zhu, X. 
Su, A. A. Berlin, S. Chan and B. Knudsen, Nano. Lett., 2007, 7, 351. 
14)   X. M. Qian, X. H. Peng, D. O. Ansari, Q. Yin-Goen, G. Z. Chen, D. 
M. Shin, L. Yang, A. N. Young, M. D. Wang and S. M. Nie, Nat. 







Possibility of live B-Lymphocytes imaging by novel 







5.1 Introduction  
B-and T-cells are lymphocytes, type of white blood cells which are 
morphologically similar.  B-cells, in particular, play a large role in mediating 
humoral immune responses as well as in autoimmune diseases like systemic 
lupus erythematosus (SLE)
1
 and rheumatoid arthritis
2
. Despite its well studied 
roles within the immune system, B-cell detection remains very challenging 
due to the morphological similarities between B-and T-cells. Current methods 
of discriminating these cells require the use of cell-specific antibodies 
involved in either immunophenotyping using flow cytometry or 
immunocytochemistry. These identification techniques while highly specific 
either activate the cells via antibody binding or kill the cells via fixation for 
immunofluorescence rendering them less desirable. These shortcomings 
warrant the needs to develop a novel fluorescent probe for B-cell that displays 
high target specificity in live cells and at the same time low potency to activate 
them. Fluorescent probes are powerful tools which enable us to visualize the 
polymeric biomolecules or cellular organelles efficiently.
3
 Fluorescent small 
molecules are the major toolbox, have been extensively used for probe 













 have been developed and 
their potential application to imaging probe development demonstrated. Our 
group have utilized combinatorial chemistry to develop several diversity-
oriented fluorescence libraries (DOFL) and successfully applied them to the 
discovery of imaging probes for a number of biological targets.
6
 Among them, 
BODIPY scaffold is ubiquitously chosen as a versatile fluorophore because of 
its high quantum yield, tunable fluorescence characteristics, high 
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photostability, and narrow emission bandwidth.
7
 So far, numerous labeling 
agents and probes derived from the BODIPY scaffold have been reported and 
even commercialized.
8a,b
 We recently reported the solution as well as solid-







Motivated by this synthesis, I have synthesized BODIPY based library, BDR, 
BDRCA and BDRAC in solid phase and applied them in development of B 
cell imaging probe. 
5.2 Objectives 
B-cells are lymphocytes that play a large role in the humoral immune 
response of our body as well as in autoimmune diseases. Via image based high 
throughput screening of BODIPY based library BDR, BDRCA and BDRAC, 
we discovered a small molecule probe and named it Compound of Designation 
green 6 (CDg6) that stains mouse B-cells selectively. Here, diversity oriented 
solid phase synthesis was adopted to successfully modify the BODIPY core 
scaffold for generating these libraries. The photophysical characterization was 
also carried out for these libraries. 
5.3 Results and Discussion 
5.3.1 Synthesis of BDR Library  
In our present work, we have synthesized, BODIPY-based library, 
BDR and its derivatives BDRCA and BDRAC using solid-phase chemistry to 
provide a set of structurally diverse fluorescent compounds. For the BDR 
library synthesis (Scheme 5.1), carboxylic acid containing BODIPY scaffold 2 
was used as the key intermediate. The general synthetic strategy of BODIPY 
acid 2 involves two steps (40% overall yield) reaction process. First, BODIPY 
ester 1 was synthesized in situ by treating BF3-OEt2 after condensation 
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reaction between the methyl 4-(chlorocarbonyl)benzoate and 2,4-dimethyl 
pyrrole then followed by mild basic hydrolysis of that ester provided the key 
intermediate of BODIPY acid 2.Then the structurally diverse BDR library was 
synthesized using previously reported robust solid phase synthesis technique.
12
 
The wide structural diversity was achieved as the solid phase secondary 
amines 5 by simple reaction between the bromopropylamine loaded resins 4 
with the series of primary amines (Chart 5.1). Then the key intermediate 2 
was coupled to this solid phase amine building block by using a standard acid–
amine coupling protocol. The final step of acidic cleavage from the solid 
supported compounds 3 yielded 80 very pure members of the BDR library 
(average purity is 90% without further purification at 350 nm, Table 5.1). 
Scheme 5.1 Synthesis of BDR library 
 
 Reagents and conditions: (a) DCM, 2,4-dimethlypyrrole, r.t , 4 h.; (b) DCM, 
BF3-OEt2, TEA, rt, 12 h.; (c) MeOH:DCM (3:1), 0.2(N) KOH, r.t, 24 h.; (d) 
DIEA, THF, 3-bromopropylamine, r.t., 12 h.; (e) DIEA, RNH2, NMP, 70 
o
C, 




This synthetic protocol provides an amino-linker in the BODIPY 
scaffold in addition to the structural diversity. Using that primary amine, I 
synthesized the acetyl and choloroacetyl version of BDR (BDRAC and 
BDRCA) compounds using solid phase activated ester chemistry. Firstly, 
active ester resins were prepared by treating the nitrophenol resin with 
chloroacetyl chloride. The reaction of the resulting resin with the highly 
reactive propylamine moiety of BDR compounds in the presence of catalytic 
amount of mild base NaHCO3 aﬀorded the corresponding BDRCA and 
BDRAC compounds (Scheme 5.2). The reaction was completed within 2 
hours and the products were obtained after a simple ﬁltration with an average 
purity of above 90% without further puriﬁcation. All the library compounds 
showed a green range of ﬂuorescence as expected (average excitation at 450 
nm and emission at 520 nm). The quantum yield of each molecule varied from 
0.3 to 0.6 reﬂecting diverse structural and electronic characteristics (Figure 
5.1, Table 5.2 and 5.3) 
Scheme 5.2 Synthesis of BDRCA and BDRAC derivatives 
 
 
Reagents and conditions: (a) DCM/ACN (7:1), NaHCO3, r.t., 2 h 
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(calc.) (M +H) abs(nm) em(nm) 
 Purity*2 
BDR 389 546.3 547.3 501 518 0.41 92 
BDR 677 562.2 563.3 502 519 0.40 90 
BDR 273 558.3 559.3 502 518 0.35 91 
BDR 388 544.3 545.3 501 517 0.39 94 
BDR 398 528.3 529.5 501 517 0.40 93 
BDR 565 582.2 583.2 502 517 0.75 85 
BDR 220 532.3 533.3 503 518 0.31 90 
BDR 240 590.3 591.3 502 517 0.32 90 
BDR 103 558.3 559.3 501 519 0.28 90 
BDR 28 620.4 621.4 502 518 0.44 91 
BDR 407 564.4 565.4 501 517 0.31 89 
BDR 262 574.3 575.3 502 518 0.34 94 
BDR 335 542.3 543.3 503 519 0.38 93 
BDR 11 549.3 550.3 502 518 0.38 93 
BDR 274 524.3 525.3 501 519 0.46 95 
BDR 124 574.3 575.3 502 517 0.36 95 
BDR 387 544.3 545.3 502 517 0.46 92 
BDR 429 520.3 521.3 501 517 0.48 92 
BDR 382 520.3 521.3 501 518 0.35 92 
BDR 230 536.3 537.4 502 519 0.36 93 
BDR 181 574.3 575.3 503 518 0.37 90 
BDR 580 648.5 649.5 502 517 0.41 90 
BDR 405 546.3 547.3 501 517 0.41 89 
BDR 193 595.4 596.4 502 517 0.4 93 
BDR 218 532.3 533.3 501 518 0.55 93 
BDR 478 542.5 543.3 502 517 0.36 92 
BDR 419 494.3 495.3 503 519 0.34 92 
BDR 386 528.3 529.3 502 518 0.51 92 
BDR 442 494.3 495.3 501 517 0.43 93 
BDR 599 604.3 605.3 501 518 0.39 91 
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BDR 477 546.3 547.3 503 519 0.40 93 
BDR 92 508.4 509.3 502 517 0.37 93 
BDR 480 562.2 563.3 501 518 0.44 91 
BDR 77 542.3 543.3 502 519 0.44 90 
BDR 368 593.4 594.4 501 518 0.37 94 
BDR 403 548.9 549.2 502 519 0.17 91 
BDR 131 556.3 557.3 503 517 0.34 91 
BDR 374 514.3 515.3 502 518 0.69 91 
BDR 185 494.3 495.3 503 519 0.35 93 
BDR 135 582.2 583.2 502 518 0.51 89 
BDR 80 550.4 551.3 501 519 0.34 90 
BDR 184 588.3 589.4 501 517 0.44 91 
BDR 153 546.2 547.3 501 518 0.69 91 
BDR 375 532.3 533.4 502 519 0.33 91 
BDR 201 556.3 557.4 503 518 0.35 92 
BDR 100 618.3 619.4 502 517 0.28 92 
BDR 177 482.3 516.0 501 517 > 0.99 91 
BDR 412 550.4 551.4 501 517 0.37 91 
BDR 319 574.3 575.3 502 518 0.22 91 
BDR 686 596.2 597.3 501 517 0.35 92 
BDR 567 578.4 579.4 502 519 0.36 91 
BDR 395 558.3 559.3 502 518 0.58 92 
BDR 554 550.4 551.4 501 517 0.9 90 
BDR 351 550.2 551.3 501 518 0.34 94 
BDR 101 528.4 529.4 502 519 0.40 90 
BDR 364 548.2 549.2 503 518 0.40 90 
BDR 414 563.3 564.4 502 519 0.31 91 
BDR 329 592.3 593.4 501 517 0.32 90 
BDR 221 548.2 549.2 502 517 0.4 94 
BDR 572 606.2 607.2 502 517 0.51 90 
BDR 656 674.5 675.5 502 518 >0.99 90 
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BDR 102 558.3 559.3 501 518 >0.99 90 
BDR 574 494.3 495.3 502 519 0.48 90 
BDR 272 535.3 536.3 502 517 0.48 89 
BDR 577 592.4 593.4 501 518 0.86 90 
BDR 420 523.3 524.3 501 519 0.29 90 
BDR 282 537.3 538.3 502 518 0.59 90 
BDR 295 494.2 495.3 503 517 0.96 93 
BDR 165 546.3 547.3 502 517 0.82 91 
BDR 167 510.3 511.3 501 517 0.75 88 
BDR 65 676.5 677.5 502 518 0.50 92 
BDR 32 542.3 543.3 501 517 0.27 91 
BDR 359 573.3 574.4 502 519 0.31 92 
BDR 361 559.3 560.3 502 518 0.40 91 
BDR 341 594.1 595.2 501 517 0.61 90 
 








BDRCA 389 622.2 623.3 501 518 0.46 90 
BDRCA 677 638.2 639.2 502 519 0.29 88 
BDRCA 273 634.3 635.3 502 519 0.37 89 
BDRCA 388 620.2 621.2 502 518 0.45 92 
BDRCA 398 604.3 605.3 501 518 0.42 91 
BDRCA 565 658.2 659.3 502 519 0.43 87 
BDRCA 220 608.2 533.3 503 519 0.53 92 
BDRCA 240 666.3 667.4 502 519 0.39 92 
BDRCA 103 634.3 635.3 502 519 0.65 91 
BDRCA 28 696.4 697.4 502 517 0.39 91 
BDRCA 407 640.3 641.3 502 517 0.31 95 
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BDRCA 262 650.3 651.4 502 519 0.31 92 















BDRCA 124 650.3 651.3 502 519 0.41 89 
BDRCA 387 620.2 621.3 502 518 0.35 92 
BDRCA 429 596.3 597.3 502 518 0.34 90 
BDRCA 382 596.3 597.3 502 517 0.72 93 
BDRCA 230 612.3 613.3 502 518 0.37 94 
BDRCA 181 650.3 651.3 503 518 0.41 90 
BDRCA 580 724.4 725.4 502 518 0.31 91 
BDRCA 405 622.2 623.2 502 519 0.45 91 
BDRCA 193 670.4 671.4 502 518 0.50 95 
BDRCA218 608.2 609.2 502 518 0.44 92 
BDRCA 478 618.3 619.3 502 517 0.36 91 
BDRCA 419 570.3 571.3 503 519 0.44 91 
BDRCA 386 604.3 605.3 502 518 0.35 90 
BDRCA 442 570.3 571.4 501 519 0.62 89 
BDRCA 599 680.3 681.3 502 519 0.46 92 
BDRCA 381 620.2 621.3 502 518 0.38 90 
BDRCA 55 682.4 683.4 502 519 0.37 93 
BDRCA 477 622.2 623.2 503 518 0.45 94 
BDRCA 92 584.3 585.2 502 519 0.36 90 
BDRCA 480 638.2 638.2 502 518 0.48 90 
BDRCA 77 618.3 619.4 502 519 0.53 92 
BDRCA 368 669.4 670.3 502 519 0.50 93 
BDRCA 403 624.2 625.2 502 519 0.32 92 
BDRCA 131 632.3 633.4 503 517 0.85 93 
BDRCA 374 590.2 591.3 502 519 0.37 87 
BDRCA 185 570.3 571.3 503 518 0.38 92 
BDRCA 135 658.2 659.3 502 517 0.38 91 
BDRCA 80 626.2 627.2 501 519 0.40 91 
BDRCA 184 664.3 665.3 502 519 0.50 93 
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BDRCA 153 658.2 659.2 502 517 0.50 95 
BDRCA 375 608.2 609.2 502 519 0.46 92 















BDRCA 412 626.2 627.2 502 518 0.43 93 
BDRCA 319 650.3 651.3 502 519 0.26 92 
BDRCA 686 672.1 673.2 502 519 0.35 93 
BDRCA 567 654.4 655.5 502 519 0.39 87 
BDRCA 395 634.3 635.3 502 518 0.50 92 
BDRCA 554 626.3 627.3 501 519 0.50 91 
BDRCA 351 626.2 627.3 502 519 0.45 91 
BDRCA 101 604.3 605.3 502 517 0.54 93 
BDRCA 364 624.2 625.2 503 518 0.46 95 
BDRCA 414 639.3 640.4 502 519 0.97 92 
BDRCA 329 704.1 705.1 502 519 0.44 90 
BDRCA 221 624.2 625.3 502 519 0.40 94 
BDRCA 572 682.2 683.3 502 518 0.42 95 
BDRCA 656 750.5 751.5 502 518 0.47 92 
BDRCA 432 571.3 572.4 501 519 0.34 91 
BDRCA 373 556.3 557.3 502 519 0.54 91 
BDRCA 425 570.3 571.3 502 519 0.53 95 
BDRCA 102 634.3 635.3 501 519 0.44 92 
BDRCA 574 570.3 571.3 502 518 0.41 91 
BDRCA 272 611.3 612.3 502 518 0.83 91 
BDRCA 577 668.4 669.4 501 519 0.52 90 
BDRCA 420 599.3 600.3 502 519 0.45 89 
BDRCA 282 613.3 614.3 502 519 0.31 92 
BDRCA 295 572.2 573.2 503 519 0.39 93 
BDRCA 165 586.3 587.3 502 519 0.55 87 
BDRCA 167 752.5 753.5 501 519 0.56 92 
BDRCA 65 618.3 619.3 502 519 0.43 91 
BDRCA 32 685.2 686.2 501 519 0.65 91 
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BDRCA 359 671.2 672.2 502 519 0.42 93 
BDRCA 361 704.1 705.1 502 519 0.61 95 
BDRCA 341 564.2 565.2 501 517 0.52 92 
 








BDRAC 389 588.2 589.4 501 518 0.46 90 
BDRAC 677 604.2 585.3 502 519 0.29 88 
BDRAC 273 600.3 601.3 502 519 0.37 89 
BDRAC 388 586.3 587.3 502 518 0.45 92 
BDRAC 398 570.3 570.6 501 518 0.42 91 
BDRAC 565 624.2 624.0 502 519 0.43 87 
BDRAC 220 574.2 555.2 503 519 0.53 92 
BDRAC 240 632.3 613.4 502 519 0.39 92 
BDRAC 103 600.3 601.4 502 519 0.65 91 
BDRAC 28 662.4 643.4 502 517 0.39 91 
BDRAC 407 606.4 607.3 502 517 0.31 95 
BDRAC 262 616.3 597.0 502 519 0.31 92 
BDRAC 335 584.3 585.1 503 518 0.41 91 
BDRAC 11 591.3 572.0 502 519 0.42 91 
BDRAC 274 566.3 567.5 502 519 0.39 90 
BDRAC 124 616.3 617.3 502 519 0.41 89 
BDRAC 387 586.3 587.1 502 518 0.35 92 
BDRAC 429 562.3 562.7 502 518 0.34 90 
BDRAC 382 562.3 562.6 502 517 0.72 93 
BDRAC 230 578.3 579.5 502 518 0.37 94 
BDRAC 181 616.3 617.2 503 518 0.41 90 
BDRAC 580 690.4 691.3 502 518 0.31 91 
BDRAC 405 588.2 587.3& 502 519 0.45 91 
BDRAC 193 636.4 617.4 502 518 0.50 95 
BDRAC218 574.2 555.2 502 518 0.44 92 
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BDRAC 478 584.3 565.0 502 517 0.36 91 
BDRAC 419 536.3 517.2 503 519 0.44 91 
BDRAC 386 570.3 571.2 502 518 0.35 90 















BDRAC 55 648.4 629.2 502 519 0.37 93 
BDRAC 477 588.2 569.4 503 518 0.45 94 
BDRAC 92 550.3 551.0 502 519 0.36 90 
BDRAC 480 604.2 585.3 502 518 0.48 90 
BDRAC 77 584.3 565.2 502 519 0.53 92 
BDRAC 368 635.4 636.3 502 519 0.50 93 
BDRAC 403 590.2 591.2 502 519 0.32 92 
BDRAC 131 598.3 599.2 503 517 0.85 93 
BDRAC 374 556.2 537.1 502 519 0.37 87 
BDRAC 185 536.3 536.7 503 518 0.38 92 
BDRAC 135 624.2 625.1 502 517 0.38 91 
BDRAC 80 592.2 592.2 501 519 0.40 91 
BDRAC 184 630.3 631.4 502 519 0.50 93 
BDRAC 153 588.3 568.7 502 517 0.50 95 
BDRAC 375 574.2 574.5 502 519 0.46 92 
BDRAC 201 598.3 598.6 503 519 0.45 90 
BDRAC 100 660.3 659.2& 502 518 0.41 90 
BDRAC 177 524.2 524.6 502 519 0.79 92 
BDRAC 412 592.2 572.6 502 518 0.43 93 
BDRAC 319 616.3 616.7 502 519 0.26 92 
BDRAC 686 638.2 639.3 502 519 0.35 93 
BDRAC 567 620.4 620.5 502 519 0.39 87 
BDRAC 395 600.3 581.0 502 518 0.50 92 
BDRAC 554 592.3 593.3 501 519 0.50 91 
BDRAC 351 592.2 591.4& 502 519 0.45 91 
BDRAC 101 570.3 551.1 502 517 0.54 93 
BDRAC 364 590.2 591.2 503 518 0.46 95 
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BDRAC 414 605.3 606.4 502 519 0.97 92 
BDRAC 329 634.2 615.0 502 519 0.44 90 
BDRAC 221 590.2 571.0 502 519 0.40 94 
BDRAC 572 648.2 649.0 502 518 0.42 95 















BDRAC 425 536.3 537.3 502 519 0.53 95 
BDRAC 102 600.3 581.0 501 519 0.44 92 
BDRAC 574 536.3 537.1 502 518 0.41 91 
BDRAC 272 577.3 578.4 502 518 0.83 91 
BDRAC 577 634.4 635.3 501 519 0.52 90 
BDRAC 420 565.3 546.3 502 519 0.45 89 
BDRAC 282 579.3 580.5 502 519 0.31 92 
BDRAC 165 538.3 539.0 502 519 0.55 87 
BDRAC 167 552.3 551.4& 501 519 0.56 92 
BDRAC 65 718.5 699.4 502 519 0.43 91 
BDRAC 32 584.3 585.2 501 519 0.65 91 
BDRAC 359 615.3 596.1 502 519 0.42 93 
BDRAC 361 601.3 582.2 502 519 0.61 95 
BDRAC 341 634.2 615.3 501 517 0.52 92 
BDRAC 295 494.3 495.2 503 519 0.39 93 
 
*1 Quantum yields were measured in DMSO, using tetramethyl BODIPY as a 
standard ( : 0.64, in DMSO). *2 Purities were determined according to UV 
absorption at 350 nm.ESI-MS positive spectra, HPLC conditions: A: H2O-
HCOOH: 99.9:0.1. B: CH3CN-HCOOH: 99.9:0.1; gradient  100% A to 95% B 
(6 min), isocratic 95% B (6-8.2min), gradient 95% B to 100% A  (8.2-9 min), 
isocratic 100% A (9-10 min). Reversephase Phenomenex C18 Luna column 
(4.6 x 50 mm
2





Figure 5.1 Absorption and emission of representative BDR, BDRCA and 
BDRAC compound. 
 
5.3.2 Discovery of B cell probe 
After the synthesis, a high throughput screening was carried out using 
all these compounds to discover a BODIPY based novel B cell probe. To do 
that, first each of B-cells and T-cells were obtained from mouse splenocytes 
after indirect immunomagnetic negative selection due to concern of cell 
activation by magnetic beads. Then, the separated B-cells and T-cells were a 
breast seeded in 384 well plate and subsequently 240 compounds from BDR, 
BDRCA and BDRAC libraries were treated at a concentration of 1 µM. After 
incubation for 1 h and 4 h, images were acquired using the 
ImageXpressMICRO system (Molecular Device), a fully-integrated hardware 
and software system for automated acquisition and analysis of high contents 
fluorescence cell images. From 1 h incubation staining, we realized that none 
of our compounds show either B or T-cell selective staining. At the 4 h 
incubation, Compound of Designation green 6(CDg6, ex/em = 502/518 nm) 
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that presents selective staining only for B-cell not T-cell was chosen as hits 
(Figure 5.2-b) and validated using flow cytometric analysis with the same 
separated B and T-cell as image screening. (Figure  5.2-c). 
 
Figure 5.2 Discovery of B-cell selective probe: CDg6 a) Chemical structure 
of CDg6 b) B-cell and T-call were prepared from mouse splenocytes after 
negative selection using magnetic beads and incubated with 1 μM of CDg6 for 
4 h and 1 μg/mL of Hoechst 33342 for nucleus staining. Scale bar: 10 μm c) 
Flow Cytometric analysis of separated mouse B-and T-cells with 1 µM of 
CDg6 at 37°C. 
 
5.3.3 Optimization of B cell staining kinetics 
For the optimization of B cell staining kinetics, splenocytes were 
loaded on flow cytometry every 20 min after staining of CDg6 at 1 µM at 37 
°C (Figure 5.3-a).  Splenocytes at 90 min after incubation started to show 
70% of separation until 240 min, while none of incubation time at 4 °C show 




Figure 5.3 B cell staining kinetics using CDg6 a) Seperation kinetics using 
CDg6 b) Flow Cytometric analysis with time of stained and unstained cells. 
 
5.3.4 Localization of CDg6 in B-cells  
 
From the 60x fluorescence image, CDg6 seems to localize at the 
plasma membrane of B-cells from splenocytes. To confirm the membrane 
localization, we use confocal microscopy to obtain high magnification and 
resolution images of B-cells in conjunction with commercially available 
CellMask
TM 
plasma membrane stain. From figure 5.4 below, similar staining 
pattern was observed between CDg6 and the commercial dye confirming its 





Figure 5.4 Comparison of staining localization of CDg6 with Invitrogen 
CellMask
TM 
plasma membrane stain. Top panel: cells stained with CDg6. 
Bottom panel: cells stained with CellMask
TM 
plasma membrane stain. Cells 
were mounted on a glass slide, CDg6 (FITC filter), Hoechst 33342 (DAPI 
filter) and CellMask
TM 
plasma membrane stain (Cy5) images were taken using 
the Nikon Confocal Microscope quipped with x 100 objective lens. Scale bar: 
5 μm. 
 
5.3.5 Cytotoxicity of CDg6 in B-cells 
To assess the cytotoxicity of CDg6, B-cell viability upon incubation 
with increasing concentrations of CDg6 with respect to non-CDg6 treated cells 
was compared. From figure 5.5, we observed that even at high concentrations 
of CDg6 (5 μM), cell viability across a 48 hour period stays similar to non-
CDg6 treated cells. In this respect, the low cytoxicity of CDg6 enables high 






Figure 5.5 Comparison of B-cell survival rates in non-CDg6 treated cells 
versus CDg6 treated cells at 1 μM, 3 μM and 5 μM over 48 h. The error bars 
are s.d. over triplicates at each time point and experiment set. 
 
5.3.6 Application of CDg6 for isolation of B cell from mouse splenocytes 
 To investigate the possibility of CDg6 for separating B-cells from 
mouse splenocytes which exist in B and T-cell together, we performed 
Fluorescent Activated Cell Sorter (FACS) after 4 h staining of CDg6 at 1 µM. 
Mouse splenocytes were separated as two populations by fluorescent intensity 
of CDg6 (Figure 5.6-a). After that, CDg6 
bright
 cells were physically sorted 
out and confirmed with immunostaining of CD45R antibody that represents B-
cell of mouse spleen (Figure 5.6-b).  For further validation of CDg6, we first 
stained with CDg6 and CD45R antibody together and loaded them on flow 
Cytometry to check whether both of them are double stained or not (Figure 
5.7-a). And also cells were allowed to observe under fluorescent microscopy 
from FITC and Cy5 filters for CDg6 and CD45R antibody, respectively 
(Figure 5.7-b). while, CDg6 
bright
 cells were overlapped with CD45R clearly, 
no double staining with CD3e antibody that represents T-cell of mouse spleen 
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shows in flow Cytometry (Figure 5.7-c) as well as fluorescent images(Figure 
5.7-d).   
 
Figure 5.6 Isolation of B-cells with CDg6 in mouse splenocytes a) FACS dot 
plot image of CDg6 stained B-cell not T-cell. b) CDg6 
bright
 cells after sorting 
were immunostained with CD45R antibody for B-cell and 1 μg/mL of Hoechst 
33342 for nucleus. All images taken by fluorescent microscopy were merged 
together. Scale bar: 10 μm. FITC filter used for CDg6 staining, Cy5 for 
CD45R antibody and DAPI for Hoechst 33342. 
 
Figure 5.7 Selective staining of B-cell against T-cell by CDg6 a) Flow 
Cytometry dot plot image CDg6 (x-axis) and CD45R antibody staining (y-
axis) b) The fluorescent images of double staining  CDg6 (green) and CD45R 
antibody (red) and white dot box image zoomed in left. c) Flow Cytometry dot 
plot image of CDg6 (x-axis) and CD43e antibody staining (y-axis) d) The 
fluorescent images of double staining of CDg6 (green) and CD3e antibody 
(red) and white dot box image zoomed in left. Scale bar: 10 μm. 
5.3.7 Structural Activity Relationship studies 
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   It is noted that the CDg6 contains 18-carbon alkyl chain which is 
derived from the olylamine as the part of structural diversity. Oleyl amine has 
one un-saturation at the 9th position in the alkyl chain and we assumed that it 
may have a role in the B-cell staining. Hence, we decided to check the 
effectiveness of B-cell staining in the saturated form of the BDR-derivatives. 
The BDR derivative (BDRCA-65) of 18-carbon saturated alkyl chain from the 
stearylamine has also B-cell staining capability and can be considered as the 
B-cell hit. As 18-carbon chain has been a hit, there is a huge curiosity to check 
the effect of chain length variation in other BDR derivatives (Table 5.4). 
Table 5.4 Structure of derivatives with alkyl chain length between 4 –18 
carbon long.  
General 
structure 























After all these it became interesting to see the Structural Activity 
Relationships beyond the 18-carbon alkyl chain. Hence, we synthesized BDR 
derivatives having alkyl chain length up to 24 carbons (Table 5.5). Among 
124 
 
them, TB-G-19CA, TB-G-21CA, TB-G-23CA and TB-G-24CA (19, 21, 23 
and 24 alkyl chain containing BODIPY respectively) were synthesized by 
using the previously described BDRCA synthesis protocol. For the TB-G-20C 
and TB-G-22C synthesis, modified protocol was used. 
 
Scheme 5.3 Synthesis of 20 and 22 carbon chain BDRCA derivatives 
 
Table 5.5 Structure of derivatives with alkyl chain length between 19 –24 
carbon long.  

















Reagents and conditions: (a) DCM, propane-1,3-diamine, r.t., 12 h.; (b) DIEA, 
RCH2Br, NMP, 70 
o
C, 12 h.; (c) DMF, HATU, DIEA, r.t. 24 h.; (d) 0.5% TFA in 
DCM , r.t., 40 min.; (e) DCM/ACN (7:1), NaHCO3, r.t., 2 h 
 
5.3.8 Alkyl chain length effect on B cell staining  
Then, the result of these compounds indicates that the newly 
synthesized BDR derivatives of more than 18 carbons also have B-cell 
staining. To check whether this theory corresponds with selectivity of B-cell 
staining as well as separation of two populations, we carried out flow 
Cytometry with splenocytes after staining of all the BDR compounds which 
have different alkyl chain length at 1 µM for 4 h at 37°C (Figure 5.8-a). From 
14 to18 carbon compounds showed two separated populations and we 
confirmed bright separation of 18 carbon compound by immunostaining. 18-
carbon 
bri
 population was overlapped with CD45R for B-cell antibody (Figure 
5.8-b), not CD3e for T-cell antibody (Figure 5.8-c). It suggests that the alkyl 




Figure 5.8 Alkyl chainlegth effect in B cell staining:  a) Flow Cytometric 
analysis of separated mouse B-and T-cells with 1 µM of various long chain 
derivatives b) and c) B- cell and T cell antibody confirmation. 
 
5.4 Conclusions 
In summary, we have developed a novel bioimaging probe CDg6 for 
B-cell detection which exhibits comparable selectivity for B-cells as 
antibodies without activating them and having low toxicity. The experimental 
results presented herein demonstrate the utility of CDg6 for the facile 
identification and isolation of B-cells from splenocytes and peripheral blood 
lymphocytes without the aid of antibodies with high degree of efficiency. To 
the best of our knowledge, no B-cell selective fluorescent probe has been 
reported yet. This new probe will be a useful tool to aid the study of B-cell 
detection, proliferation and migration in the immune system which is key 
information in the study of role of B-cell in autoimmune diseases and humoral 
immunity.  
5.5 Experimental methods 
  Material and methods 
Amine and few bromide building block and all other chemicals and 
solvents for the synthesis were purchased from the Alfa Aesar, Fluka, Acros, 
MERCK, and Sigma Aldrich and were used without any purification. Merck 
Silica Gel 60 (particle size: 0.04-0.063 mm, 230-400 mesh) was used for the 
normal phase column chromatographic purification. From BeadTech Inc., 
Korea, 2-chlorotrityl alcohol resin (1.37 mmol/g) was purchased. For 
analytical characterization of BDR compounds HPLC-MS (Agilent-1200 
series) with a DAD detector and a single quadrupole mass spectrometer (6130 
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series) with an ESI and sometimes with an APCI probe were used. Analytical 
process, except specified: eluents: A: H2O (0.1% HCOOH), B: ACN (0.1% 
HCOOH), C18 (2) Luna column (4.6 x 50mm
2




C-NMR spectra were recorded on both Bruker Avance 300 
MHz and 500 MHz NMR spectrometer, and chemical shifts are expressed in 
parts per million (ppm) and approximate coupling constants were calculated in 
Hz. Quantum yields and all other photophysical properties of BDR derivatives 
were performed in Biotek reader spectrophotometer (Molecular Devices) 
instrument and the obtained data were analyzed using the Microsoft Office 
Excel 2007.  
 
5.5.1 Characterization data for CDg6 (BDRCA-656) and other BDR 
derivatives 
CDg6 (9 mg, 25%) 
 
LCMS (APCI): calc for C43H62BClF2N4O2 (M+H) 751.46; found: 751.5 
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HRMS (APCI): calc for C43H62BClF2N4O2 (M+H) 751.4622; found: 751.4702 
1
H-NMR (500 MHz, CDCl3): δ 7.50 (d, 2H, J= 8.0 Hz), 7.37 (d, 2H, J= 8.0 
Hz), 5.94 (s, 2H), 5.29-5.33 (m, 2H), 4.07 (s, 2H), 3.62 (t, 2H, J=5.5 Hz), 3.39 
(t, 2H, J=5.5 Hz), 3.16 (t, 2H, J=7 Hz), 2.55 (s, 6H), 1.39 (s, 6H), 1.03-1.25 
(m, 30H), 0.85 (t, 3H, J=7 Hz). 
13
C-NMR (125 MHz, CDCl3): δ 164.16, 164.12, 155.96, 145.23, 142.71, 
128.40, 127.22, 121.46, 53.31, 50.87, 49.57, 42.72, 41.68, 39.43, 36.29, 31.89, 
31.86, 29.73, 29.69, 29.65, 29.51, 29.43, 29.34, 29.30, 29.16, 29.09, 28.97, 
27.46, 27.39, 27.22, 27.17, 27.12, 26.75, 26.59, 14.64, 14.60, 14.01, 14.07 
BDRCA-28 (8 mg, 15%) 
 
  LCMS (APCI): calc for C39H56BClF2N4O2 (M+H) 697.42; found: 697.4 
HRMS (APCI): calc for C39H56BClF2N4O2 (M+H) 697.4153; found: 697.4232 
1
H-NMR (500 MHz, CDCl3): δ 7.49 (d, 2H, J=8 Hz), 7.36 (d, 2H, J=8 Hz), 
5.98 (s, 2H), 4.06 (s, 2H), 2.54 (s, 6H), 1.85 (t, 2H, J=6 Hz)), 1.46-1.52 (m, 




BDRCA-55 (5 mg, 10%) 
 
LCMS (APCI): calc for C38H54BClF2N4O2 (M+H) 683.40; found: 683.40 
HRMS (APCI): calc for C38H54BClF2N4O2 (M+H) 683.3996; found: 683.4076 
1
H-NMR (500 MHz, CDCl3): δ 7.50 (d, 2H, J=8 Hz), 7.37 (d, 2H, J=7.5 Hz), 
5.99 (s, 2H), 4.07 (s, 2H), 2.55 (s, 6H), 2.09 (m, 2H), 1.63 (m, 12H), 1.40 (s, 
6H), 1.25 (m, 4H), 0.71-0.86 (m, 15H). 




LCMS (APCI): calc for C43H64BClF2N4O2 (M+H) 753.48; found: 753.5 
HRMS (APCI): calc for C43H64BClF2N4O2 (M+H) 753.4779; found: 753.4859  
1
H-NMR (500 MHz, CDCl3): δ 7.50 (d, 2H, J=8.5 Hz), 7.37 (d, 2H, J=8 Hz), 
5.99 (s, 2H), 4.07 (s, 2H), 2.55 (s, 6H), 1.85 (m, 2H), 1.504-1.518 (m, 4H), 
1.40 (s, 6H), 1.03-1.27 (m, 34 H), 0.87 (t, 3H, J=6.5 Hz). 
BDRCA-407 (10 mg, 25%) 
 
LCMS (APCI): calc for C35H48BClF2N4O2 (M+H) 641.35; found: 641.4 
HRMS (APCI): calc for C35H48BClF2N4O2 (M+H) 641.3527; found: 641.3606 
1
H-NMR (500 MHz, CDCl3): δ 7.50 (d, 2H, J=8.5 Hz), 7.36 (d, 2H, J=8 Hz), 
5.98 (s, 2H), 4.06 (s, 2H), 2.55 (s, 6H), 1.84-1.86 (m, 2H), 1.46-1.51 (m, 4H), 
1.39 (s, 6H), 1.03-1.27 (m, 18 H), 0.86 (t, 3H, J=7 Hz) 




LCMS (APCI): calc for C34H46BClF2N4O2 (M+H) 627.34; found: 627.30 
HRMS (APCI): calc for C34H46BClF2N4O2 (M+H) 627.3370; found: 627.3449 
1
H-NMR (500 MHz, CDCl3): δ 7.50 (d, 2H, J=8 Hz), 7.37 (d, 2H, J=8 Hz), 
5.99 (s, 2H), 4.07 (s, 2H), 2.55 (s, 6H), 1.84-1.86 (m, 2H), 1.47-1.57 (m, 4H), 
1.40 (s, 6H), 1.03-1.27 (m, 16 H), 0.86 (t, 3H, J=7 Hz) 
BDRCA-567 (6 mg, 18%) 
 
LCMS (APCI): calc for C36H50BClF2N4O2 (M+H) 655.37; found: 655.40 
HRMS (APCI): calc for C36H50BClF2N4O2 (M+H) 655.3683; found: 655.3762 
1
H-NMR (500 MHz, CDCl3): δ 7.50 (d, 2H, J=8 Hz), 7.36 (d, 2H, J=8 Hz), 
5.99 (s, 2H), 4.07 (s, 2H), 2.55 (s, 6H), 1.84-1.86 (m, 2H), 1.50-1.52 (m, 4H), 
1.39 (s, 6H), 1.03-1.27 (m, 20 H), 0.86 (t, 3H, J=6.5 Hz) 





LCMS (APCI): calc for C37H52BClF2N4O2 (M+H) 669.38; found: 669.4 
HRMS (APCI): calc for C37H52BClF2N4O2 (M+H) 669.3840; found: 669.3919 
1
H-NMR (500 MHz, CDCl3): δ 7.50 (d, 2H, J=8 Hz), 7.37 (d, 2H, J=8 Hz), 
5.98 (s, 2H), 4.07 (s, 2H), 3.63-3.64 (m, 2H), 3.39-3.40 (m, 2H), 3.16 -3.19 
(m, 2H), 2.55 (s, 6H),.4 (s, 6H), 1.03-1.25 (m, 22 H), 0.86 (t, 3H, J=7 Hz) 
BDRCA-580 (8 mg, 22%) 
 
LCMS (APCI): calc for C41H60BClF2N4O2 (M+H) 725.45; found: 725.5 
HRMS (APCI): calc for C41H60BClF2N4O2 (M+H) 725.4466; found: 725.4546 
1
H-NMR (500 MHz, CDCl3): δ 7.50 (d, 2H, J=8.5 Hz), 7.37 (d, 2H, J=8 Hz), 
5.99 (s, 2H), 4.07 (s, 2H), 3.39-3.4 (m, 2H), 3.18-3.19 (m, 2H), 2.55 (s, 6H), 







BDR-28 (10 mg, 20%) 
 
  LCMS (ESI): calc for C37H55BF2N4O (M+H) 621.44; found: 621.40 
1
H-NMR (500 MHz, CDCl3): δ 7.51 (d, 2H, J=10 Hz), 7.37 (d, 2H, J=5.5 Hz), 
5.98 (s, 2H), 2.55 (s, 6H), 1.97-2.24 (m, 6H), 1.38 (s, 6H), 1.03-1.23 (m, 26 
H), 0.87 (t, 3H, J=3.5 Hz) 
BDR-55 (7 mg, 18%) 
 




H-NMR (500 MHz, CDCl3): δ 7.54 (d, 2H, J=7 Hz), 7.38 (d, 2H, J=7 Hz), 
5.98 (s, 2H), 2.55 (s, 6H), 2.16-2.22 (m, 2H), 2.04-2.10 (m, 4H), 1.38 (s, 6H), 
1.07-1.18 (m, 10H), 0.72-0.84 (m, 17H). 
BDR-65 (12 mg, 25%) 
 
LCMS (ESI): calc for C41H63BF2N4O (M+H) 677.51; found: 677.40 
1
H-NMR (500 MHz, CDCl3): δ 7.51 (d, 2H, J=9 Hz), 7.37 (d, 2H, J=7 Hz), 
5.98 (s, 2H), 2.55 (s, 6H), 2.06-2.21 (m, 6H), 1.38 (s, 6H), 1.03-1.23 (m, 34 
H), 0.87 (t, 3H, J=7 Hz) 
BDR-407 (15 mg, 30%) 
 




H-NMR (500 MHz, CDCl3): δ 7.53 (d, 2H, J=10 Hz), 7.37 (d, 2H, J= 5.5 
Hz), 5.98 (s, 2H), 2.55 (s, 6H), 2.16-2.20 (m, 6H), 1.39 (s, 6H), 1.03-1.23 (m, 
18 H), 0.86 (t, 3H, J=7 Hz). 
BDR-554 (15 mg, 30%) 
 
LCMS (ESI): calc for C32H45BF2N4O (M+H) 551.37; found: 551.4 
1
H-NMR (500 MHz, CDCl3): δ 7.52 (d, 2H, J=7 Hz), 7.37 (d, 2H, J=5.5 Hz), 
5.98 (s, 2H), 2.55 (s, 6H), 2.02-2.24 (m, 6H), 1.38 (s, 6H), 1.04-1.27 (m, 16 
H), 0.85 (t, 3H, J=7 Hz). 
BDR-567 (9 mg, 23%) 
 




H-NMR (500 MHz, CDCl3): δ 7.52 (d, 2H, J=6.5 Hz), 7.37 (d, 2H, J=7.5 
Hz), 5.98 (s, 2H), 2.55 (s, 6H), 2.16-2.20 (m, 6H), 1.38 (s, 6H), 1.04-1.25 (m, 
20 H), 0.86 (t, 3H, J=6.5 Hz) 
BDR-577 (6 mg, 15%) 
 
LCMS (ESI): calc for C35H51BF2N4O (M+H) 593.41; found: 593.40 
1
H-NMR (500 MHz, CDCl3): δ 7.50 (d, 2H, J=8 Hz), 7.38 (d, 2H, J=6 Hz), 
5.98 (s, 2H), 2.55 (s, 6H), 2.04-2.16 (m, 6H), 1.38 (s, 6H), 1.23-1.25 (m, 22 
H), 0.86 (t, 3H, J=6.5 Hz). 




LCMS (ESI): calc for C39H59BF2N4O (M+H) 649.47; found: 649.60 
1
H-NMR (500 MHz, CDCl3): δ 7.52 (d, 2H, J=7 Hz), 7.38 (d, 2H, J=7.5 Hz), 
5.98 (s, 2H), 2.55 (s, 6H), 2.16-2.22 (m, 6H), 1.38 (s, 6H), 1.19-1.24 (m, 28 
H), 0.87 (t, 3H, J=6.5 Hz) 
BDR-656 (15 mg, 30%) 
 
LCMS (ESI): calc for C41H61BF2N4O (M+H) 675.49; found: 675.40  
1
H-NMR (500 MHz, CDCl3): δ 7.52 (d, 2H, J=7.0 Hz), 7.37 (d, 2H, J=7.0 
Hz), 5.98 (s, 2H), 5.29-5.34 (m, 2H), 3.19 (t, 2H, J=6.5 Hz), 2.55 (s, 6H), 1.97 
(t, 4H, J=6.5 Hz) 1.38 (s, 6H), 1.03-1.24 (m, 30H), 0.86 (t, 3H, J=7 Hz).  
13
C-NMR (125 MHz, CDCl3): δ 156.07, 142.59, 136.76, 136.32, 131.10, 
130.09, 130.01, 129.69, 129.69, 129.54, 128.53, 127.63, 121.52, 53.40, 49.98, 
41.79, 37.16, 32.58, 31.88, 29.72, 29.67, 29.50, 29.46, 29.34, 29.30, 29.10, 





Characterization by HPLC-MS (APCI) of BODIPY derivatives: greater 
than 18-carbon alkyl chain 
HPLC conditions: A: H2O-HCOOH: 99.9:0.1. B: CH3CN-HCOOH: 
99.9:0.1; gradient 5% B to 100% B (7 min), isocratic 100% B (7-18 min), 
gradient 100% B to 95% B(18-18.1 min), isocratic 5% B (18.1-20 min). 
Reversephase Phenomenex C18 Luna column (4.6 x 50 mm
2
) 3.5 m, flow 
rate: 1.0 mL/min. 
TB-G-19CA (orange solid, 3.5 mg, 20%) 
 








 DAD1 A, Sig=254,16 Ref=off (RAJU\RAJ 2011-09-22 20-02-57\1HA-0101.D)






 DAD1 B, Sig=350,16 Ref=off (RAJU\RAJ 2011-09-22 20-02-57\1HA-0101.D)
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TB-G-20CA (orange solid, 3 mg, 15%) 
 









 DAD1 A, Sig=254,16 Ref=off (RAJU\RAJ 2011-09-28 20-45-47\1GA-0101.D)







 DAD1 B, Sig=350,16 Ref=off (RAJU\RAJ 2011-09-28 20-45-47\1GA-0101.D)
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TB-G-21CA (orange solid, 1.5 mg, 8%) 
 








 DAD1 A, Sig=254,16 Ref=off (RAJU\TB-G-21CA.D)





 DAD1 B, Sig=350,16 Ref=off (RAJU\TB-G-21CA.D)

























TB-G-22CA (orange solid, 2 mg, 12%) 
 









 DAD1 A, S ig=254,16 Ref=off (RAJU\TB-22CA1.D)









 DAD1 B, S ig=350,16 Ref=off (RAJU\TB-22CA1.D)
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TB-G-23CA (orange solid, 1.3 mg, 6%) 
 








 DAD1 A, S ig=254,16 Ref=off (RAJU\TB-23CA1.D)










 DAD1 B, S ig=350,16 Ref=off (RAJU\TB-23CA1.D)
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TB-G-24CA (orange solid, 0.8 mg, 6%) 
 








 DAD1 A, S ig=254,16 Ref=off (RAJU\TB-23CA1.D)










 DAD1 B, S ig=350,16 Ref=off (RAJU\TB-23CA1.D)
































5.5.2 Synthesis procedure and characterization 
Compound 1 
 
Methyl 4-(chlorocarbonyl)benzoate (1 g, 5.03 mmol, 1 eq.) and 2,4-
dimethyl pyrrole (1.05 mL, 11.07 mmol, 2.2 eq.) were dissolved in DCM (100 
mL) and the  reaction mixture was stirred under nitrogen at room temperature 
for 4 hours until reaction was completed.  Then the BF3-OEt2 (4.8 mL, 35.21 
mmol, 7 eq.) and Triethylamine (3.4 mL, 25.15 mmol, 5 eq.) were added in 
situ to the reaction mixture and stirred at room temperature for 12 hours. After 
complete of reaction, the reaction mixture was washed with water and then 
organic layer was collected (3 x 100 mL) and purified by a normal-phase silica 
column using Hexane-EtOAc (ranging from 100:0 to 90:10) as the eluting 
solvent and got) pure orange colored solid compound 1. Yield: 700 mg, 36%. 




H-NMR (500 MHz, CDCl3): δ 8.05 (d, 2H, J=8.0 Hz), 7.27 (d, 2H, J=8.0 
Hz), 5.85 (s, 2H), 3.83 (s, 3H), 2.42 (s, 6H), 1.22 (s, 6H). 
13
C-NMR (125 MHz, CDCl3): δ 166.42, 155.96, 142.83, 140.18, 139.81, 
130.89, 130.78, 130.33, 129.47, 128.35, 121.44, 52.35, 14.57, 14.46. 
Compound 2 
 
The compound 1(700 mg, 1.83 mmol, 1eq.) was dissolved in solvent 
mixture of DCM:MeOH (3:1)(v/v) (500 mL). Then, 90 mL of 0.2 N KOH in 
H2O (1.06 g, 18.3 mmol, 10 eq) was added to the solution. The resulting 
mixture was stirred at room temperature for 24 hours.  After complete 
hydrolysis, the reaction mixture was quenched with 100 mL of AcOH-H2O 
(1:1) and then MeOH was removed from the reaction mixture under reduced 
pressure. Then the DCM was added to solution and the organic layer was 
collected (3 x 100 mL), washed with water and purified by a normal-phase 
silica column using Hexane-EtOAc (ranging from 100:0 to 40:60) as the 
eluting solvent to obtain pure orange colored solid compound 2. Yield: 670 
mg, 99%. 
LCMS (ESI): calc for C21H21BF2N2O2 (M-H) 367.15; found: 367.20 
1
H-NMR (500 MHz, DMSO-d6): δ 8.04 (d, 2H, J=8.0 Hz), 7.31 (d, 2H, J=8.0 
Hz), 6.17 (s, 2H), 2.44 (s, 6H), 1.33 (s, 6H). 
13
C-NMR (125 MHz, DMSO-d6): 
δ 154.32, 142.21, 141.61, 130.03, 129.41, 126.54, 120.86, 20.79, 13.70, 13.47 
146 
 
General procedure for the preparation of solid supported secondary 
amines 
Most of the general procedures for the preparation of resins which 
were either used in diversified library synthesis or the derivatization of library 
compounds have been covered in the chapter 2 and chapter 3. Here the few 
more procedures are given that have been used for the SAR studies. 
General procedure for synthesis of solid supported secondary amines with 
alkyl bromide  
For each reaction, resin (solid supported 3-diaminoproane) (25 mg, 
0.025 mmol, 1 eq, 1 mmol/g) was suspended in 500 L of N-
Methylpyrrolidone (NMP) in a 2 mL of glass vial. 7 eq. of each alkyl-bromide 
(0.7 mmol) and 14 eq. of DIEA (1.4 mmol) were then added to the reaction 
mixture .The reaction mixture was then shaken for overnight at 70 
o
C 
temperature in the heat block and then the resin was filtered through 5 mL 
syringe fitted with cartridge and washed with DMF (5X 3 mL), methanol (5X 
3mL), and dichloromethane (5X 3mL). The solid supported secondary amine 
resins obtained, were dried and used for next step reactions. 
General procedure for synthesis of BDR library 
 To synthesize BDR library, each of (solid supported secondary amine) 
resin  (50 mg, 0.035 mmol, 1eq, 0.7 mmol/g ) was suspended in 3 mL of DMF 
in a 10 mL syringe then 25 mg, 0.07 mmol, 2 eq 1, 30 mg, 0.77 mmol, 2.2 eq 
2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HATU) and 30 L, 0.168 mmol, 4.8 eq DIEA were 
added. At a time 40 individual reaction mixtures were placed on orbital shaker 
for 24 h at room temperature and after completion of the reaction the resin was 
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filtered through 10 mL cartridge and then washed with DMF (5X 5mL), 
methanol (5X 5mL), and dichloromethane (5X 5mL) consecutively. The resin 
was dried under high vacuum to afford solid supported compounds resin 2 and 
then the subsequently the dried resin of 50 mg was treated with 0.5% TFA in 
dichloromethane (5 mL) for 10X 4 mins. The solution was drained in to the 20 
mL vial followed by quenched with 100 L of 7 (N) NH3 in methanol and 
then organic layer was washed with the saturated NaHCO3 solution, and then 
the organic layer was separated and then purified by using short column and 
dried using Speed Vacuum to afford the BDR library products (orange solid 
with average 25% yield). Each of BDR compound was primarily characterized 






General procedure for synthesis of BDRCA and BDRAC libraries 
To synthesized BDRCA and BDRAC libraries, each of 1 mol BDR 
library compound (80 compounds) was taken according to their plate code in 
the 2 mL of 96-deep well plate. About 30 mg (~ 20 mol, 20 eq.) of respective 
active-ester resin was added to the each well of the BDR library containing 
plate. Then, DCM:ACN (7:1) solvent mixture of around 500 L and catalytic 
amount of saturated solution of NaHCO3 were poured in to each well. The 
plate was kept in the shaker with moderate shaking for 2 hours. Then, the 
solution was filtered from the resin and dried to obtain pure products.  
5.5.3 Cytotoxicity assay of CDg6 on purified B-cells 
Stock solution of 10
6
 cells/mL of purified mouse B-cells isolated from 
spleen was prepared as described above. 1 μM, 3 μM and 5 μM of CDg6 were 
used in this assay. To three wells of a 96-well plate, 100 μL of cell culture 
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medium was added to serve as negative control. 100 μL of each stimulant was 
added in triplicate sets to the remaining wells. To each well, 100 μL of B-cells 
were added (10
5
cells/well) and the cells homogenously mixed with the 
stimulants via repeated inversion of the micropipette tip. The plates were then 
incubated at 37 
o
C, 5% CO2 for 4 hour, 24 hour and 48 hour respectively. 1 
μM of Hoechst 33342 (Invitrogen) was added to each well for cell counting 
using ImageXpressMICRO system (Molecular Device). 
 
5.5.4 Isolation of B cell and T cell 
Isolation of T cells  
Spleen and blood (500 L from heart) were obtained from six or seven 
week old C57BL/6J mouse. T cells were isolated from spleen and blood cells 
using indirect immunomagnetic separation. Red blood cells (RBCs) lysis was 
achieved using a 0.165M solution of NH4Cl (Sigma-Aldrich). Biotinylated 
monoclonal antibodies to mouse CD45R/B220, CD11b (Integrin αM chain) 
Ly-6G and Ly-6C (Gr-1) and TER-119/Erythroid Cells (Ly-76) were added 
and incubated for at 4
oC. BD IMag™ Streptavidin Particles Plus – DM (BD 
Bioscience Co.) were then added and bind to cells bearing biotinylated 
antibodies. The tube containing the labeled cell suspension was then placed 
within the magnetic field of the BD IMagnet™ (BD Bioscience Co.) with 
IMag buffer (BD Bioscience Co.). T cell isolation was achieved via depletion 
of cells committed to the B-lymphocytic, myeloid (monocytic and 
granulocytic), and erythroid lineages. The purity of the isolated T cells was 
92% as assessed by flow cytometric analysis. 
Isolation of B cells  
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Spleen, bone marrow and blood (500 L from heart) were obtained 
from six or seven week old C57BL/6J mouse. B cells were isolated from 
spleen, bone marrow and blood cells using indirect immunomagnetic 
separation. RBCs lysis was achieved using a 0.165M solution of NH4Cl 
(Sigma-Aldrich). Biotinylated monoclonal antibodies to mouse CD3e (CD3 ε 
chain), CD4, CD8, CD11b (Integrin αM chain), Ly-6G and Ly-6C (Gr-1) and 
TER-119/Erythroid Cells (Ly-76) were then added and incubated for at 4 
o
C. 
BD IMag™ Streptavidin Particles Plus – DM (BD Bioscience Co.) were then 
added and bind to cells bearing biotinylated antibodies. The tube containing 
the labeled cell suspension was then placed within the magnetic field of the 
BD IMagnet™ (BD Bioscience Co.) with IMag buffer (BD Bioscience Co.). B 
cell isolation was achieved via depletion of cells committed to the T-
lymphocytic, myeloid (monocytic and granulocytic), and erythroid lineages. 
The purity of the isolated B cells was 91% as assessed by flow cytometric 
analysis.  
5.5.5 B- Cell screening 
Dulbecco's Modified Eagle Medium (DMEM) (4.5g/L glucose) 
(Gibco) + 10% Fetal Bovine Serum (FBS) + 0.1% Beta-mercaptoethanol + 1% 
Penicilin Streptomycin (P/S) was used as the medium for cell culture. T- and 
B- cells from mouse spleen were used for image based screening of DOFL. 
5000 T-cell and B-cells isolated using immunomagnetic separation were 
placed in each well on a 384-well plate. Cells were counted in 
hematocytometer and cell viability was assessed by Trypan blue staining. 
DOFLs screens and analysis to detect compounds showing high fluorescent 
cell image was performed with all the BDR derivatives using the following 
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procedures. 1 M of BDR derivatives dissolved in dimethyl sulfoxide 
(DMSO) was added to each well in the 384-well plate and incubated at 37 
o
C. 
1 M of Hoechst 33342 (Invitrogen) dye was added 15 minutes prior to 
screening. After incubation for 1 hour and 4 hour, images were acquired using 
the ImageXpress
MICRO
 system (Molecular Device) which is a fully-integrated 
hardware and software system for automated acquisition and analysis of high 
contents fluorescence cell images. The image information was converted into 
digital information for high-throughput and high-content analysis. In parallel, 
we double checked the images manually. The compounds which stain only B-
cell selectively were chosen as hits and subjected to subsequent secondary 
screening and flow cytometric analysis. 
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5.5.6 Flow cytometry 
300,000 each of splenocytes, peripheral blood lymphocytes, bone 
marrow cells, isolated T- and B- cells were incubated with 1 M of 
compounds for 4 h at 37
o
C with cell culture medium. After incubation the 





 at pH 7.3 and resuspended in 100 L of PBS. The cells are then mixed 
with a combination of 0.5 μL each of PE-Cy5 conjugated monoclonal 
antibodies to mouse CD3e and biotin-conjugated monoclonal antibodies to 
mouse CD45R/B220 and incubated for 25 minutes at 4 °C. In testing out the 
maturity state of B-cells, the cells are mixed with a combination of 0.5 μL 
each of APC conjugated monoclonal antibodies to mouse CD45R/B220 and 
biotin-conjugated monoclonal antibodies to mouse IgD incubated for 25 
minutes at 4°C. After incubation, the cells were again washed with PBS and 
suspended in 100 μL of PBS before 0.5 μL Streptavidin-APC-cy7 was added 
for three-color flow cytometry.  
5.5.7 Localization study  
8 μL of CellMask™ Deep Red plasma membrane stain (Invitrogen) was added 
to 1 mL of B-cells (10
5
 cells/mL) in a 5 mL polystyrene tube (8 μg/mL 
working concentration) and incubated for 5 minutes at 37 
o
C. The cells were 
washed, mounted on a glass slide and imaged immediately using confocal 
microscopy.  
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Synthesis of Rhodol library (RDR) and development of 














6.1 Introduction  
Fluorescence techniques have extensively been used and are still 
enjoying rising interest from chemistry to many areas of biology due to high 
sensitivity, simplicity, quick response, rich of molecular information, and 
ability to spatial imaging.
1
 However, the possibility of using ﬂuorescence 
techniques for a particular purpose is often restricted by the availability of 
suitable ﬂuorescent molecules. Moreover, there are very few, theoretical 
approaches for rational design of fluorescent probes.
2
 On the other hand, 
combinatorial assembly of libraries of ﬂuorescent molecules has been 
demonstrated to be a very powerful and promising approach
3
 with a number of 
remarkable discoveries of novel ﬂuorescent probes4. Therefore, synthesis of 
fluorescent library using biologically less explored scaffolds may have higher 
chance to discover novel fluorescent probes. As a candidate scaﬀold, we 
focused on rhodol for systematic library generation due to its limited examples 
about the applications in probe development process. So far, rhodol dyes have 
been effectively employed as scaﬀolds for ﬂuorescence probes to detect 
hydrogen peroxide, zinc ion, peroxynitrite, and hypoxia. Rhodol
5
 is the hybrid 
structure of ﬂuorescein and rhodamine. It also named “Rhodaﬂuor”6. This 
scaffold shows excellent photophysical properties such as high extinction 
coefﬁcients, quantum yields, photostability, and solubility in a variety of 
solvents, yet low pH-dependence
5b
. Moreover, the fluorescence property such 
as emission wavelength and quantum yield can easily be tuned by changing 
the substitution patterns of the nitrogen atom in a similar manner to 
rhodamine.
7
 Although, they inherit excellent photophysical properties there 
are limited availability of rhodol based fluorescent probes,
6,8
 probably owing 
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to lack of enough synthetic reports . Utilizing all these opportunities and 
adopting our robust solid phase synthesis methodology, I synthesized diversity 
oriented rhodol library, RDR, RDRCA and RDRAC and utilized these 
compounds in the mitotic phase screening in live cells to find out live mitotic 
phase visualizing agent. 
6.1.1 Cell division: mitosis 
Cell cycle is a crucial process where a parent cell divides into two or 
more daughter cells. Overall, the cell cycle development consists of four 
different phases
9
: G1 phase, S phase, G2 phase, and mitosis. Mitosis is very 
important for the living organism for many reasons. It critically helps in 
growth, cell replacement, regeneration and vegetative reproduction of a living 
organism. However, uncontrolled mitotic cell division causes neoplasia. 
Neoplasia
10
 (the formation of new strange tissues) occurs when a cell suffers 
mutation in its genetic material, loses the ability to control its own division 
and the failure is transmitted to its descendants. Cancers are malignant 
neoplasias. The term malignant means that neoplastic cells can disseminate to 
distant sites invading other organs and tissues. Neoplasias whose cells cannot 
disseminate to distant sites are called benign neoplasias. Moreover, according 
to the recent study, the monitoring of cell proliferation and its distinction 




 During the mitotic process one eukaryotic cell divides into two cells identical 
to the parent cell (generally identical, since alterations in genetic material can 
occur, more or less organelles may be distributed between the daughter cells, 
etc.). In the mitotic cell cycle, the cell is created and finishes when it is divided 
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by mitosis creating two daughter cells. Mitosis
12
 propagates through the 4 
different stages: prophase, metaphase, anaphase, and telophase. During the 
mitosis, mitotic apparatus display critical role in cell division. Mitotic 
apparatus consists of the set of aster fibers, radial structures around each 
centriole pair, plus the spindle fibers, fibers that extend across the cell between 
the two centriole pairs located in opposite cell poles
13
. The mitotic apparatus 
appears in prophase and has important role in the orientation and gripping of 
chromosomes and other cellular elements causing them to separate and 
migrate to opposite cell poles.  
To monitor and quantify cell division in live cells, and reliably distinguish 
between  acytokinesis  and  endoreduplication, there are few current 
approaches  which are  limited  and  complicated  in determination  of stem 
cell pool identities
11
. Thus, there is an urgent demand to develop novel 
fluorescent probe for monitoring cell proliferation.   
6.2 Objectives 
Here we developed the solid phase diversity-synthesis methodology of 
80-member rhodol library RDR. These RDR compounds were further 
diversified to their corresponding actyl (RDRAC) and chloroacetyl (RDCA) 
derivatives using a simple but powerful solid phase activated ester chemistry. 
Next, we performed the full photophysical characterisation of these rhodol 
libraries. With the interest to develop mitotis phase selective fluorescent 
probe, RDR, RDRCA and RDRAC libraries were screened against 
RPE1:H2B:GFP cells which were seeding in 384-well plate, synchronized by 
Tubulyzine B and then compound  RDR-567 was identified as a mitotic phase 
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probe that can distinguish between interphase and mitotic phase cells using 
micropsope. 
6.3 Results and discussion  
6.3.1 Design and synthesis 
In this particular section, the synthesis characterisation and the 
applications of RDR libraries are discussed. As shown in the Scheme 6.1, the 
general synthetic strategy of rhodol acid involves five steps reactions. At first, 
methyl protection (1) of 8-hydroxyjulolidine was carried out obtain the good 
yield in Friedel-Crafts reaction which was performed with methyl 4-
(chlorocarbonyl) benzoate in presence of AlCl3 to get compound 2. In the 
following step, demethylation was performed to obtain compound 3 using 
BBr3 as the demethylating agent. Now, the methanesulfonic acid mediated 
standard ring cyclization reaction was carried out using resorcinol and 
demthylated product to obtain the corresponding rhodol ester, 4 which was 
then hydrolyzed using 2 N KOH , a standard base catalyzed ester hydrolysis 












Scheme 6.1 Synthesis of RDR acid 
 
 
 Reagent and conditions (a) (CH3)2SO4, NaH, THF, rt; (b) methyl 4-
(chlorocarbonyl)benzoate, AlCl3, DCM, 0 
o
C, 2 h; (c) BBr3, DCM, -78 
o
C, 2 h; 
(d) Resorcinol, MeSO3H, seal tube, 80 
o
C, 2 h; (e) 2 N KOH, MeOH, rt, 2 h. 
After synthesizing rhodol acid, our robust solid phase methodology as 
discussed in the chapter 2 was applied to synthesize RDR library (Scheme 6.1 
and 6.2, Chart 6.1). Then, RDRCA and RDRAC compounds were 
synthesized according to the previous mention protocol (chapter 3). All the 
compounds in the library were characterized by HPLC-MS and 80 relatively 
pure compounds (average purity is 90%, measured at 350 nm (Table 6.1, 6.2 
and 6.3) were collected for further study. Excellent photophysical properties 
are reflected from the displaying quantum yield and spectral characteristists 







Scheme 6.2 Synthesis of RDR library 
 
Reagents and conditions: (a) DIEA, THF, 3-bromopropylamine, r.t., 12 h.; (b) 
DIEA, RNH2, NMP, 70 
o
C, 12 h.; (c) HATU, DIEA, r.t. 24 h.; (d) 1% TFA in 




















Scheme 6.3 RDRCA and RDRAC library synthesis 
 
Reagent and Conditions (a) DCM/ACN (1:1), NaHCO3, 2 h, r.t 
 






















RDR 28 663.4 664.4 545 587 0.45 93 
RDR 49 601.3 602.2 546 587 0.49 93 
RDR 55 649.4 650.4 544 586 0.40 96 
RDR 77 585.3 586.4 545 586 0.44 93 
RDR 80 593.2 594.2 545 586 0.42 92 
RDR 92 551.3 552.4 545 587 0.37 97 
RDR 100 661.3 662.4 545 587 0.36 95 
RDR 101 571.3 572.4 546 587 0.36 95 
RDR 103 601.3 602.4 545 586 0.35 92 
RDR 95 509.3 510.4 545 586 0.36 95 
RDR 124 617.3 618.4 546 587 0.40 91 
RDR 131 599.3 600.4 545 586 0.36 91 
RDR 135 625.2 626.2 546 587 0.38 93 
RDR 148 602.3 603.2 546 587 0.39 92 
RDR 165 539.3 540.4 546 587 0.38 92 
RDR 175 507.3 508.2 545 586 0.40 92 
RDR 177 525.3 526.2 546 586 0.42 91 
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RDR 181 617.3 618.2 546 587 0.36 93 
RDR 182 537.3 538.4 544 586 0.41 90 
RDR 185 537.3 538.4 545 586 0.39 91 
RDR 201 599.3 600.4 546 586 0.47 92 
RDR 211 571.3 572.2 545 586 0.40 92 
RDR 218 575.3 576.4 546 586 0.43 93 
RDR 220 575.3 576.2 544 586 0.43 95 
RDR 221 591.2 592.2 546 586 0.44 91 
RDR 222 509.3 510.2 545 586 0.42 88 
RDR 230 579.3 580.4 544 587 0.45 91 
RDR 240 633.3 634.4 545 586 0.47 91 
RDR 262 617.3 618.4 546 586 0.44 96 
RDR 272 578.3 579.4 545 586 0.43 91 
RDR 273 601.3 602.4 545 586 0.41 92 
RDR 275 599.3 600.4 546 586 0.46 90 
RDR 277 565.3 566.4 546 586 0.38 91 
RDR 282 580.3 581.4 545 586 0.39 90 
RDR 318 600.3 601.4 546 587 0.50 91 
RDR 335 585.3 586.4 546 586 0.42 96 
RDR 341 635.2 636.4 544 587 0.47 94 
RDR 356 647.3 648.2 545 586 0.42 94 
RDR 361 602.3 603.2 546 587 0.48 94 
RDR 363 602.3 603.2 545 587 0.40 94 
RDR 364 591.2 592.2 546 586 0.47 94 
RDR 368 636.4 637.4 544 586 0.48 95 
RDR 373 523.3 524.2 545 587 0.37 93 
RDR 374 557.3 558.3 545 586 0.41 95 
RDR 375 575.3 576.2 545 587 0.41 96 
RDR 382 563.3 564.4 545 587 0.44 94 
RDR 387 587.3 588.4 546 586 0.45 89 
RDR 388 571.3 572.3 546 586 0.40 96 
RDR 395 601.3 602.2 545 587 0.42 91 
RDR 396 571.3 572.2 546 586 0.41 92 
RDR 398 571.3 572.4 544 587 0.40 90 
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RDR 399 593.2 594.2 545 587 0.35 98 
RDR 403 591.2 592.2 545 586 0.35 91 
RDR 405 589.3 590.2 546 586 0.37 93 
RDR 407 607.4 608.4 544 587 0.45 91 
RDR 414 606.4 607.4 546 586 0.34 92 
RDR 419 537.3 538.4 544 587 0.45 96 
RDR 420 566.3 567.4 545 587 0.45 94 
RDR 425 537.3 538.4 545 586 0.43 93 
RDR 442 537.3 538.4 546 586 0.47 95 
RDR 447 625.3 626.4 544 586 0.40 94 
RDR 457 593.2 594.2 546 587 0.35 93 
RDR 477 589.3 590.4 545 587 0.41 94 
RDR 478 585.3 586.4 545 587 0.44 94 
RDR 480 605.2 606.2 546 586 0.38 93 
RDR 487 523.3 524.4 546 586 0.37 93 
RDR 522 613.3 614.4 544 587 0.31 91 
RDR 531 625.2 626.2 545 586 0.45 93 
RDR 554 593.4 594.4 546 587 0.29 92 
RDR 565 625.2 626.2 545 587 0.39 91 
RDR 567 621.4 622.4 545 587 0.41 92 
RDR 572 649.2 650.2 545 586 0.45 92 
RDR 574 537.3 538.2 545 586 0.49 96 
RDR 575 521.3 522.2 545 587 0.41 92 
RDR 602 551.3 552.4 545 586 0.34 93 
RDR 617 589.3 590.4 545 586 0.42 89 
RDR 621 653.2 654.2 545 586 0.45 93 
RDR 631 635.2 636.2 545 586 0.44 91 
RDR 677 605.2 606.2 545 586 0.37 92 




























RDRCA 28 739.4 740.4 544 586 0.34 93 
RDRCA 49 677.2 678.2 544 585 0.33 92 
RDRCA 55 725.4 726.4 544 586 0.38 93 
RDRCA 77 661.3 662.2 544 585 0.41 96 
RDRCA 80 669.2 670.2 544 586 0.29 93 
RDRCA 92 627.3 628.2 544 585 0.45 92 
RDRCA 100 737.3 738.2 544 586 0.31 97 
RDRCA 101 647.3 648.2 544 586 0.38 95 
RDRCA 103 677.3 678.2 544 585 0.40 95 
RDRCA 95 585.2 586.2 544 586 0.38 92 
RDRCA 124 693.3 694.2 544 585 0.34 95 
RDRCA 131 675.3 676.2 544 585 0.41 91 
RDRCA 135 701.2 702.2 544 585 0.39 91 
RDRCA 148 678.2 679.2 544 586 0.31 93 
RDRCA 165 615.2 616.2 544 586 0.42 92 
RDRCA 175 583.2 584.2 544 586 0.30 92 
RDRCA 177 601.2 602.2 544 586 0.40 92 
RDRCA 181 693.3 694.2 544 585 0.37 91 
RDRCA 182 613.3 614.2 544 586 0.32 93 
RDRCA 185 613.3 614.2 544 585 0.37 90 
RDRCA 201 675.3 676.4 544 586 0.47 91 
RDRCA 211 647.3 648.2 544 585 0.43 92 
RDRCA 218 651.2 652.2 544 586 0.38 92 
RDRCA 220 651.2 652.2 544 586 0.33 93 
RDRCA 221 667.2 668.2 544 585 0.37 95 
RDRCA 222 585.2 586.2 544 586 0.27 91 
RDRCA 230 655.3 656.2 544 586 0.29 88 
RDRCA 240 709.3 710.4 544 585 0.46 91 
RDRCA 262 693.3 694.2 544 586 0.34 91 
RDRCA 272 654.3 655.2 544 585 0.36 96 
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RDRCA 277 641.3 642.2 544 586 0.30 90 
RDRCA 282 656.3 657.2 544 586 0.35 91 
RDRCA 318 676.3 677.2 544 585 0.45 90 
RDRCA 335 661.3 662.2 544 586 0.31 91 
RDRCA 341 711.1 712.0 544 586 0.18 96 
RDRCA 356 723.3 724.2 544 585 0.34 94 
RDRCA 361 678.2 679.2 544 586 0.31 94 
RDRCA 363 678.2 679.2 544 585 0.27 94 
RDRCA 364 667.2 668.2 544 586 0.45 94 
RDRCA 368 712.4 713.4 544 585 0.40 94 
RDRCA 373 599.3 600.2 544 586 0.29 95 
RDRCA 374 633.2 634.2 544 586 0.23 93 
RDRCA 375 651.2 652.2 544 585 0.23 95 
RDRCA 382 639.3 640.2 544 586 0.25 96 
RDRCA 387 663.2 664.2 544 585 0.40 94 
RDRCA 388 647.3 648.2 544 586 0.25 89 
RDRCA 395 677.3 678.2 544 585 0.43 96 
RDRCA 396 647.3 648.2 544 586 0.32 91 
RDRCA 398 647.3 648.2 544 586 0.41 92 
RDRCA 399 669.2 670.2 544 585 0.35 90 
RDRCA 403 667.2 668.2 544 586 0.32 98 
RDRCA 405 665.2 666.2 544 585 0.41 91 
RDRCA 407 683.3 684.2 544 586 0.28 93 
RDRCA 414 682.3 683.2 544 586 0.34 91 
RDRCA 419 613.3 614.2 544 585 0.30 92 
RDRCA 420 642.3 643.2 544 586 0.25 96 
RDRCA 425 613.3 614.2 544 585 0.32 94 
RDRCA 442 613.3 614.2 544 586 0.47 93 
RDRCA 447 701.2 702.2 544 585 0.35 95 
RDRCA 457 669.2 670.2 544 586 0.31 94 
RDRCA 477 665.2 666.2 544 586 0.37 93 
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RDRCA 522 689.3 690.2 544 586 0.31 93 
RDRCA 531 701.2 702.2 544 585 0.44 91 
RDRCA 554 669.3 670.2 544 586 0.38 93 
RDRCA 565 701.2 702.2 544 586 0.33 92 
RDRCA 567 697.4 698.2 544 585 0.34 91 
RDRCA 572 725.2 726.2 544 586 0.25 92 
RDRCA 574 613.3 614.2 544 586 0.29 92 
RDRCA 575 597.2 598.2 544 586 0.18 96 
RDRCA 602 627.3 628.2 544 585 0.32 92 
RDRCA 617 665.2 666.2 544 586 0.47 93 
RDRCA 621 729.1 730.0 544 585 0.31 89 
RDRCA 631 711.2 712.2 544 586 0.48 93 
RDRCA 677 681.2 682.2 544 586 0.37 91 
RDRCA 686 715.2 716.2 544 585 0.48 92 
 






















RDRAC 28 705.5 706.4 545 587 0.51 94 
RDRAC 49 643.3 644.2 546 587 0.46 93 
RDRAC 55 691.4 692.4 544 586 0.40 94 
RDRAC 77 627.3 628.3 545 586 0.32 97 
RDRAC 80 635.3 636.2 545 587 0.30 94 
RDRAC 92 593.3 594.4 545 587 0.40 93 
RDRAC 100 703.3 704.2 545 586 0.34 96 
RDRAC 101 613.3 614.2 546 586 0.45 94 
RDRAC 103 643.3 644.2 545 587 0.41 94 
RDRAC 95 551.3 552.2 546 586 0.38 93 
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RDRAC 124 659.3 660.2 545 587 0.34 94 
RDRAC 131 641.3 642.2 546 587 0.49 92 
RDRAC 135 667.2 668.2 546 587 0.53 92 















RDRAC 177 567.3 568.2 545 587 0.44 91 
RDRAC 181 659.3 660.2 546 587 0.50 90 
RDRAC 182 579.3 580.4 546 586 0.40 94 
RDRAC 185 579.3 580.4 546 586 0.41 91 
RDRAC 201 641.3 642.2 544 587 0.39 92 
RDRAC 211 613.3 614.2 545 586 0.43 93 
RDRAC 218 617.3 618.2 546 587 0.41 93 
RDRAC 220 617.3 618.2 544 587 0.44 94 
RDRAC 221 633.2 634.2 545 587 0.36 96 
RDRAC 222 551.3 552.2 545 586 0.36 92 
RDRAC 230 621.4 622.4 545 586 0.39 89 
RDRAC 240 675.3 676.2 545 587 0.37 92 
RDRAC 262 659.3 660.2 546 587 0.35 92 
RDRAC 272 620.3 621.2 545 586 0.39 95 
RDRAC 273 643.3 644.2 546 586 0.34 92 
RDRAC 275 641.3 642.2 545 587 0.51 93 
RDRAC 277 607.3 608.2 546 586 0.38 92 
RDRAC 282 622.3 623.2 546 587 0.39 93 
RDRAC 318 642.3 643.2 544 587 0.44 91 
RDRAC 335 627.3 628.2 545 587 0.36 91 
RDRAC 341 677.2 678.2 546 587 0.50 95 
RDRAC 356 689.3 690.2 545 586 0.35 95 
RDRAC 361 644.3 645.2 546 586 0.28 95 
RDRAC 363 644.3 645.2 546 587 0.35 96 
RDRAC 364 633.2 634.2 546 587 0.49 93 
RDRAC 368 678.4 679.4 544 586 0.49 93 
RDRAC 373 565.3 566.2 545 586 0.39 94 
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RDRAC 374 599.3 600.2 545 587 0.33 92 
RDRAC 375 617.3 618.2 546 586 0.40 93 
RDRAC 382 605.3 606.2 545 587 0.35 95 
RDRAC 387 629.3 630.2 546 587 0.33 92 















RDRAC 398 613.3 614.2 545 586 0.50 93 
RDRAC 399 635.3 636.2 546 587 0.43 91 
RDRAC 403 633.2 634.2 546 587 0.56 94 
RDRAC 405 631.3 632.2 544 586 0.27 92 
RDRAC 407 649.4 650.2 545 586 0.42 94 
RDRAC 414 648.4 649.2 546 587 0.34 92 
RDRAC 419 579.3 580.4 545 586 0.35 91 
RDRAC 420 608.3 609.2 546 587 0.42 95 
RDRAC 425 579.3 580.2 546 587 0.45 93 
RDRAC 442 579.3 580.2 546 587 0.37 94 
RDRAC 447 667.3 668.2 544 587 0.37 93 
RDRAC 457 635.3 636.2 545 586 0.42 93 
RDRAC 477 631.3 632.2 546 586 0.46 92 
RDRAC 478 627.3 628.2 544 587 0.37 93 
RDRAC 480 647.3 648.2 545 587 0.37 95 
RDRAC 487 565.3 566.2 545 586 0.44 94 
RDRAC 522 655.3 656.4 545 586 0.21 94 
RDRAC 531 667.2 668.2 546 587 0.55 92 
RDRAC 554 635.4 636.4 545 586 0.38 93 
RDRAC 565 667.2 668.0 546 587 0.46 93 
RDRAC 567 663.4 664.4 546 587 0.31 94 
RDRAC 572 691.2 694.2 544 587 0.42 93 
RDRAC 574 579.3 580.4 545 586 0.47 93 
RDRAC 575 563.3 564.2 546 586 0.31 95 
RDRAC 602 593.3 594.4 545 587 0.36 93 
RDRAC 617 631.3 632.2 546 587 0.38 94 
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RDRAC 621 695.2 696.2 546 586 0.43 90 
RDRAC 631 677.3 678.2 546 586 0.50 94 
RDRAC 677 647.3 648.2 544 586 0.35 92 
RDRAC 686 681.2 682.2 545 587 0.36 90 
 
*1 Quantum yields were measured in DMSO, using Rhodamine B as a 
standard ( : 0.49, in DMSO).*2 Purities were determined according to UV 
absorption at 350 nm. 
ESI-MS positive spectra, HPLC conditions: A: H2O-HCOOH: 99.9:0.1. B: 
CH3CN-HCOOH: 99.9:0.1; gradient  100% A to 95% B (6 min), isocratic 
95% B (6-8.2min), gradient 95% B to 100% A  (8.2-9 min), isocratic 100% A 
(9-10 min). Reversephase Phenomenex C18 Luna column (4.6 x 50 mm
2 
) 3.5 
m, flow rate: 1.0 mL/min. 
 
 
Figure 6.1 Absorption and emission of RDR, RDRCA, RDRAC 
6.3.2 Discovery of  Mitotic phase probe 
For the mitotic cell imaging, RPE1:H2B:GFP (retinal pigmented 
epithelial cell line stably expressed with histone H2B fused to GFP) cells and 
M-phase synchronized RPE1:H2B:GFP cells were screened with the RDR 
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library compounds. Here tubulin binding compound, Tubulyzine B was used 
for (10 M for 24 h) the synchronization. The compounds with various 
concentrations and with the duration of 1 h were used for the primary 
screening. The staining results (Figure 6.2) indicate that one of our RDR 
compounds, RDR-567 (RDR-H2) stained brightly to the synchronized cells 
compared to the control cells. 
 
Figure 6.2 Live cell imaging of mitotic cells by RDR-567. A) The work flow 
of primary screening for seeking M-phase probes. (B) The structure of RDR-
567. (C) Representative FACS data showed cell cycle arrested at G1 phase 
(control, DMSO) after DMSO treatment for 24 h. Tubulyzine B-treated 
RPE1:H2B:GFP cells resulted in a clear accumulation of G2/M phase (red 
box).(D) Representative Texas red (red)/GFP (green) image showed RDR-567 
signal (red) and GFP signal (green) at M-phase (control, Tubulyzine B) after 
RDR-567 (1 µM) treatment for 1 h. Upper panel, control with RDR-567; 
down panel, Tubulyzine B with RDR-567; Our probes-treated cells were taken 
an image using ImageXpress Macro
TM
 cellular imaging system with 10X 
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phase contrast at 1 h. These data are representative of at least three 
independent experiments.  
 
6.3.3 Dose dependent study 
To check the dose dependent staining pattern of our probe, different 
concentrations of RDR-567/H2 were treated against the control of 
RPE1:H2B:GFP cells and tubulyzine B-treated RPE1:H2B:GFP cells. 
Consequently, figure 6.3 demonstrated the dose-dependency of RDR-567 
stained RPE1:H2B:GFP cells. Here, control and tubulyzine B-treated 
RPE1:H2B:GFP cells were tretaed with RDR-567 ( 0.1, 0.2, 0.4, 0.8 and 1.6 
µM) for 1 h. 
 
Figure 6.3 Selective staining of M-phase cells by RDR-567 (A) The structure 
of RDR-567. (B) dose-dependent RDR-567 stained RPE1:H2B:GFP cells. 
Control and Tubulyzine B-treated RPE1:H2B:GFP cells were added by RDR-
567 (0, 0.1, 0.2, 0.4, 0.8, 1.6 M) for 1 h. These data are representative of at 
least three independent experiments (Texas Red signal). 
 
6.3.4 Monitoring the M-phase progression in live cells 
The figure 6.4-A (time course images) indicates that our probe can 
nicely distinguish between the interphase and mitosis of the cell cycles. 
Mitosis cells are nicely stained with our probe. During the mitosis cell 
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staining, the signal intensity from the probe also increases with time (Figure 
6.4-A and B) 
 
Figure 6.4 Monitoring the M-phase progression in live cells with RDR-H2 
(A) Representative GFP (  ) Texas Red (  ) image showed hit candidate signal 
at M-phase after RDR-H2 (0.8 M) treatment for 3 h. To obtain the live cell 
imaging, fluorescence microscopy was performed on a Nikon N-
STORM/TIRF (40X) microscopy with a CoolSNAPHQ digital camera. (B) 
The intensity graph of mitosis phase-dependent changes in RPE1:H2B:GFP 




In conclusion, I successfully synthesized rhodol libraries (RDR, 
RDRCA and RDRAC) using efficient solid phase method. To the best of our 
knowledge, this is the first systematic report of rhodol library synthesis. 
Moreover, these compounds inherit excellent photophysical properties. As a 
result, compounds are suitable enough to utilize them in biological function 
detection or in probe discovery. Preliminary staining results/finding and with 
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further detailed study in future may render a suitable mitotic phase probe that 
can provide a convenient approach for developing detailed predictive models 
of cell cycle progression. 
6.5 Experimental methods 
Material and methods 
Amine and few bromide building block and all other chemicals and 
solvents for the synthesis were purchased from the Alfa Aesar, Fluka, Acros, 
MERCK, and Sigma Aldrich and were used without any purification. Merck 
Silica Gel 60 (particle size: 0.04-0.063 mm, 230-400 mesh) was used for the 
normal phase column chromatographic purification. From BeadTech Inc., 
Korea, 2-chlorotrityl alcohol resin (1.37 mmol/g) was purchased. For 
analytical characterization of RDR compounds HPLC-MS (Agilent-1200 
series) with a DAD detector and a single quadrupole mass spectrometer (6130 
series) with an ESI and sometimes with an APCI probe were used. Analytical 
process, except specified: eluents: A: H2O (0.1% HCOOH), B: ACN (0.1% 
HCOOH), C18 (2) Luna column (4.6 x 50mm
2




C-NMR spectra were recorded on both Bruker Avance 500 
MHz NMR spectrometer, and chemical shifts are expressed in parts per 
million (ppm) and approximate coupling constants were calculated in Hz. 
Quantum yields and all other photophysical properties of RDR derivatives 
were performed in Spectramax M2 instrument and the obtained data were 
analyzed using the Microsoft Office Excel 2007.  





To a suspension of 8-hydroxyjulolidine (1.0 g, 5.3 mmol) and sodium 
hydride (0.45 g, 11 mmol) in THF (50 mL), dimethylsulfate (1.0 mL, 11 
mmol) was added in ice-bath and the mixture was stirred at room temperature 
for 24 hrs. The reaction mixture was then evaporated and extracted with 
EtOAc three times. The combined organic layers were washed with water and 
brine, dried over MgSO4 and evaporated to give the crude product. This was 
purified by silica gel column chromatography (eluent: Hexane : EtOAc = 5 : 2, 
Rf = 0.88 ) to obtain the pure product as viscous oil. Yield: (0.7 g, 65%); 
LCMS (ESI): calc for C13H17NO (M+H) 204.1; found: 204.2 
 
 
To a solution of methyl 4-(chlorocarbonyl) benzoate (1.1 g, 5.6 mmol) 
and AlCl3 (0.80 g, 5.6 mmol) in CH2Cl2 (60 mL), 1 (1.1 g, 5.6 mmol) was 
slowly and the mixture was stirred under nitrogen at 0℃ for 1hrs. The mixture 
was poured into aqueous HCl and extracted with CH2Cl2 three times. The 
organic layers were washed with brine, dried over MgSO4 and evaporated to 
give the crude products. This was dissolved in 50 mL of MeOH and a catalytic 
amount of sulfuric acid was added. The reaction mixture was heated at reflux 
3 hrs with stirring and cooled to room temperature. The solvent was removed 
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on the rotary evaporator and extracted with EtOAc and H2O three times. The 
organic phase was dried over MgSO4 and evaporated. This was purified by 
silica gel column chromatography (eluent: Hexane : EtOAc = 5 : 1, Rf = 0.37) 
to obtain the pure product as yellow solids. Yield: 0.44 g (24 %).   
1
H- NMR 
(500 MHz, CDCl3); δ 1.96 (m, 4H), 2.69 (t, 2H, J=6Hz), 2.74 (t, 2H, J=6Hz), 
3.25 (m, 4H), 3.46 (s, 3H), 3.93 (s, 3H), 7.06 (s, 1H), 7.79 (d, 2H, J=9Hz), 




To a stirred solution of 2 (0.42 g, 1.15 mmol) in 10 mL of dry CH2Cl2, 
a solution of 10 mL of BBr3 (5 mmol) in CH2Cl2was added at -78℃. After 1 
hr, the mixture was warmed to -25℃. After completion, the mixture was 
quenched with saturated sodium bicarbonate. The mixtured was extracted with 
CH2Cl2 three times. The combined organic layers were washed with water and 
brine, dried over MgSO4 and evaporated to give the crude product. It was 
recrystallized from EtOH/H2O solution to the pure product as red solids. 
Yield: 24 mg (60 %); 
1
H- NMR (500 MHz, Methanol-d4); δ 1.95 (m, 4H), 2.54 
(t, 2H, J=6Hz), 2.74 (t, 2H, J=6Hz), 3.27 (m, 4H), 3.95 (s, 3H), 6.82 (s, 1H), 
7.62 (d, 2H, J=8.5Hz), 8.12 (d, 2H, J=8.5Hz). 
13
C-NMR (125 MHz, 
Methanol-d4); δ  19.89, 20.67, 21.71, 27.38, 29.69, 49.82, 50.22, 52.31, 105.7, 
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108.16, 112.87, 128.40, 129.35, 130.84, 131.4, 143.4, 149.42, 161.41, 166.59, 




3 (200 mg, 0.56 mmol ) and resorcinol (100 mg, 0.91 mmol) were 
combined in methanesulfonic acid acid (1.0 ml) in a sealed tube and heated at 
80℃ for 2.0 hrs. The cooled brick melt was pulverized. The solid was 
collected on a frit, washed thoroughly with hot water and dried in vacuo. This 
was purified by silica gel column chromatography (Eluent: CH2Cl2 : MeOH = 
10 : 1, Rf = 0.42) to obtain the pure product as red solids. Yield: 25 mg (10 
%);   4 (25 mg, 0.058 mmol) and 0.06 ml of 2 N KOH (0.12 mmol) solution 
were taken in methanol and stirred at rt for 2 hrs. Reaction was monitored by 
TLC. Then methanol was removed in vacuum and then compound from 
aqueous layer was extracted with DCM. The organic layer was dried over 
vacuum and crude was purified by silica gel column chromatography (Eluent: 
CH2Cl2 : MeOH = 9 : 1, Rf = 0.40). . Yield: 10 mg (40 %). 
1
H-NMR (500 
MHz, Methanol-d4):  1.95 (m, 4H), 2.16-2.20 (m, 6H), 2.54 (t, 2H, J=6Hz), 
2.74 (t, 2H, J=6Hz), 3.27 (m, 4H), 3.95 (s, 3H), 6.1 (s, 1H), 6.31 (d, 1H, 
J=5Hz), 6.42 (d, 1H, J=5Hz), 6.82 (s, 1H), 7.62 (d, 2H, J=8.5Hz), 8.12 (d, 2H, 
J=8.5Hz). 
LCMS (ESI): calc for C26H21NO4 (M+H) 412.1; found: 412.2 
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Characterization data for RDR-H2 (RDR-567) compound 
 
LCMS (ESI): calc for C40H51N3O3 (M+H) 622.4; found: 622.4 
1
H- NMR (500 MHz, Methanol-d4); δ 0.89 (t, 3H, J=6.5 Hz), 1.01-1.22 (m, 16 
H), 1.92 (m, 4H), 2.12-2.21 (m, 6H),2.53 (t, 2H, J=6Hz), 2.75 (t, 2H, 6Hz), 
3.26 (m, 4H), 3.96 (s, 3H), 6.14 (s, 1H), 6.32 (d, 1H, J=5Hz), 6.41(d, 1H, 
J=5Hz), 6.81 (s, 1H), 7.61 (d, 2H, J=8.5Hz), 8.11 (d, 2H, J=8.5Hz).
 13
C-NMR 
(125 MHz, Methanol-d4); δ  7.81, 12.98, 13.01, 19.00, 19.14, 20.04, 22.29, 
25.59, 26.10, 27.18, 28.17, 28.62, 29.06, 29.22, 29.33, 31.61, 37.07, 41.91, 
46.53, 49.41, 50.98, 51.44, 102.10, 116.04, 116.36, 126.81, 127.01, 127.68, 












LC-MS of RDR-H2 









 DAD1 D, Sig=500,16 Ref=off (RAJU\RDR-H2.D)










 DAD1 E, Sig=560,16 Ref=off (RAJU\RDR-H2.D)
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 DAD1, 5.356 (429 mAU, - ) of RDR-H2.D
 
 
6.5.2 Live mitotic cell imaging using ImageXpress Macro
TM
 cellular 
imaging system  
Mitotic block was induced to RPE:H2B:GFP cells by treatment with or 
without tubulyzine B (10 M) for 24 h before analysis. For synchronization of 
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mitosis, RPE1:H2B:GFP cells were seeding in 96 (or 12) xwell plate, 
synchronized by Tubulyzine B (10 M) for 24 h. RDR-H2/567 treated- cells at 
0.1 to 1 M were stained for 1 h. To visualize the nuclear, our probe-stained 
cells were added 1 µM of Hoechst 33342 from 30 min. The live cell images 
were taken by well randomly using ImageXpress Macro
TM
 cellular imaging 
system with 10X phase contrast objectives at various time points throughout 
the experiment. All controls in subsequent experiments included 0.1% DMSO. 
To obtain the live cell imaging with spectrum, fluorescence microscopy was 
performed on a A1P+ confocal microscope (100X) or N-STORM/TIRF (40X) 
microscopy with a CoolSNAP HQ digital camera.  
6.5.3 Cell culture 
RPE1:H2B:GFP (retinal pigmented epithelial cell line stably expressed 
with histone H2B fused to GFP) cells were cultured on a cell culture dish in 
Dulbecco‟s Modified Eagle Medium (Sigma) with 10% FBS and 1% PS. 
6.5.4 Cell synchronization  
 For synchronization of Mitosis, RPE1:H2B:GFP cells were seeding in 
384xwell plate, synchronized by Tubulyzine B (10 µM) for 24 h. Test reagent 
treated- cells were stained at 1 µM of Hoechst 33342 from 30 min. The live 
cell images were taken for an image using ImageXpress Macro
TM
 cellular 
imaging system with x10 phase contrast objectives at various time points 
throughout the experiment. All controls in subsequent experiments included 
0.1% DMSO. To obtain the live cell imaging, fluorescence microscopy was 
performed on a Nikon Ti inverted microscope with a CoolSNAP HQ digital 
camera. 
6.5.5 Cell cycle analysis 
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For synchronization of mitosis, RPE1:H2B:GFP cells were seeding in 
384xwell plate, synchronized by Tubulyzine B (10 M) for 24 h. RDR-
567/H2 (0.8 M) treated- cells were stained for 1 h. For FACS analysis with 
PI staining and live condition, cell samples were harvested with trypsinization. 
To stain the DNA content, cells were fixed with cold 100% Methanol and 
stained with PI at a final concentration f 10 g/ml. To stain the DNA content 
in live cells, our probe-stained cells were added 1 µM of Hoechst 33342 from 
30 min. Cell cycle phase distributions were analyzed by flow cytometry (BD 
Bioscience). 
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7.1 Introduction  
Functional fluorescent molecules are useful in many fields of scientific 
research, including analytical chemistry or cell biology. For example, 
fluorescent molecules, whose fluorescence properties can be changed by 
binding to or reacting with ions, small molecules, or enzymes, enable us to 
estimate the concentration or activity of the targets.
1,2
 Although some 
theoretical approaches to the design of such sensors have been reported,
 2,3
 
most currently available sensors were developed empirically. Combinatorial 
synthesis of libraries of fluorescent molecules is an effective approach.
4
 Chang 
et al have developed libraries of styryl dyes bearing DNA sensitive fluorescent 
sensors
5
 and  an amyloid sensors,
6
 and Finney et al. developed a fluorescent 
Hg
2+
 sensor via construction of a library.
7
 Coumarins are of interest because of 
their pharmacological activity
8
 and photophysical properties, and they have 
been applied as laser dyes
9





 and Wang et al.
12
 reported coumarin libraries with diversity at the 3-
position via Suzuki Miyaura, Heck, Sonogashira Hagihara, or Husigen 
cycloaddition reactions; they obtained coumarins with a wide range of 
absorbance, fluorescence wavelength, and fluorescence intensity. This work 
also confirmed the conclusion that electron-donating groups at 7-position of 
coumarins 
13
 showed strong enhancement of the fluorescence and dominated 
the emission color. Keeping all that in mind, we opted a coumarin scaffold 
which contains dimethyl amino group at 7- position for better photophysical 
property and acid group at 4-position for diversification. Over all, we 
constructed a coumarin library (COR, CORCA and CORAC) with diversity at 
the 4-position using our efficient solid phase synthesis to explore these 
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Herein, we report the diversity oriented solid synthesis of coumarin 
library. To the best of our knowledge, this the first report of coumarin library 
where modification has been performed in the 4-postion of the coumarin 
scaffold. This chapter mainly covers the synthesis and evaluations of the 
photophysical properties of coumarin library and their future prospect for the 
study of biological functions. 
7.3 Results and Discussion  
For the COR library synthesis (Scheme 7.1), carboxylic acid 
containing coumarin scaffold 1 was used as the key intermediate. The general 
synthetic strategy of coumarin acid 2 involves two steps (40% overall yield) 
reaction process. First, coumarin ester 1 was synthesized according to 
procedures (Song et al.)
14
, with modifications, by Pechmann cyclization of 3-
dimethylamino phenol with diethyloxalacetate (DEOA), then followed by 
basic hydrolysis of that ester provided the key intermediate of coumarin acid 
2.Then the structurally diverse COR library was synthesized using previously 
reported robust solid phase synthesis technique.
15
  Here, the wide structural 
diversity was introduced by the use of solid phase secondary amines 5 
utilizing a simple reaction between the bromopropylamine loaded resins 4 
with the series of primary amines (Chart 7.1). Then the key intermediate of 
coumarin acid 2 was coupled to this solid phase amine building block by using 
a standard acid–amine coupling protocol. The final step of acidic cleavage 
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from the solid supported compounds 3 yielded 80 very pure members of the 
COR library (average purity is 90% without further purification at 350 nm, 
Table 7.1, 7.2 and 7.3). 
Scheme 7.1 Synthesis of COR library. 
 
Reagents and conditions (a) Sodium ditheyloxalacetate, ZnCl2, EtOH, reflux, 
15 h.; (b) 2M LiOH, THF:H2O (3:1), 0 
o
C to rt, 0.5 hr.; (c) DIEA, THF, 3-
bromopropylamine, r.t., 12 h.; (d) DIEA, RNH2, NMP, 70  
o
C, 12 h.; (e) DMF, 
HATU, DIEA, r.t. 24 h.; (f) 2% TFA in DCM , r.t., 40 min. 
 
Then, CORCA and CORAC compounds were synthesized according to 
the previous mention protocol (chapter 3). All the compounds in the library 
were characterized by HPLC-MS and 80 relatively pure compounds (average 
purity is 90%, measured at 350 nm (Table 7.1, 7.2 and 7.3) were collected for 
further study. The high stokes shift of this library is reflected from the spectral 









Scheme 7.2 CORCA and CORAC library synthesis 
 













































COR 28 485.4 486.4 386 530 0.26 90 
COR 49 423.2 424.2 386 530 0.22 95 
COR 65 541.4 542.4 386 530 0.19 96 
COR 77 407.2 408.2 386 530 0.25 93 
COR 92 373.2 374.2 386 530 0.24 90 
COR 100 483.3 484.4 386 530 0.29 89 
COR 101 393.2 394.2 386 530 0.18 94 
COR 103 423.2 424.2 386 530 0.31 92 
COR 107 462.3 463.2 386 530 0.19 92 
COR 124 439.2 440.2 386 530 0.21 95 
COR 131 421.2 422.2 386 530 0.33 92 
COR 135 447.1 448.2 386 530 0.27 94 
COR 153 411.2 412.2 386 530 0.25 94 
COR 165 361.2 362.2 386 530 0.25 89 
COR 167 375.2 376.2 386 530 0.27 90 
COR 177 347.2 348.2 386 530 0.19 91 
COR 181 439.2 440.2 386 530 0.3 90 
COR 185 359.2 460.2 386 530 0.26 91 
COR 193 459.3 460.2 386 530 0.22 93 
COR 218 397.2 398.2 386 530 0.18 90 
COR 220 397.2 398.2 386 530 0.14 92 
COR 221 413.2 414.2 386 530 0.17 90 
COR 230 401.3 402.2 386 530 0.26 95 
COR 240 455.2 456.2 386 530 0.28 92 
COR 262 439.2 440.2 386 530 0.19 93 
COR 266 453.2 454.2 386 530 0.14 90 
COR 273 423.2 424.2 386 530 0.25 91 
COR 274 389.2 390.2 386 530 0.13 92 
COR 275 421.2 423.2 386 530 0.2 93 
COR 277 387.3 388.2 386 530 0.19 94 
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COR 336 469.2 470.2 386 530 0.22 92 
COR 351 415.2 416.2 386 530 0.21 93 
COR 358 439.2 440.2 386 530 0.22 92 
COR 359 438.2 439.2 386 530 0.17 90 
COR 364 413.2 414.2 386 530 0.12 94 
COR 373 345.2 346.2 386 530 0.21 95 
COR 374 379.2 380.2 386 530 0.16 96 
COR 381 409.2 410.2 386 530 0.19 92 
COR 382 385.2 386.2 386 530 0.15 93 
COR 387 409.2 410.2 386 530 0.13 94 
COR 388 409.2 410.2 386 530 0.15 95 
COR 389 411.2 413.2 386 530 0.12 93 
COR 395 423.2 424.2 386 530 0.19 95 
COR 396 393.2 394.2 386 530 0.19 96 
COR 398 393.2 394.2 386 530 0.3 90 
COR 399 415.2 416.2 386 530 0.12 89 
COR 403 413.2 414.2 386 530 0.18 94 
COR 405 411.2 412.2 386 530 0.19 91 
COR 412 415.2 416.2 386 530 0.13 92 
COR 414 430.3 431.2 386 530 0.11 92 
COR 419 359.2 360.2 386 530 0.19 94 
COR 420 390.3 391.2 386 530 0.18 91 
COR 425 359.2 360.2 386 530 0.17 92 
COR 427 376.2 377.2 386 530 0.2 91 
COR 441 385.2 386.2 386 530 0.24 92 
COR 442 359.2 360.2 386 530 0.19 93 
COR 457 415.2 416.2 386 530 0.17 94 
COR 477 411.2 412.2 386 530 0.29 92 
COR 478 407.2 408.2 386 530 0.17 95 
COR 480 427.2 428.2 386 530 0.18 92 
COR 511 515.2 516.2 386 530 0.16 91 
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COR 554 415.3 416.2 386 530 0.27 91 
COR 567 443.3 444.2 386 530 0.2 91 
COR 572 471.1 472.2 386 530 0.26 92 
COR 574 359.2 360.2 386 530 0.21 92 
COR 575 343.2 344.2 386 530 0.21 91 
COR 577 457.3 458.2 386 530 0.24 92 
COR 580 513.4 514.4 386 530 0.2 92 
COR 599 469.2 470.2 386 530 0.28 95 
COR 602 373.2 374.2 386 530 0.25 96 
COR 608 431.1 432.2 386 530 0.19 93 
COR 621 475.1 476.2 386 530 0.22 90 
COR 631 457.2 458.2 386 530 0.24 88 
COR 656 539.4 540.4 386 530 0.32 90 
COR 677 427.2 428.2 386 530 0.32 89 
 






















CORCA 28 561.3 562.2 388 528 0.33 91 
CORCA 49 499.2 500.2 388 528 0.22 92 
CORCA 65 617.4 618.4 388 528 0.31 94 
CORCA 77 483.2 484.2 388 528 0.29 90 
CORCA 92 449.2 450.2 388 528 0.22 90 
CORCA 100 559.2 560.2 388 528 0.24 88 
CORCA 101 469.2 470.2 388 528 0.16 93 
CORCA 103 499.2 500.2 388 528 0.23 91 
CORCA 107 538.2 539.2 388 528 0.02 94 
CORCA 124 515.2 516.2 388 528 0.17 93 
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CORCA 131 497.2 498.2 388 528 0.29 91 
CORCA 135 523.1 524.2 388 528 0.17 92 
CORCA 153 487.2 488.2 388 528 0.24 93 















CORCA 181 515.2 516.2 388 528 0.2 90 
CORCA 185 435.2 436.2 388 528 0.26 92 
CORCA 193 535.3 536.2 388 528 0.29 94 
CORCA 218 473.2 474.2 388 528 0.12 94 
CORCA 220 473.2 474.2 388 528 0.18 96 
CORCA 221 489.1 490.2 388 528 0.21 91 
CORCA 230 477.2 478.2 388 528 0.32 96 
CORCA 240 531.2 532.2 388 528 0.18 95 
CORCA 262 515.2 516.2 388 528 0.2 93 
CORCA 266 529.2 530.2 388 528 0.27 95 
CORCA 273 499.2 500.2 388 528 0.29 92 
CORCA 274 465.2 466.2 388 528 0.24 93 
CORCA 275 497.2 498.2 388 528 0.21 91 
CORCA 277 463.2 464.2 388 528 0.28 93 
CORCA 329 533.1 534.2 388 528 0.21 95 
CORCA 335 483.2 484.2 388 528 0.22 92 
CORCA 336 545.2 546.2 388 528 0.3 92 
CORCA 351 491.1 492.2 388 528 0.23 92 
CORCA 358 515.2 516.2 388 528 0.29 97 
CORCA 359 514.2 515.2 388 528 0.04 96 
CORCA 364 489.1 490.2 388 528 0.18 93 
CORCA 373 421.2 422.2 388 528 0.27 94 
CORCA 374 455.2 456.2 388 528 0.19 93 
CORCA 381 485.2 486.2 388 528 0.21 95 
CORCA 382 461.2 462.2 388 528 0.32 93 
CORCA 387 485.2 486.2 388 528 0.2 92 
CORCA 388 485.2 486.2 388 528 0.26 94 
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CORCA 389 487.2 488.2 388 528 0.1 95 
CORCA 395 499.2 500.2 388 528 0.3 95 
CORCA 396 469.2 470.2 388 528 0.23 92 
CORCA 398 469.2 470.2 388 528 0.2 91 















CORCA 412 491.1 492.2 388 528 0.2 91 
CORCA 414 506.3 507.2 388 528 0.08 90 
CORCA 419 435.2 436.2 388 528 0.32 93 
CORCA 420 466.2 467.2 388 528 0.13 94 
CORCA 425 435.2 436.2 388 528 0.29 94 
CORCA 427 452.2 453.2 388 528 0.06 92 
CORCA 441 461.2 462.2 388 528 0.27 94 
CORCA 442 435.2 436.2 388 528 0.26 93 
CORCA 457 491.1 492.2 388 528 0.16 94 
CORCA 477 487.2 488.2 388 528 0.25 92 
CORCA 478 483.2 484.2 388 528 0.4 94 
CORCA 480 503.1 504.2 388 528 0.25 93 
CORCA 511 591.1 592.2 388 528 0.18 93 
CORCA 522 511.2 512.2 388 528 0.27 92 
CORCA 531 523.1 524.2 388 528 0.18 93 
CORCA 548 545.2 546.2 388 528 0.29 92 
CORCA 554 491.3 492.4 388 528 0.32 91 
CORCA 567 519.3 520.4 388 528 0.34 91 
CORCA 572 547.1 548.2 388 528 0.27 93 
CORCA 574 435.2 436.2 388 528 0.24 95 
CORCA 575 419.2 420.2 388 528 0.29 94 
CORCA 577 533.3 534.2 388 528 0.31 93 
CORCA 580 589.4 590.4 388 528 0.38 92 
CORCA 599 545.2 546.2 388 528 0.32 92 
CORCA 602 449.2 450.2 388 528 0.3 92 
CORCA 608 507.1 508.2 388 528 0.19 93 
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CORCA 621 551.1 552.0 388 528 0.17 95 
CORCA 631 533.1 534.2 388 528 0.16 91 
CORCA 656 615.4 616.4 388 528 0.34 92 
CORCA 677 503.1 504.2 388 528 0.26 92 
       






















CORAC 28 527.4 528.4 383 530 0.3 91 
CORAC 49 465.2 466.2 383 530 0.31 92 
CORAC 65 583.4 584.4 383 530 0.46 94 
CORAC 77 449.2 450.2 383 530 0.22 92 
CORAC 92 415.2 416.4 383 530 0.23 92 
CORAC 100 525.3 526.2 383 530 0.23 88 
CORAC 101 435.2 436.2 383 530 0.05 93 
CORAC 103 465.2 466.2 383 530 0.2 92 
CORAC 107 504.3 505.2 383 530 0.04 94 
CORAC 124 481.2 482.2 383 530 0.07 93 
CORAC 131 463.2 464.4 383 530 0.22 94 
CORAC 135 489.1 490.2 383 530 0.16 93 
CORAC 153 453.2 454.2 383 530 0.45 92 
CORAC 165 403.2 404.2 383 530 0.31 90 
CORAC 167 417.2 418.2 383 530 0.22 92 
CORAC 177 389.2 390.2 383 530 0.41 93 
CORAC 181 481.2 482.2 383 530 0.17 91 
CORAC 185 401.2 402.2 383 530 0.4 92 
CORAC 193 501.3 502.2 383 530 0.35 92 
CORAC 218 439.2 440.2 383 530 0.26 91 
CORAC 220 439.2 440.2 383 530 0.22 93 
CORAC 221 455.2 456.2 383 530 0.33 92 
CORAC 230 443.3 444.4 383 530 0.36 93 
CORAC 240 497.2 498.4 383 530 0.14 91 
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CORAC 262 481.2 482.2 383 530 0.56 92 
CORAC 266 495.2 941.7 383 530 0.36 92 
CORAC 273 465.2 466.2 383 530 0.46 91 
CORAC 274 431.2 432.2 383 530 0.52 93 
CORAC 275 463.2 464.4 383 530 0.14 92 















CORAC 336 511.2 512.2 383 530 0.42 92 
CORAC 351 457.2 458.2 383 530 0.26 92 
CORAC 358 481.2 482.2 383 530 0.33 91 
CORAC 359 480.2 481.2 383 530 0.42 92 
CORAC 364 455.2 456.2 383 530 0.28 93 
CORAC 373 387.2 388.2 383 530 0.41 92 
CORAC 374 421.2 422.2 383 530 0.3 93 
CORAC 381 451.2 452.2 383 530 0.28 91 
CORAC 382 427.2 428.4 383 530 0.36 92 
CORAC 387 451.2 452.2 383 530 0.11 94 
CORAC 388 451.2 452.2 383 530 0.39 94 
CORAC 389 453.2 454.2 383 530 0.22 94 
CORAC 395 465.2 466.4 383 530 0.34 96 
CORAC 396 435.2 436.2 383 530 0.28 94 
CORAC 398 435.2 436.2 383 530 0.45 90 
CORAC 399 457.2 458.2 383 530 0.04 91 
CORAC 403 455.2 456.2 383 530 0.58 93 
CORAC 405 453.2 454.2 383 530 0.75 92 
CORAC 412 457.2 458.2 383 530 0.17 91 
CORAC 414 472.3 473.2 383 530 0.03 91 
CORAC 419 401.2 402.2 383 530 0.42 93 
CORAC 420 432.3 433.2 383 530 0.14 92 
CORAC 425 401.2 402.2 383 530 0.55 92 
CORAC 427 418.3 419.2 383 530 0.15 89 
CORAC 441 427.2 428.4 383 530 0.28 91 
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CORAC 442 401.2 402.2 383 530 0.35 89 
CORAC 457 457.2 458.2 383 530 0.55 89 
CORAC 477 453.2 454.2 383 530 0.42 92 
CORAC 478 449.2 450.2 383 530 0.44 93 
CORAC 480 469.2 470.2 383 530 0.32 91 
CORAC 511 557.2 558.2 383 530 0.46 92 















CORAC 554 457.3 458.2 383 530 0.39 94 
CORAC 567 485.3 486.4 383 530 0.47 93 
CORAC 572 513.1 514.2 383 530 0.2 92 
CORAC 574 401.2 402.2 383 530 0.5 92 
CORAC 575 385.2 386.2 383 530 0.31 96 
CORAC 577 499.3 500.4 383 530 0.33 95 
CORAC 580 555.4 556.4 383 530 0.13 93 
CORAC 599 511.2 512.4 383 530 0.33 92 
CORAC 602 415.2 416.2 383 530 0.19 92 
CORAC 608 473.2 474.2 383 530 0.21 91 
CORAC 621 517.1 518.2 383 530 0.08 94 
CORAC 631 499.2 500.2 383 530 0.38 89 
CORAC 656 581.4 582.2 383 530 0.27 91 
CORAC 677 469.2 470.2 383 530 0.26 96 
 
*1 Quantum yields were measured in DMSO, using Dansylamide as a 
standard ( : 0.66, in DMSO). *2 Purities were determined according to UV 
absorption at 350 nm.ESI-MS positive spectra, HPLC conditions: A: H2O-
HCOOH: 99.9:0.1. B: CH3CN-HCOOH: 99.9:0.1; gradient  100% A to 95% B 
(6 min), isocratic 95% B (6-8.2min), gradient 95% B to 100% A  (8.2-9 min), 
isocratic 100% A (9-10 min). Reversephase Phenomenex C18 Luna column 
(4.6 x 50 mm
2





Figure 7.1 Absorption and emission spectra of representative COR, CORCA 
and CORAC compound. 
 
7.4 Conclusions 
I have succesufully synthesized large stoke shift (~ 150 nm) coumarin 
dye library, COR, in solid phase.  I have also successfully modified them with 
chloroacteyl and acetyl version (CORCA and CORAC). These set of library 
could be used in bio-imaging applications as well as construction of longer 
wavelength FRET dyes.   
7.5 Experimental methods 
Material and methods 
Amine and few bromide building block and all other chemicals and 
solvents for the synthesis were purchased from the Alfa Aesar, Fluka, Acros, 
MERCK, and Sigma Aldrich and were used without any purification. Merck 
Silica Gel 60 (particle size: 0.04-0.063 mm, 230-400 mesh) was used for the 
normal phase column chromatographic purification. From BeadTech Inc., 
Korea, 2-chlorotrityl alcohol resin (1.37mmol/g) was purchased. For analytical 
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characterization of COR compounds HPLC-MS (Agilent-1200 series) with a 
DAD detector and a single quadrupole mass spectrometer (6130 series) with 
an ESI was used. Analytical process, except specified: eluents: A: H2O (0.1% 
HCOOH), B: ACN (0.1% HCOOH), C18 (2) Luna column (4.6 x 50mm
2
, 5m 




C-NMR spectra were recorded on both 
Bruker Avance 300 MHz and 500 MHz NMR spectrometer, and chemical 
shifts are expressed in parts per million (ppm) and approximate coupling 
constants were calculated in Hz. Quantum yields and all other photophysical 
properties of COR derivatives were performed in Spectramax M2 instrument 
and the obtained data were analyzed using the Microsoft Office Excel 2007.  
7.5.1 Synthesis of Coumarin acid 
 
To synthesize coumarin ester 1, m-dimethylaminophenol (12 g, 87.5 
mmol), sodium diethyloxalacetate (20.2 g, 96.2 mmol, 1.1 equiv.) and ZnCl 2 
(14.31 g, 105 mmol) were dissolved in absolute ethanol (50 mL). The reaction 
mixture was heated at reﬂux for 15 h. The reaction mixture was cooled to 
room temperature. Then, the reaction mixture was poured into ice-water. The 
precipitate formed was ﬁltered and air-dried and purified by silicagel colum 
chromatography (eluent: DCM: MeOH = 15: 1, Rf = 0.30) to obtain orange 
solid (10 g, 43%).
1
H- NMR (500 MHz, Methanol-d4); δ 1.67 (t, 3H, J=7Hz), 
3.31 (s, 3H), 4.68 (q, 2H, J=7Hz), 6.75 (d, 1H, J=2Hz), 6.79 (s, 1H), 6.99 (dd, 
1H, J=9Hz), 8.28 (d, 1H, J=9Hz). 
13
C-NMR (125 MHz, Methanol-d4); δ 
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14.05, 62.07, 98.21, 105.62, 109.42, 111.92, 127.44, 142.90, 152.84, 156.62, 
161.49, 14.54. 
LCMS (ESI): calc for C14H15NO4 (M+H) 261.1; found: 262.0 
 
 
To Coumarin ester 1 (10 g, 36.32 mmol) was dissolved in THF–H 2O 
(3 :1) (60 mL) and cooled to 0 
o
C. 2 M LiOH solution (36.3 mL, 72.64 mmol, 
2.0 equiv.) was added dropwise. The reaction mixture was stirred at room 
temperature for 0.5 h. Water (60 mL) was added, the aqueous layer was 
extracted with Et2O (3 X50 mL). The aqueous layer was acidiﬁed to pH 2 by a 
2 M HCl solution. Crude compound was extracted out from the aqueous layer 
with DCM (5X 50 ml). Organic layer was dried to get crude product which 
was purified by silica gel column chromatography (eluent: DCM : MeOH = 8 : 
1, Rf = 0.45) to obtain the pure product as yellow solids. Yield: (4 g, 44%).  
1
H- NMR (500 MHz, Methanol-d4); δ 3.06 (s, 6H), 6.06 (s, 1H), 6.53 (d, 1H, 
J=2Hz), 6.75 (d, 1H, J=9Hz), 7.75 (d, 1H, J=9Hz). 
13
C-NMR (125 MHz, 
Methanol-d4); δ 40.09, 96.50, 105.71, 107.42, 110.52, 129.17, 154.64, 157.81, 
165.21. 
LCMS (ESI): calc for C12H11NO4 (M-H) 232.1; found: 232.2 
7.5.2 General procedure for solid phase synthesis of COR library 
All the general procedures for the coumarin library synthesis is similar 
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8.1 Conclusions  
It is quite obvious from the available wide range of literature reports 
that the progress of diversity orientedfluorescent library approach along with 
the high throughput screening lead to novel bio-imaging probes/sensors 
discovery in a relatively faster manner. However, for the case presented here, 
efficient solid phase chemistry needs to be devised to provide a robust 
synthetic route for generating a large number of fluorescent libraries in a short 
span of time. In this view, I developed an elegant solid phase route to 
systemically apply in the synthesis of fluorescent libraries that cover wide 
emission color spectra from Vis to NIR. We designed the novel diversity 
oriented fluorescent libraries where each library contains single emission 
wavelength to develop both cell imaging and in vivo imaging probe. Single 
wavelength with different structural diversity provided a useful toolbox as it 
allowed easier structural activity relationships studies (B cell probe 
development).  
 Based on the previous work by our group, I have synthesized ultraphotostable 
, NIR cyanine dye libraries (CyR and its CA, AC and lipoic acid  derivatives)  
utilizing CyNA-414 , the most  photostable dye from CyNA library. From 
macrophage screening of CyR derivatives, we developed a novel in vivo 
imaging macrophage probe (CyRCA-E4).  From the SERS screening of the 
CyRLA compounds, we discovered the highly SERS-active compound 
CyRLA-E10 which has been utilized as the multiplexing partner with the 
Cy7LA and Cy7.5LA compounds to detect teratoma in vitro. Modifying the 
stable tetramethyl BODIPY scaffold, I have synthesized BDR library and its 
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CA and AC derivatives to generate green emission compounds. From the cell 
based screening, we discovered a B-cell selective probe CDg6. For the SARs 
study, I synthesized BODIPY derivatives containing long alkyl chains (upto 
24 carbons). I also synthesized BODIPY derivative with different colors 
emissions keeping the chain length (18-C) same using condensation and 
coupling reactions.  
Rhodol scaffold, a mixed hybrid from rhodamine and fluorescein was 
employed to produce longer wavelength, dye library (RDR and its CA, AC 
derivatives) in the range of orange emission color. Rhodol library inherited 
excellent photophysical properties such as good quantum yield, high 
extinction coefficient. Using cell based screening, we primary results for 
discovering mitotic phase specific probe, RDR-H2 which specifically stains to 
the mitosis compared to the inter phase cells. 
I synthesized COR library and its respective chloroacetyl (CA) and acetyl 
derivatives (AC) to cover the large stokes shift (150 nm), green emission dyes. 
Here, based on the previous work and the studies,  I opted a coumarin scaffold 
which contains dimethyl amino group at 7- position for better photophysical 
property and acid group at 4-position for diversification. Over all, I 
constructed a coumarin library (COR, CORCA and CORAC) with diversity at 
the 4-position using our efficient solid phase synthesis to explore these 
compounds in the evaluation of biological function via cell based and in vitro 
screening. 
8.2 Future prospectives 
Bio-imaging research needs arsenals of fluorescent probes to be 
developed.  To accelerate the discovery of new bioimaging probes, we have 
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developed a new chemical toolbox that contains a set of fluorescent dyes with 
diverse structural, chemical and spectral properties. Due to the unbiased 
construction of these fluorescent dyes, varieties of in vitro or cell imaging 
probes can be developed using the high-throughput screening. Our simple but 
robust solid phase synthesis methodology would be applicable in designing 
and synthesizing new fluorescent libraries. Additionally, although, I have 
recently finished the coumarin library synthesis, due to the lack of enough 
time, we did not perform the cell based or in vitro screening using these 
compounds. The screening may offer coumarin based sensors or probes for 
further biological research. 
The bio-imaging techniques recently have been attracted much 
attention for the development of new fluorescence probes based on single 
fluorophores. However, single emission intensity as a sensing signal can 
readily be perturbed
1
 by environmental factors, such as pH, temperature, and 
solvent polarity. Hence, the development of precise fluorometrical analysis 
under complex biological assay may pave way the cellular bioimaging studies. 
Generally, single fluorophores are suffered from their unknown concentration 
and inhomogeneous location inside the cells
2
. Therefore, probes consisting 
two different wavelengths may represent an intriguing avenue for extracting 
biological information from living subjects since they can be monitored with 
safe, noninvasive optical imaging techniques. Our research group have been 
successfully demonstrated (as described in chapter 1) the potentiality of 
diversity oriented fluorescence library approach (DOFLA) to develop 
chemosensors/probes
3
 for a number of biomolecules in one dimensional single 
fluorophore approach. Utilizing our DOFL approach and my fluorescent 
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libraries resources, two dimensional fluorescent libraries can be constructed to 
visualize the biological events to increase the chance of lead compound 
generation from high throughput screening (HTS).  
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